University of New Mexico

UNM Digital Repository
Biomedical Sciences ETDs

Electronic Theses and Dissertations

7-1-2014

Engineering Catalytic Molecular Logic Devices for
Biodetection
Carl Brown III

Follow this and additional works at: https://digitalrepository.unm.edu/biom_etds
Part of the Medicine and Health Sciences Commons
Recommended Citation
Brown, Carl III. "Engineering Catalytic Molecular Logic Devices for Biodetection." (2014). https://digitalrepository.unm.edu/
biom_etds/113

This Dissertation is brought to you for free and open access by the Electronic Theses and Dissertations at UNM Digital Repository. It has been
accepted for inclusion in Biomedical Sciences ETDs by an authorized administrator of UNM Digital Repository. For more information, please contact
disc@unm.edu.

Carl W. Brown, III
Candidate

Biomedical Sciences
Department

This dissertation is approved, and it is acceptable in quality and form for publication:
Approved by the Dissertation Committee:
Steven W. Graves, Ph.D , Chairperson
Darko Stefanovic, Ph.D.
Larry A. Sklar, Ph.D.
Dave Whitten, Ph.D.
Bridget Wilson, Ph.D.

i

ENGINEERING CATALYTIC MOLECULAR LOGIC DEVICES
FOR BIODETECTION

BY
CARL W. BROWN, III

B.S. Biomedical Engineering, University of Rochester, 2008

DISSERTATION
Submitted in Partial Fulfillment of the
Requirements for the Degree of
Doctor of Philosophy
Biomedical Sciences
The University of New Mexico
Albuquerque, New Mexico
July 2014

ii

DEDICATION
I would like to dedicate this dissertation to my wife, Karen Brown. Her love and
support for me over the years has been one of the few constants in an everchanging graduate experience for me. She was there through exciting
discoveries and disappointing letdowns, and waited patiently as I repeatedly
underestimated how long it would take me to finish my experiments. Her support
for me never waivered, even as late nights grew later and deadlines drew closer.
She served as a constant reminder of keeping things in perspective, and that
sometimes, the right answer really is “potato”. Nothing more need be said.

iii

ACKNOWLEDGEMENTS
I would like to sincerely thank my advisor and mentor Dr. Steve Graves for all of
his advice, input, and guidance over the years. He gave me a tremendous
amount of intellectual freedom on each of the many projects I have worked on,
displaying a trust in me even when experimental results might have suggested a
different course. Being allowed to take risks helped me gain a knowledge and
understanding of my work that could not have been achieved otherwise and a
wonderful satisfaction of the work we accomplished together. I would also like to
thank my co-advisor Dr. Darko Stefanovic, who broadened my perspectives on
the more theoretical and abstract ideas and has been instrumental in my
professional development. I am grateful and honored to have worked for both
mentors, who have made my graduate career a positive and rewarding
experience. I would like to thank my committee members, Dr. Larry Sklar, Dr.
Dave Whitten, and Dr. Bridget Wilson, for their guidance over the years.
I would like to thank Dr. Matthew Lakin, who worked on these projects
side-by-side with me for years. Assuming the role of post-doc, mentor, co-worker,
and friend, he has influenced nearly every aspect of my graduate development
and I am a better researcher for it. I would also like to thank Dr. Menake
Piyasena, whose guidance and support was invaluable to my early development.
I have also had the privilege to mentor many fantastic researchers over
the years, which has made me a better scientist, mentor, and person. I would
especially like to thank the two undergraduates, Hannah West and Eli Horwitz,
who each worked with me for a considerable amount of time. I appreciate their
dedication, hard work, and great conversation over that time. They were mature
beyond their years. I cannot thank them enough.
Finally, I would like to thank my friends and family who have supported me
throughout the years. I would like to thank my parents, for instilling in me the
confidence and the competitive spirit to never settle for anything less than what I
could accomplish. I would also like to thank my in-laws, Keith and Lynne Miller,
for their unconditional support and encouragement, and my grandmother Lenora
Brown, who is the epitome of a lifelong learner. Meliora.
iv

ENGINEERING CATALYTIC MOLECULAR LOGIC DEVICES
FOR BIODETECTION
BY
Carl W. Brown, III
B.S. Biomedical Engineering, University of Rochester, 2008
Ph.D. Biomedical Sciences, University of New Mexico, 2014
ABSTRACT
This dissertation describes the development of DNA computing techniques and
molecular logic devices specifically engineered for direct translation to biological
sample detection. As disease states originate at the molecular level, it is critical
to design diagnostic and therapeutic devices that are capable of molecular-scale
sensing and decision-making in the cellular environment. The predictable nature
of DNA hybridization and secondary structure formation enables programmable
interactions, providing a stable, cost-effective, and biocompatible mechanism for
making decisions on the molecular scale. The incorporation of DNAzymes, DNA
strands that can perform a variety of chemical reactions, adds innate catalysis
and a rich biochemical diversity to DNA logic. By regulating DNAzyme activity
via hybridization-based approaches, we have developed a new mechanism for
implementing DNA logic, referred to as DNAzyme displacement. This mechanism
was used for the construction of DNA logic gates, extended logic cascades, and
sensitive biosensors, each capable of operating in non-pristine conditions and
under minimal purification and setup restrictions. Logic cascades were
constructed through the development of a signal propagation molecule known as
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a structured chimeric substrate (SCS), which was able to pass a signal between
any DNAzyme pair, resulting in the longest synthetic DNA cascade to date. A
multi-step DNAzyme displacement reaction was developed for the construction of
modular biosensor gates, capable of rapidly multiplexing samples with a limit of
detection of 7.4 pM. Other innovative experimental characterization included
high-throughput screening efforts of a DNAzyme and alternative methods of
compartmentalization including surface-based and lipid-conjugated DNA and
protein reactions. This work shows the potential of using DNA to implement
molecular logic for the development of intelligent biosensors.
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Chapter 1.
Introduction
1.1 Biodetection, Theranostics, and the Biological Computer
The ideal of personalized medicine and point-of-care detection has generated
considerable excitement in the biomedical community. There is a considerable
allure to an individual-specific approach to understanding the interaction and
progression of disease and infection to provide the most advanced and relevant
treatment possible. This is a noble goal indeed, but if we are to provide truly
personalized medicine – to detect the onset of disease, the source of infection, or
the mutation of an oncogenic protein – we must set our sights on the molecular
underpinnings of these events and seek to identify and treat disease states in the
complex biochemical interactions of the cellular milieu. On the front end of this
problem lies the issue of biodetection. Significant time and effort has been
devoted to the symptomatic detection of diseases with considerable success, but
for effective treatment many diseases require identification before symptoms
appear. Biodetection at the molecular level is a tantalizing prospect, but a much
more intractable problem; issues such as sequence mutations, low target
concentrations, specificity, and sensitivity each present their own unique
challenges to the development of biosensors. On the back end lies the prospect
for treatment and the development of targeted therapeutics to be released under
the proper conditions. Unification of both detection and treatment aspects under
a single device may then culminate in an autonomous theranostic device capable
of operating at the cellular or molecular level, a true biological computer. The first
step to fulfilling this vision of personalized point-of-care medicine requires the
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development of molecular scale detection capabilities in order to directly interface
with the molecules indicative of disease states.
To improve biodetection capabilities to this degree, we require a
technological advance akin to the molecular valves of Isaac Asimov’s Multivac in
The Last Question – a mechanism for making sophisticated decisions using the
information available to us at the level of individual molecules. Cells, experts in
this field for four billion years, rely on complex networks of proteins; our
knowledge currently falls short of using de novo protein design for synthetic
decision networks. However, the advent of DNA nanotechnology, self-assembly,
and computation through the predictable formation of nucleic acid interactions
has provided us with the principles and building blocks needed to realize the
vision of “molecular valves” using natural biochemistry.
Already an impressive amount of work has demonstrated the ability of
DNA to make decisions, spawning the field of DNA computation, but the
application of these computational principles for biodetection remains an
untapped potential. There have been many different mechanisms developed to
use DNA to make decisions; here we focus on the use of innately catalytic DNA
strands called DNAzymes. My thesis is that precise thermodynamic and kinetic
design of nucleic acid structures will enable the development of scalable DNA
computational circuits robust enough for use in biodetection assays. This has
applications for basic scientific advances in DNA nanostructure design, dynamic
DNA interactions, and intermolecular interaction regulation, and lays the
groundwork for continued work towards a new generation of biological-inspired
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and targeted theranostic devices, yet another step toward a true biological
computer1.
1.2 DNA computation and Molecular Logic
Even with the initial discovery of DNA, Watson and Crick immediately recognized
the structure being conducive to the transmission of information2. Since then, the
thermodynamics of DNA hybridization has been studied extensively3-6, and the
simplicity of Watson-Crick base pairing (A binds to T, G binds to C) has led to the
development of modeling software7-9, which can accurately predict DNA
sequence interactions and secondary structure formation. As science has yet to
unlock the complex thermodynamics that underlie protein folding, the
predictability of DNA hybridization and secondary structure has generated
considerable excitement for the prospects of engineering specific and directed
molecular interactions, giving rise to the fields of DNA nanotechnology10,11 and,
later, DNA computation.
The field of DNA computation began 20 years ago with the seminal paper
by Leonard Adleman, in which he demonstrated that DNA hybridization could be
programmed to devise solutions to computationally intractable problems, in this
case an instance of the directed Hamiltonian path problem12. Since this initial
demonstration of computation, DNA nanotechnology has been applied to many
other dynamic nanoscale processes such as self-assembly13-15, actuation16-19,
molecular walkers17,20, and motors18. Although there have been other
implementations of molecular computing such as using naturally occurring
proteins21-24, the programmability of base pair interactions and the predictability
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of secondary structure through established hybridization models6 makes DNA an
ideal substrate for the development of de novo molecular logic gates, circuits,
and computers.
To date, there have been several different implementations using DNA to
create logic gates and circuits, including tile self-assembly25,26

27,28

, hairpin

assembly29-31, ribozymes32,33, DNAzymes34-37, and strand displacement38-40. The
computation of tile self-assembly implements an algorithm for the construction of
highly ordered DNA nanostructures, which can encode results of an arbitrary
computation, emulating the capabilities of silicon-based digital computers41,42.
DNAzyme-based and DNA strand displacement-based systems both compute
using dynamic interactions between separate nucleic acid complexes to
propagate signals. Unfortunately, there has been very little integration between
logic gates of different biochemical mechanisms43. Circuits tend to be
homogenous, consisting only of the base technology (e.g. strand displacement,
loop-regulated E6 DNAzymes, etc.), limiting the potential responses that could be
achieved by the integration of different types of DNA logic gates. This scientific
and technological gap must be bridged for the full biodetection potential of
molecular computing algorithms to be realized.
1.3 DNAzymes and functional nucleic acids for protein-free biosensing
The use of functional nucleic acids as an enzyme-free biosensor platform holds
considerable promise for the development of low-cost biodetection diagnostics
and the subsequent evolution of such devices for the implementation of
biomedical theranostics44. DNA itself is a natural information carrier through
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sequence-specific hybridization; its biocompatibility, stability, and decreasing
synthesis costs make it an ideal candidate for use in biosensors. Although the
use of hybridization-based probes has seen considerable interest and success
45,46

, the use of functional nucleic acids richly expands the potential utility for

DNA-based probes and the diversity of their targets.
Functional nucleic acids (FNA), which include ribozymes, DNAzymes (also
known as deoxyribozymes or DNA enzymes in the literature), aptamers, and
aptazymes, contain specific sequences that confer additional functionality44. In
the case of ribozymes and DNAzymes, these sequences act as a catalyst for a
specific biochemical reaction. Aptamers, on the other hand, are sequences that
possess an intrinsic affinity for a selected target, which are typically small
molecules like ATP47 but can be larger targets as well. Aptazymes are hybrid
sequences of aptamers and DNAzymes in which the binding of the aptamer
target leads to the modulation of DNAzyme activity48-50. Assays utilizing FNAs
have been developed for a diverse set of input modalities, including heavy metal
sensing51-53,

small

molecule

sensing47-49,

nucleic

acid-based

pathogen

detection54,55, cellular binding and analysis1,56,57, and molecular logic and
computation34-37,58-60. FNAs have also demonstrated a wide variety of output
modalities30, such as optical61, surface plasmon resonance62, fluorescence36,
electrochemical63-66, in vivo mRNA knockdown67-75, and gold nanoparticle
aggregation51,52,76-81. The outputs can also include the release of therapeutic
compounds1,56,82, such as the release of a caged anti-tumorgenic compound
through aptameric conformation change83-85 or DNAzyme to cleave a target
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mRNA71 has already been demonstrated. The diversity of input and output
alternatives holds promise for the development of a wide variety of biosensors
tailored to specific conditions or targets86, which share common chemical and
computational principles.
One of the biggest challenges in biosensor development is achieving the
sensitivity necessary to detect the low target concentrations of pathogenic
sequences typically available in prepared solutions. One class of FNAs that
appear ideally suited to address this challenge is DNAzymes, which are single
DNA oligomers capable of catalyzing chemical reactions68,72,87 previously thought
to be catalyzed only by proteins. Their existence was hypothesized after the
discovery of naturally occurring ribozymes, although no naturally occurring
DNAzymes have been discovered to date. All known DNAzyme catalytic motifs
have been artificially selected for using the Systematic Evolution of Ligands by
Exponential Enrichment (SELEX) process58,88. Since the discovery of the first
DNAzyme89, many more catalytic sequences have been discovered, capable of
catalyzing a broad set of biochemical reactions58 including RNA hydrolysis89,90,
RNA ligation91,92, DNA ligation93, DNA phosphorylation94, HRP-like activity95,96,
and DNA hydrolysis97,98. Due to the stability, ease of use, and low cost of
synthesis, DNAzymes have generated a significant amount of interest in the
scientific community.
The family of RNA-cleaving DNAzymes have some of the fastest catalytic
rates of all DNAzymes, although this is still orders of magnitude slower than their
protein counterparts. For example, the 8-17 DNAzyme achieves a 108 rate
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enhancement over spontaneous RNA hydrolysis, while RNase A is capable of a
1014 rate enhancement. This fact has made them the best characterized and
most widely used. Many different sequences have been discovered that can
perform this reaction, generally named for the round of selection in which they
were discovered. Of these, the most prominent DNAzymes are E689, 8-1790,99,
and 10-23100, most frequently used due to their small size and relatively high
catalytic rate. The structure of these DNAzymes consist of a fixed catalytic core
flanked by two substrate binding arms. Mutational analysis has been conducted
for the 8-17 DNAzyme core101, which showed the highly conserved nature in
general as well as the necessity of certain bases within the core, which likely play
a major role in catalysis of the RNA cleavage reaction. Although RNA folding
software9,102 predicts a small stem forming through hybridization within the
catalytic core, it is likely that this structure is more complex. The RNA-cleaving
DNAzymes are highly dependent on divalent metal cation cofactors, which likely
assist directly in the RNA hydrolysis by associating with the catalytic core103,104.
The thermodynamic tables used as the basis for thermodynamic structure
prediction software such as NUPACK are not parameterized for these salt
conditions, which makes prediction of the structure of the catalytic core
challenging and research on the interaction and conformation of this secondary
structure is ongoing105,106. Due to this divalent metal cofactor dependence, many
of these DNAzyme sequences can be used as natural heavy metal sensors107,108.
Although originally selected for in the presence of lead, subsequent selection
experiments have found sequences highly active in other metals such as
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magnesium, manganese, and zinc, and moderately active with many other
divalent metal cations109.
While substrate specificity in protein enzymes is achieved through tertiary
conformational interactions, which are difficult to predict110, DNAzymes rely on
secondary conformation and hybridization via the substrate binding arms. It is
typically assumed that the substrate binding arms are completely unconstrained,
although it is possible that single bases near the catalytic core may still be
necessary for function101. These interactions are easily modeled using nucleic
acid folding software such as NUPACK9, which uses nearest neighbor stacking
interactions6 to predict folding and the design of secondary structures102. This
property makes these DNAzymes very attractive for scientific and engineering
purposes,

as

it

allows

for

the

sequence

specific

programming

of

DNAzyme/substrate interactions. This interaction is highly specific and requires
the hybridization of both substrate binding arms; a single arm binding is
insufficient to obtain substrate cleavage. The cleavage reaction can be monitored
using a variety of methods including PAGE analysis, radiolabeling, and FRETbased fluorescence measurements (Figure 1.1).
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Figure 1.1 – The mechanism of DNAzyme-catalyzed RNA cleavage. Here, the 817 DNAzyme binds to its corresponding substrate through hybridization with the
substrate binding arms. The catalytic core (cc) is black, while the individual
substrate binding arms are colored orange and green. The RNA base is
hydrolyzed, which results in the formation of two shorter product strands, which
freely dissociate from the DNAzyme. Fluorescence increase results from a loss
of FRET.
We focus our efforts on the 8-17 DNAzyme99, originally discovered in 1997
by Santoro and Joyce using Mg2+ as the metal ion cofactor90. A Zn2+ optimized
version was later discovered in 2000 by Li et al109, and this sequence serves as
the basis for nearly all of the RNA-catalysis experiments conducted herein. This
DNAzyme is highly active around a pH of 7 and activity has been characterized
in presence of a wide variety of divalent metal cations. It has a catalytic core of
15 nucleotides (nt), one of the smallest DNAzymes cores discovered to date,
making it easy to manipulate. It also has one of the highest catalytic rates of all
RNA-cleaving DNAzymes, at ~1/min under typical high salt buffer conditions.
Given the rate of 10-7/min for spontaneous RNA hydrolysis, this corresponds to
roughly a 108 rate enhancement of RNA hydrolysis111. Conversely, the rate
enhancement attained by the near-perfect protein catalyst RNAse A is roughly a
1012 rate enhancement. The limitation of the DNAzyme on rate enhancement
compared to RNAse A does not appear to be a hard biochemical limit112; indeed,
efforts to improve the cleavage rate by engaging additional biochemical
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mechanisms would be highly desirable. The biochemical mechanism of this
DNAzyme is discussed in detail in Chapter 7.
1.4 DNAzymes for molecular computation
The first experimental demonstration of using DNAzymes for molecular
logic gate construction was in 2002 by Stojanovic and Stefanovic in the Journal
of the American Chemical Society36, an extension of their earlier work combining
DNAzymes with molecular beacons113. Here, they use both the 8-17 and E6
DNAzymes for the development of Boolean logic gates, specifically YES, NOT,
AND, and XOR. In the case of YES and AND gates, inhibition was achieved
through molecular beacon-type stem loops, which bind back on one or both
substrate binding arms to create an intramolecular interaction, thereby blocking
any interaction with the substrate. The addition of an input oligomer sequence
would bind to these loops, creating a more favorable duplex between the input
and loop than the competing hybridization between the loop and DNAzyme. This
opens up the loop and allows the substrate to productively bind the DNAzyme,
resulting in an output signal via loss of FRET after substrate cleavage. Although
the cleavage rate of E6 is notably slower than that of 8-17 (0.04/min vs. 1/min),
the catalytic core of the E6 DNAzyme is larger and more flexible, which allowed
an additional stem loop to be added to the core of the E6 DNAzyme without
significantly affecting DNAzyme catalysis. This properly enabled the construction
of a NOT gate, in which the binding of an input oligomer would hybridize to the
loop and deform the catalytic core to deactivate the DNAzyme.
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Because the substrate specificity of DNAzymes is achieved through basepair hybridization, multiple such gates could be run in parallel in the same
solution. This was initially implemented in a large-scale automaton114, capable of
playing tic-tac-toe, and subsequently improved upon in a second iteration by
removing many of the restrictions of the original design115. This was a critical step
in the use of DNAzymes to construct automated decision-making, and
demonstrated the potential complexity of information process by biomolecular
circuits116. However, the loop-based approach to DNAzyme inhibition generally
uses high (µM) target input concentrations, orders of magnitude above the
sensitivity necessary for biosensor detection. These interactions are typically
concentration driven; although the input binding may be more thermodynamically
favorable, the intramolecular binding of the loop to the DNAzyme is kinetically
favorable. This necessitates the high input concentrations in order to bias the
reaction to activate.
Since this demonstration, several other groups have demonstrated
alternative molecular logic gate implementations using DNAzymes, including
DNA ligation37, DNA-cleavage34, and split DNAzymes117. Of particular interest is
the split DNAzymes, which have been developed into large libraries of computing
subunits35,118, even demonstrating operation in a cellular environment119. This
mechanism works by separating the catalytic core of the DNAzyme (either E6 or
10-23) into two subunits. The structure of the DNAzyme is modified slightly in this
case; in addition to the catalytic core there are two input recognition arms
opposite the substrate arms. With the addition of a target input, these arms are
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brought together to reform the catalytic core, which can now cleave the chimeric
substrate. Although this mechanism is highly specific, it also slows down the
catalysis rate of the DNAzyme, likely due to inefficiencies in the reforming of the
catalytic core.
The use of DNAzymes for biomolecular circuit development holds several
key advantages over strand displacement. As DNAzymes can catalyze RNA
hydrolysis in multiple turnover reactions, they provide each logic gate with an
innate signal amplification capability without requiring additional strands in
solution. Signal amplification is especially important for biodetection, where target
strands may be present in low concentrations, which can be anywhere from
nanomolar to femtomolar. The minimization of strands in solution is an important
factor for the development of complex circuits capable of operating in a random
DNA background, as well as for reducing device costs. Furthermore, the
incorporation of DNAzymes into biodetection circuits provides access to the wide
array of DNAzyme-catalyzed reactions, which could lead to the development of
hybrid circuits capable of regulating many different interactions via covalent
chemical modifications.
However, the use of RNA-cleaving DNAzymes poses a significant barrier
to the development of serial logic gates, which is necessary for the
implementation of more complex logic functions. To connect DNAzyme-based
logic gates, there must be an intrinsic mechanism for passing a signal from one
gate to another – a process referred to as cascading. Success in this area has
been limited to split DNAzymes; the first instance sequestered downstream
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activator sequence in a multi-strand complex,35,118 while another developed twolayer cascades where the downstream DNAzyme generated a colorimetric
readout.96 However, the first case uses of a multi-strand complex as the
mediator, which increases the number of strands and the complexity of circuit
preparation, while the second case uses a downstream DNAzyme that prevents
further signal propagation within the molecular circuit, limiting the potential size
and complexity of the circuit. Additionally, the structure of the core and the
interactions with the divalent metal ion cofactors make modeling problematic.
Although the use of DNAzymes presents many exciting opportunities for the
implementation of DNA computation, these technological hurdles must be
addressed for this to remain a viable technology.
1.5 DNA strand displacement
An alternative method for DNA computing is called DNA strand displacement (or
toehold-mediated strand displacement, TMSD)120. This method relies solely on
the thermodynamic favorability of base pair hybridization between multiple DNA
strands121,122. The mechanism is outlined in Figure 1.2. Here, a preformed DNA
duplex, consisting of strands B and C are present in solution. Although most of
the two strands are complementary, there is a small, single-strand region left
unhybridized on strand C, referred to as a toehold. The addition of a third strand
(strand A), fully complementary to strand C, binds to the toehold in a reversible
process. Because strand A and strand B are both complementary to strand C,
they are able to compete for the same binding domain. However, as strand A is
also complementary to strand C in the toehold region, it is able to form a longer,
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more thermodynamically favorable complex. After strand A binds to the strand C
toehold, it initiates a process known as branch migration. After strand A fully
competes off strand B, strand B cannot rebind to the complex as all available
regions are now hybridized, and is therefore released into solution. In this way,
the addition of strand A can be considered the input, while the release of strand
B can be considered the output. This reaction is thermodynamically favorable,
typically through an enthalpy gain through the formation of additional base
pairs123 although entropic gain through the release of strands into solution can be
achieved as well121.

Figure 1.2 – The mechanism of toehold-mediated strand displacement.

Due to the predictability between hybridization reactions and the specificity
with which these reactions proceed, TMSD has become the dominant method for
implementing programmable DNA nanotechnology, including DNA computing.
This mechanism was initially used in the construction of DNA tweezers by Yurke
et al.16, which showed how a nanomechanical process could be cycled multiple
times by the addition of fuel oligonucleotides. TMSD has also been used
extensively in DNA computation, for the construction of Boolean logic gates38, as
well

as

more

complex

circuit

behavior

such

as

thresholding

and

amplification30,31,39,121,124-127. Signal amplification has also been demonstrated
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using a related DNA hybridization technology, catalytic hairpin assembly29-31.
These principles have led to circuits of impressive performance, such as the
calculation of square roots39,124, most notably through the use of the standardized
“seesaw” gate design developed by Qian and Winfree40.
Strand displacement has several advantages over DNAzymes. The use of
thermodynamic principles ensures that reactions can be highly specific and
sensitive without relying on concentration effects to drive the reaction. As the
reactions rely solely on hybridization, strand interactions are relatively easy to
predict, and are amenable to rapid scaling into larger circuits because a
displaced strand can serve directly as the input of another logic gate. Prediction
of these interactions has been aided by the development of structure prediction
and strand displacement modeling software, such as NUPACK4,5,9 and Visual
DSD7,128,129. Using these programs, unwanted interactions can be identified and
addressed. Despite these significant advances, the use of strand displacement
alone in biosensors poses challenges. Although signal amplification has been
demonstrated using strand displacement, it requires an explicit design with
additional strands and reactions38,120,121,126 30,31. This is undesirable for both in vitro
and in vivo biosensors, as it can increase biosensor cost, circuit complexity, and
provide more failure modes for the reaction. The most successful biosensors,
such as molecular beacons130, are single step reactions, illustrating the
importance of minimizing complexity to achieve optimal performance. In addition,
as each of the gates relies only on hybridization this can cause problems with
larger scale circuits, where each additional strand and complex increases the
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probability of cross-reactive sequences. Finally, performance of these circuits
has been significantly improved through the use of PAGE purification of DNA
complexes39, but this is an expensive and time-consuming process. This method
would likely be cost-prohibitive in the development of biosensors and not easily
amenable to large-scale preparation of biodetection devices. It would be highly
desirable to simplify the circuit composition while retaining the signal
amplification properties, all while using low-cost unpurified DNA strands.
1.6 Molecular logic for in vitro biosensing
Although a significant effort has been devoted to the development of DNA logic
gates and many have extolled their potential for in vitro biosensing applications,
the demonstrations of this key concept have been surprisingly limited. Some
forms of DNA computation have been shown to incorporate biological proteins for
the development of in vitro and in vivo synthetic transcriptional circuits56,131-134.
While these circuits display a wide range of interesting computational behaviors,
the use of proteins is less advantageous in the development of biosensors. As
previously mentioned, the complexity of protein folding has prevented the
development of de novo protein-based biosensors, limiting the use of proteins to
the availability of characterized interactions. Although proteins have a wide
diversity of structure and can catalyze many chemical reactions, they are also
much more expensive than nucleic acid probes, requiring a considerable time
and cost investment for the expression, purification, and storage. They typically
operate at physiological temperatures or require the use of temperature cycles
and are typically are stored at cold temperatures, and use at room temperature
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often leads to protein degradation. This requires additional equipment
infrastructure, which may not be available outside of a laboratory setting. DNA,
on the other hand, is highly stable, can easily be lyophilized for long-term
storage, and assays using DNA, even DNA enzymes, can be operated at
isothermal conditions.
There have been several groups that have utilized DNAzymes for in vitro
nucleic acid detection. Gerasimova et al developed a two layer DNAzyme
cascade for the visualization of bacterial RNA. Here, the presence of an RNA
target brought together both detection arms of a split 10-23 DNAzyme117. This
now functional DNAzyme can cleave an inhibited peroxidase-like (G-quadruplex)
DNAzyme, activating the sequence, which can now produce a colored substrate.
Other groups have also used the DNAzymes as visualization probes of DNA
samples54,135-137, however, these examples do not employ molecular logic.
Although there is significant promise in the use of DNA or DNAzyme biosensors,
several basic parameters must be optimized before in vitro and in vivo detection
of real world disease or pathogen signatures. These parameters include, but are
not limited to, detection sensitivity, availability of target sequences, selection of
additional aptamer sequences for small molecules, multi-input integration, gate
and network signal reproducibility, and the compartmentalization of signal
transduction. These wide ranging needs necessitate the continued development
of a variety of DNA computational implementations.
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1.7 Multi-input integration and multiplex analysis
Logic-based integration of multiple inputs is critical for DNA computation to truly
distinguish itself from the myriad of other biosensors for the construction of
intelligent in vitro biosensors. Utilization of multiple input signatures can provide a
more comprehensive understanding of the biochemical environment, beyond the
presence or absence of a given target. Many complex target applications could
take advantage of this property, including in vitro applications such as multi-strain
typing and differentiation as well as in vivo applications such as cancer or autism.
Many conditions are defined by the many targets, due to the up- or downregulation of many different RNA transcripts or the presence of multiple single
nucleotide polymorphisms (SNPs)138,139. While there are many alternative
biodetection methods that offer competitive or even superior sensitivity for
individual targets, including PCR and ELISAs, the use of DNA in molecular
computing devices places it in a unique position for the development of
sophisticated decision networks integrating multiple input signatures.
Although the aforementioned in vivo applications require significant
technological advances for detection and computation to be truly feasible, many
such in vitro sensing applications are possible with current technology.
Particularly of interest are multi-strain pathogens, such as the single-stranded
RNA virus Dengue or Shiga-toxin bearing E. coli (STEC) bacteria. The presence
of four serotypes of Dengue has led to difficulties with the development of
vaccines covering all of the serotypes simultaneously140, and the predominance
of infection in tropical and sub-tropical third world nations necessitates the
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development of comprehensive, low-cost diagnostics assays141-143. Serotyping is
critical as the onset of severe disease states such as dengue hemorrhagic fever
and dengue shock syndrome is generally induced through the infection of
multiple serotypes144. Although O157 is the most prominent and wellcharacterized STEC serotype145,146, over 100 different serotypes have been
implicated in enterohemorrhagic illness147-149. In addition, positive STEC
identification is also dependent on various targets, which differ across
serotypes150-154. Concurrent sensing of all serotypes, including multiple
diagnostic targets, would be a significant benefit for agriculture and food
processing companies, where bacterial culturing can take upwards of two weeks.
Although DNA computation appears well suited to the integration of
multiple inputs, there are significant technological hurdles that must be
addressed for this to be a viable technology. As previously mentioned, the use of
RNA-cleaving DNAzymes presents a significant challenge to the development of
large, multi-input decision networks due to the limitations in gate interactions.
The use of parallel gates limits the logical computation to the number of inputs a
single gate can accept, necessitating the construction of molecular signal
intermediaries that can pass a signal between gates to scale up the complexity of
the circuit. Work in this area remains limited35,96. Although complex strand
displacement circuits have been demonstrated, indicating the potential of
solution-based multi-input detection approach, their use against physiologically
relevant targets has not been demonstrated.
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1.8 Scaling up circuit complexity through compartmentalization
One of the biggest challenges facing DNA computing is the ability to segregate
gates and sequences to prevent spurious interactions. This has hindered the
scaling of size and complexity of solution-based cascades, stunting their
development for multi-input integration and intelligent biosensing applications. In
DNAzyme cascading, compartmentalization has been achieved through the
construction of multi-strand intermediary complexes35, and in TMSD through the
blocking of toehold sequences, referred to as toehold inactivation120. However,
both of these technologies are typically run in a well-mixed solution, which means
that molecules are free to interact at any time. This puts a significant pressure on
the circuit design to sequester hybridization interactions until a specified temporal
activation is desired. Additionally, each component must be designed separately,
typically through the use of different, non-interacting sequences to ensure the
activation of a specific pathway via directed hybridization. This also makes the
scaling of circuits difficult; silicon-based circuits can contain millions of identical
transistors due to their physical segregation on a microchip. Biology employs a
similar solution, achieving physical separation of components into organelles
through the use of biological membranes. It would be highly desirable to apply
the concept of physical compartmentalization to DNA computing as well, which
may enable for the reuse of circuit components.
This concept has been explored by several groups. In the initial
demonstration of DNA logic component compartmentalization, DNA oligomers
may be physically separated on the surface of particles using a non-covalent
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biotin-streptavidin conjugation. In the first demonstration of this approach, Frezza
et al. constructed two layer TMSD cascades attached to sepharose beads,
transmitting a DNA signal from one bead population to another via the addition of
an input strand155. While this demonstrated the feasibility of this approach, the
authors noted a decrease in expected input-to-output stoichiometry as a result of
an increased reaction time. Additionally, the authors noted that supernatant
filtration was required at each step of the cascade to prevent non-specific
interaction. In related work, Stojanovic and colleagues demonstrated a two layer
E6 DNAzyme cascade attached to microspheres, in which the addition of an
input DNA oligomer deprotects a chimeric substrate (RNA/DNA hybrid oligomer),
allowing it to be cleaved from the microsphere surface156. This cleavage product
then can bind to the stem loop of a second E6 DNAzyme on another bead
population, opening the stem loop and activating the DNAzyme. This DNAzyme
can now cleave its corresponding substrate, and the signal exchange between
beads can be measured via fluorescence. Although this was an innovative
method to implement DNAzyme cascades, this required the use of high
concentrations of input, DNAzyme, and substrate. As the beads are immobilized
on the surface, this approach ensures that DNAzymes can only cleave
substrates within their physical proximity, thus a high concentration of DNAzymes
relative to substrates was necessary to ensure this condition. This resulted in the
loss of signal amplification ability, negating one of the strongest advantages of
using DNAzymes.
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Nevertheless, this implementation enabled cascades to be performed
using these DNAzymes while simultaneously simplifying gate structure for such
interactions. These results argue strongly for the potential of physical
compartmentalization for DNAzyme-based cascades and circuits. To overcome
the biggest limitation of this system, the signal amplification issue, the system
would require dynamic interaction of separate components on the surface. This
would enable DNAzyme strands to seek out and bind with multiple substrates on
the surface, while still being constrained to the surface. One possible solution to
this is the use of supported lipid bilayers.
Originally developed by Bayerl and Bloom in 1990157, this technology uses
silica microspheres as a template to adsorb a lipid bilayer to the surface. This
produces a single bilayer mimicking the structure typically found in biology, as
opposed to alternative technologies that use multi-lamellar vesicles. Importantly,
the lipids also retain their natural fluidity158. These bilayers have been used for
many applications, including the study of transmembrane and membraneassociated proteins and dynamics, with potential applications in biosensing as
well159,160. This system appears amenable to bead-based DNAzyme circuits, in
which the lipids provide the lateral fluidity necessary to encourage productive
interactions between multiple substrate molecules via lateral diffusion of DNA
circuits components attached to functionalized lipid head groups.
There are other notable efforts to explore the interface between DNA and lipid
membranes, including both DNA origami161 as well as DNA logic on cell surfaces.
Several

groups

have

constructed
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transmembrane

pores

through

DNA

origami162,163, most notably the creation of a large synthetic lipid membrane
channel detailed in a 2012 Science report from the Simmel group164. For
computation and diagnostic purposes, Rudchenko and colleagues constructed a
strand displacement cascade conjugated to antibodies for cell typing82. As this
field continues to expand and mature, a more detailed understanding of the DNAlipid bilayer interface will be critical for the development of compartmentalized
DNA computers. The continued development of bead-based computation,
combined with multiplexed flow cytometry analysis, may also provide an
additional method for scaling up input detection. Multi-input analysis of
microspheres has been well characterized for flow cytometry, where multiplex
beads sets are commercially available and are able to distinguish between many
different bead populations165. The use of physical separation of computational
and/or detection elements may improve the scaling of target sequences.
1.9 Present Studies
In the work described here, we have created a hybrid logic gate mechanism,
using toehold-mediated strand displacement to regulate the activity of an RNAcleaving DNAzyme. This approach combines the advantages of strand
displacement,

particularly

the

highly

specific,

thermodynamically

driven,

programmable reactions, with the innate catalysis of the 8-17 DNAzyme. We
then utilized this regulation mechanism to create robust multi-layer DNAzyme
cascades through the rational design of a structured chimeric substrate
intermediary, in which we demonstrate the longest DNAzyme cascade to date.
We also developed a new DNAzyme-based gate structure specifically designed
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as an efficient biosensor, capable of integrating directly with our DNAzyme
cascades. Finally, we explore basic principles for the future development of
compartmentalized DNA circuit components using both bead-based and
supported lipid bilayer-based platforms.
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Chapter 2.
Goals and Overview of this Work
The goal of this work is to develop and characterize DNA computational
principles using the class of functional nucleic acids known as DNAzymes,
engineered specifically for the purpose of biodetection and biosensor
development. These implementations would have advantages over existing DNA
circuits as they benefit from a ground-up, rationally designed approach that
contains advantages and considerations specific to use in real-world biodetection
devices. The focus on practical applications ensures that designs have been
tested using minimal purification standards, ensuring reduced cost and time of
preparation. The principles explored here also lay the groundwork for expanded
development of DNA computation for biosensing, and opens the potential for new
DNA computational frameworks.
The

studies

in

Chapter

3,

published

as

a

communication

in

ChemBioChem, describe the mechanism of DNAzyme displacement, which
combines the strengths of DNA strand displacement with inclusion of DNAzymes
for the construction of DNA logic gates. Strand displacement ensures highly
specific and sensitive strand hybridization, relieving the previous issues of high
concentration and competitive hybridization that hindered earlier DNAzyme
regulation mechanisms. The combination of DNAzymes and strand displacement
regulation ensures that the addition of a single input is able to generate multiple
output signals through multiple turnover reactions while minimizing the circuit
architecture necessary to execute this response. This work also introduced the
concept of arbitrary sequence detection through the rational introduction of
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mismatches between the DNAzyme and inhibitor. This has general applications
for strand displacement circuits, whereby the release of a sequence is triggered
by the addition of two unrelated sequences. The functionality of these gates was
demonstrated through the construction of a circuit to evaluate a three-input logic
function. The format of this chapter is as follows: abstract, body of manuscript
(individual sections are not delineated in communications), materials and
methods, acknowledgements, and references. Additional controls, along with the
Supporting Information of the manuscript, are included in Appendix 1. Additional
chapters are formatted in the same manner to ensure consistency throughout
this dissertation.
The work in Chapter 4, accepted as a communication for Angewandte
Chemie International Edition, introduces the design and function of a structured
chimeric substrate (SCS), a single-stranded molecule that can transmit a DNA
signal

between

two

DNAzyme

displacement

gates.

This

enabled

the

straightforward scaling of a DNAzyme cascade, for the construction of a fivelayer cascade, the longest such cascade to date. This has important implications
for DNA computing and protein signaling cascades, as communication between
DNAzymes offers a model framework for the design and construction of synthetic
enzyme networks. This work also demonstrated that the SCS molecule could
communicate between logic gates other than 8-17 DNAzyme displacement
gates. This indicates the feasibility of developing hybrid DNA computational
circuits, including DNAzymes containing different core sequences. This work also
demonstrated the benefit of strand displacement regulation by showing signal
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amplification for each successive layer of a four layer cascade. The SCS signal
transmission was also highly resistant to a random DNA background, which
holds promise for biosensor performance of these cascades in non-pristine
conditions.

Finally, a bioassay circuit was developed to demonstrate the

potential application for pathogen typing, in which a patterned circuit was
implemented against each of the four Dengue virus serotypes. Here, three
synthetic target sequences taken directly from the Dengue genome were used to
test for the presence of a given serotype, with a positive signal attained only in
the presence of all three targets.
Chapter 5 details the rational design process for the design of the SCS
structure. This effort confirmed two key hypotheses for the SCS and DNAzyme
cascades. First, we hypothesized that by focusing on the thermodynamic balance
of the structure between the pre- and post- cleaved states, we could execute a
function specific to a given structure while not specific to the individual
sequences of the structure. In short, the design of a single SCS structure could
be altered to match any two gate sequences. The five layer cascades proved this
hypothesis correct, as each layer used the same SCS structure, each with a
different sequence corresponding to the connecting gates. Second, we
hypothesized that through an iterative process of structural design, we can
achieve the desired kinetic rates in the absence of appropriate modeling
software. This is an important principle for dynamic DNA nanotechnology, as
most software determines DNA hybridization and structure at thermodynamic
equilibrium, we are often unable to reliably predict dynamic structural
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interactions. However, with an understanding of the underlying processes that
govern structural formation and hybridization interactions, the desired results can
still be attained.
After the success of DNAzyme displacement and subsequent cascading,
we redesigned the gate structure to decouple the detection and reporter
domains, referred to as modular gates. Implementation and characterization of
these gates are detailed in Chapter 6. Each gate can now detect an arbitrary
input sequence and serve as an individual biosensor. By disconnecting the
detection and reporter domains, we are free to independently vary either domain.
By fixing the reporter domain while varying the detection domain, we are able to
create a massively multiplexable OR gate, in which the presence of any target
sequence will result in a positive signal. The reporter domain can also vary and
differing substrates can be used to read out results in multiple fluorescent
channels. This new modular gate structure is highly sensitive, achieving an LOD
of 7.4 pM. Gates were suitable for detection of ssDNA, dsDNA, RNA, and small
molecules and initial efforts to cascade modular gates showed promise, as did
their performance in a random DNA background. Structural optimizations
reduced spurious activation and additional improvements are detailed. The new
gate design offers unique advantages for biosensor implementation.
As each DNAzyme is selected under specific circumstances, we
hypothesized that the presence of a scaffold library consisting of millions of small
molecule compounds may elucidate new DNAzyme activity. RNA-cleaving
DNAzymes are orders of magnitude slower than their protein counterparts. This
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is likely due to the underutilization of all available biochemical mechanisms for
the hydrolysis of the RNA base. In Chapter 7, we discuss the results of a highthroughput small molecule screen of the 8-17 DNAzyme. Although we did not
find any compounds that elicited an increase in the catalytic rate of the
DNAzyme, we did find several inhibitors of unknown mechanism. This work may
lead to a deeper understanding of the RNA world hypothesis and the discovery of
new biochemical mechanisms as well as improved practical applications that
may benefit from enhanced DNAzyme catalysis.
The work in Chapter 8 describes initial efforts in DNAzyme and DNAbased circuit compartmentalization. We explore various attachment strategies to
microspheres of both DNA and proteins, including direct bead attachment using
biotin-streptavidin, 6xHis tags/Ni-NTA headgroup labeled lipids for non-covalent
protein attachment and thiolated DNA/maleimide headgroup labeled lipids to
form thioether bonds for covalent attachment to supported lipid bilayers. We
demonstrate the ability to perform strand displacement reactions off microsphere
surfaces and DNAzyme cleavage off supported lipid bilayers. Future work will
expand these efforts to standardize circuit components and improve the potential
of DNA computation through the use of physical separation of components.
Taken as a whole, this work represents a concerted effort to advance the
field of DNA computation for the practical use in biodetection through the
understanding and direction of both the underlying basic science and engineering
principles of DNAzyme activity and regulation. These advances should be
broadly applicable to DNAzymes of similar size and structure, with future
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directions and other targets for biodetection optimization detailed in Chapter 9.
Construction of complex circuit designs and behaviors are ongoing, as are efforts
to use existing designs and cascades for the detection of real-world pathogenic
targets under physiological conditions. Hence this dissertation provides a
comprehensive report of the initial efforts and results for the design,
characterization, and demonstration of DNAzyme-based logic circuits for
biodetection applications.
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3.1 Abstract
Chemical reactions catalysed by DNAzymes offer a route to programmable
modification of biomolecules for therapeutic purposes. To this end, we have
developed a new type of catalytic DNA-based logic gates in which DNAzyme
catalysis is controlled via toehold-mediated strand displacement reactions. We
refer to these as DNAzyme displacement gates. The use of toeholds to guide
input binding provides a favourable pathway for input recognition, and the innate
catalytic activity of DNAzymes allows amplification of nanomolar input
concentrations. We demonstrate detection of arbitrary input sequences by
rational introduction of mismatched bases into inhibitor strands. Furthermore, we
illustrate the applicability of DNAzyme displacement to compute logic functions
involving multiple logic gates. This work will enable sophisticated logical control
of a range of biochemical modifications, with applications in pathogen detection
and autonomous theranostics.
3.2 Body of Manuscript
Biomolecular computing devices show promise for the integrated detection,
analysis, and processing of signals from the chemical environment,1-3 with
applications

in

directed

nanoscale

assembly4-6

and

actuation,7-10

and

autonomous nucleic acid biosensors and theranostics.11-13 A variety of DNAbased computational logic gates have been developed and characterized,
including strand displacement,14-16 hairpin assembly,17-19 ribozymes,20,21 and
DNAzymes22-25. DNA strand displacement is a particularly robust, well-known
method with many advantages for programming reaction pathways in
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biomolecular computing devices.26 Single-stranded domains called toeholds
serve as nucleation sites for invading strand hybridization27,28 and allow
subsequent branch migration reactions to be programmed based on sequence
specificity. The kinetics of toehold-mediated strand displacement and strand
exchange reactions, and their dependence on toehold lengths, have been
previously studied.29 With a judicious choice of toehold lengths, the reaction can
be biased in a particular direction based on thermodynamic considerations14,30
without relying on concentration-driven effects. While circuits based solely on
hybridization and strand displacement are known to exhibit signal amplification
capabilities,15,16,18,19,30-33 these typically require additional strands or structures,
thereby increasing circuit complexity. Furthermore, the ability of pure DNA strand
displacement devices to interface with other chemistries is limited because
strand displacement gates communicate exclusively by means of strand release.
The ability to control other chemical reactions, such as RNA cleavage and
phosphorylation, using DNA strand displacement would be of great interest for
biomedical applications. To address this need, in this paper we use strand
displacement reactions to control the activity of inherently catalytic DNAzymes.
This approach could be applied to exercise control over a range of chemical
reactions catalyzed by DNAzymes, such as cleavage of RNA34,35 and DNA,22,36-38
phosphorylation,39,40 ligation,41 synthesis of branched nucleic acids42 and
peroxidase-like oxidation reactions.43,44 This has potential applications in
synthetic logic circuits for conditional gene silencing, and for support of failing
cellular metabolisms. Our DNAzyme-based approach is much simpler than
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tackling similar problems via de novo protein engineering45, although previous
work has demonstrated computational capabilities using existing protein
enzymes.2,46-48 As shown in Figure 3.1, we inactivate a DNAzyme (Dz) through
hybridization with a partially complementary inhibitor strand (Inh), which binds to
at least one of the substrate recognition arms (the s1 domain) and also deforms
the catalytic core of the DNAzyme (the cc domain). This prevents the DNAzyme
from binding to, and cleaving, its complementary FRET substrate, sequestering
the DNAzyme in a catalytically inactive complex (Dz-Inh). Activating inputs are
single-stranded oligomers (Act) that bind to a complementary toehold (t*) on the
inhibitor strand and initiate branch migration across the s1 and cc domains. This
results in displacement of a catalytically active DNAzyme strand (Dz) from the
complex, which can cleave the complementary substrate (Sub) to produce two
shorter cleavage products (Prod1 and Prod2). We call this process DNAzyme
displacement. Here we focus on the 8-17 DNAzyme,35,49 due to its small size and
high catalytic efficiency (1.35 min-1) in the presence of Zn2+ metal ion
cofactors.50,51 However, our approach is broadly applicable to structurally similar
DNAzymes,

such

as

the

RNA-cleaving

10-23

DNAzymes,22,36-38 ligases,25,41 and peroxidases.43,44
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motif,35,52

DNA-cleaving

Figure 3.1 DNAzyme displacement reaction mechanism. DNAzyme
displacement reaction mechanism. The catalytic activity of the DNAzyme strand
(Dz) is inhibited by hybridization to a partially complementary inhibitor strand
(Inh) with a short overhanging toehold (t*), resulting in an inactive DNAzyme
complex (Dz-Inh). The DNAzyme is activated by a toehold-mediated strand
displacement reaction: an activator strand (Act) binds to the complex (Dz-Inh) via
the t toehold (step 1). The input initiates a branch-migration reaction across the
s1 and cc domains that eventually displaces the DNAzyme strand (Dz), leaving
an inert waste complex (Act-Inh). The DNAzyme strand then folds into a
catalytically active conformation (step 2) and proceeds to bind to substrate
molecules (Sub) and cleave them, producing shorter cleavage products (step 3).
The cleavage reaction causes separation of the fluorophore-quencher pair
attached to the cleavage products (Prod1 and Prod2), which causes an increase
in bulk fluorescence due to loss of FRET.
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We have implemented a set of DNAzyme displacement logic gates complete for
Boolean logic. This expands on previous work in the Ellington group43 by
coupling input logic to the gates, and by displacing DNAzymes which catalyze
nucleic acid reactions that could engage in further logic functions, rather than
producing a colorimetric readout. Here, “true” (logic 1) is encoded by the
presence of a particular input species, and “false” (logic 0) is encoded by the
absence of that species. Figure 3.2A shows the action of a sensor (YES) gate
that accepts an input complementary to the inhibitor strand. When the active
DNAzyme is displaced from the complex, it cleaves a chimeric RNA/DNA
substrate molecule labeled with a FRET pair, producing a fluorescent readout.
Figure 3.2B demonstrates a NOT logic gate, where the input is an inhibitor
strand that binds to the DNAzyme and prevents it from cleaving the FRET
substrate. In Figure 3.2C we implement AND logic by extending the inhibitor to
be complementary to the entire DNAzyme strand, with a toehold at each end (t1
and t2). The active DNAzyme can only be displaced by both input strands
simultaneously, in cooperative strand displacement reactions across the s1 and
s2 substrate binding domains and both halves of the catalytic core (cc1 and cc2).53
The AND gate may respond more slowly because two input strands must
simultaneously bind and completely displace the Dz strand; additionally we
observed direct activator-substrate interactions, likely due to sequence overlap
(Figure A1.1). Importantly, all gates and inputs were ordered and used without
additional purification. This is especially important for cost control and ease of
use in real-world bioassays. We found that adding the inhibitor in 10-20% excess
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relative to the DNAzyme produced optimal performance, as this provides a
sufficient margin of error to accommodate concentration variations between
stocks without the excess inhibitor slowing the response to low input
concentrations (Figure A1.2). DNAzyme displacement gates function well at
near-equimolar concentrations of the gate, inhibitor, and input species because
they rely on thermodynamically driven hybridization to drive the reactions. This
allows us to use multiple-turnover output reactions to signal the presence of low
concentrations of inputs relative to the gate concentration (Figure A1.2), which is
a key consideration in the development of practical bioassays.

Figure 3.2 Logic gates implemented using DNAzyme displacement reactions. A)
The YES gate detects its input via the reaction mechanism shown in Figure 1B.
B) The NOT gate accepts an inhibitor strand as input, which deactivates a
previously active DNAzyme. C) The AND gate has a full-length inhibitor with
toeholds (t3 and t4) on each end, and both input strands must be present to
release the active DNAzyme via a cooperative strand displacement reaction.
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In the experiments discussed above, the input strands had certain sequence
restrictions. To be able to displace the DNAzyme strand from the inhibitor
complex, the input strands shared some sequence with the fixed catalytic core of
the DNAzyme. For practical applications that involve detecting the presence of
arbitrary sequences, such as pathogen markers,11,13 it is necessary to avoid
sequence restrictions. We addressed this by developing a DNAzyme
displacement AND gate that can detect arbitrary input sequences, as shown in
Figure 3.3A. (Similar techniques could be used to develop a YES gate.) The
input strands bind cooperatively to the AND gate as before, but they do not
contain the conserved catalytic core sequence. Hence, they cannot completely
displace the DNAzyme from the complex, and the 15 nt catalytic core of the 8-17
DNAzyme is too long for rapid spontaneous dissociation. Therefore we rationally
introduced mismatched bases in the cc* domain of the inhibitor, producing a
mismatched cc*MM domain. This destabilized the binding between the inhibitor
and the DNAzyme core54 and promoted unbinding of the active DNAzyme while
discouraging rebinding. We also extended the input toeholds to 10 nt to provide
an additional bias towards activation. Figure 3.3B shows the operation of
DNAzyme displacement AND gates based on this principle, with 0, 1, 2, or 3
mismatched bases in the core inhibitor. Since the AND gate inhibitor binds the
entire DNAzyme, mismatched bases in the core do not significantly destabilize
the complex in the absence of inputs and thus we see no signal under these
conditions for each inhibitor variant. As expected, with a fully complementary
inhibitor there is very little activation of the DNAzyme in the presence of both
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inputs. Increasing the number of mismatches increases the activation rate, with 3
mismatched bases giving the fastest response. Figure 3.3C demonstrates that
very little activation is seen with just one input present, hence we obtain AND
logic. Appendix 1 contains a more detailed analysis of the mismatched AND
gate design.
Figure 3.4 illustrates the application of DNAzyme displacement gates to
evaluate a three-input logic function. This circuit uses the AND gate with 3
mismatches from Figure 3.3 in conjunction with the NOT gate from Figure 3.2B,
and an implicit logical OR function is achieved because gates cleave substrates
that are monitored in the same fluorescent channel. This demonstrates the
potential of our approach for precise control of output chemistries by the
calculation of non-trivial logic functions.
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Figure 3.3 Detection of arbitrary input sequences using mismatched inhibitors.
A) Mechanism for an AND gate that detects two arbitrary input sequences. Since
these inputs no longer displace the catalytic core, mismatched bases are added
to the part of the inhibitor strand that binds to the core, to encourage unbinding of
the DNAzyme strand in the presence of both inputs. B) Kinetic traces for the AND
gate design using mismatched inhibitors, for different numbers n=0,1,2,3 of
mismatched bases in the cc*MM domain. For clarity, we only plot the responses
with both inputs present (solid lines) and with neither input present (broken lines
with corresponding colors). C) Complete characterization of the AND gate with 3
mismatched bases in the cc*MM domain. We still see very strong inhibition of the
AND gate in the presence of a single input, even when 3 mismatches are present
in the inhibitor
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Figure 3.4 Demonstration of a logic computation using DNAzyme displacement
gates. A) Diagram of example logic circuit. B) Experimental validation of the
corresponding DNAzyme displacement circuit. Responses below the broken red
line are interpreted as Out=0 and those above are interpreted as Out=1. The
circuit responds correctly for each input combination, with a high signal-to-noise
ratio. The fluorescence value in the fourth column is higher because both the
AND gate and the NOT gate are active simultaneously in this case, resulting in
both substrate populations being cleaved to produce a higher overall
fluorescence level.
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In summary, we have demonstrated that toehold-mediated strand displacement
reactions are a robust, programmable means of regulating the catalytic activity of
DNAzymes. Previous work on DNAzyme-based logic has used a number of
control mechanisms, such as intramolecular loop-based inhibition24,55 and selfassembly of multi-component DNAzymes in the presence of inputs.56-58 Loopinhibited DNAzymes have been used in DNAzyme logic circuits23,59-61 and
decision-making automata.55,62,63 While the scale and performance of such
circuits has been impressive, they typically require high (µm) input concentrations
so that input binding overcomes the intramolecular loop re-inhibition reaction,
which makes them less suited to biosensor applications. Applications of multicomponent DNAzymes to amplified detection of low concentrations of DNA
typically introduce autocatalysis to compensate for this, for example using ligase
DNAzymes64-66 or assembly of larger structures.67-69 In our approach, controlling
toehold lengths allows reaction pathways to be directed based primarily on
thermodynamic considerations rather than concentration gradients, which also
allows detection and amplification of nanomolar concentrations of inputs using
DNAzyme and inhibitor concentrations also in the nanomolar range. Rational
introduction of mismatched bases allows rapid detection of arbitrary input
sequences, and the inherent catalytic activity of DNAzymes allows amplifying
sequence detectors to be constructed with minimal design effort and without
extensive purification of strands or complexes. This work will enable DNA strand
displacement circuits to be used to control a range of DNAzyme-catalyzed
chemical reactions.
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The mechanism and potential utility of DNAzymes for in vivo theranostics
remains an open area of research, due to their dependence on millimolar
concentrations of divalent metal cations.70-74 In particular, the 8-17 DNAzyme
performs optimally in the presence of Zn2+,51 which may not be available in the
intracellular environment. However, the performance of the 10-23 DNAzyme has
been investigated in physiological conditions75-77 and, due to its size and
structural similarity to the 8-17 DNAzyme, the 10-23 DNAzyme should also be
amenable to regulation by DNAzyme displacement35,78. In vitro evolution
experiments under stringent physiological conditions or using directed targets
may also yield additional potential candidates.79 If these potential issues are
resolved, these techniques may find applications in synthetic cellular regulatory
networks and isothermal, nucleic acid-based, amplified detection of viruses and
other pathogens.
3.3 Materials and Methods
3.3.1 Oligonucleotide sequences and sequence design.
Conserved sequences for the catalytic core of the 8-17 DNAzyme were obtained
from the literature51. Sequences for the remaining domains were analyzed using
the NUPACK web server80,81 and manually optimized to limit the formation of
unwanted secondary structure. All oligonucleotides were purchased from
Integrated DNA Technologies (Coralville, IA). DNAzymes, inhibitors, and input
strands were ordered purified with standard desalting. DNA/RNA chimeric FRET
reporter substrates were ordered purified using RNase-free HPLC. All sequences
are listed in Appendix 1, along with their respective concentrations in each
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experiment. Oligonucleotides were resuspended in RNase-free H2O (SigmaAldrich) in accordance with the manufacturer-provided specifications at a stock
concentration (50 µM). Working stocks were made by adding the resuspended
oligonucleotide solution (50 µL) into buffer (950 µL). All reactions were run in a
buffer of NaCl (1M), HEPES (50 mM), and ZnCl2 (1mM), at pH 7.0.
3.3.2 Logic Gate Preparation.
DNAzyme-inhibitor complexes were prepared by annealing the DNAzyme and
inhibitor strands at 95 °C for 3 minutes on a heat block and cooled to room
temperature over a minimum of 90 minutes to anneal.
3.3.3 Logic Gate Characterization Assays.
Characterization of logic gate behavior was monitored as a time-based kinetic
loss of FRET assay using a chimeric DNA substrate with an RNA base at the
cleavage site. Dequenching of a 5’ FAM group by the 3’ TAMRA group indicated
cleavage. Reagents were added in the order of logic gate, input, and subsequent
addition of substrate to initiate the reaction. Characterization of individual logic
gates (Figure 3.2) was performed on a PTI (Birmingham, NJ) Quantamaster-40
fluorimeter at an excitation wavelength of 492 nm and an emission wavelength of
518 nm. Characterization of concentration profiles (Figure A1.2), the AND gate
for detection of arbitrary sequences (Figure 3.3), and the logic circuit
demonstration (Figure 3.4) were taken on a Spectramax M2e plate reader
(Molecular Devices, Sunnyvale, CA). In the experiment demonstrating input
signal amplification (Figure A1.2), each kinetic trace was baseline-subtracted
from the first point of that trace.
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3.3.4 Logic Circuit Demonstration.
The circuit was set up in a manner similar to the logic gate characterization
experiments. Gates were added first, followed by input, in the concentrations
denoted in Table A1.5. To assess the final state of the circuit, inputs were
allowed to react with gate complexes in the absence of reporter for 15 minutes.
Upon addition of substrate, an endpoint fluorescent value was taken after 15
minutes. The t=0 fluorescence value for the case where IN1=0, IN2=0 and IN3=1
was used as a baseline (since in this case we would expect minimal DNAzyme
activity) and this value was subtracted from all of the endpoint fluorescence
values.
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4.1 Abstract
Signal propagation through enzyme cascades is a critical component of
information processing in cellular systems. Although such systems have potential
as biomolecular computing tools, rational design of synthetic protein networks
remains infeasible. DNA strands with catalytic activity (DNAzymes) are an
attractive alternative, enabling rational cascade design through predictable basepair hybridization principles. Multi-layered DNAzyme signaling and logic
cascades are now reported. Signaling between DNAzymes was achieved using a
structured chimeric substrate (SCS) that releases a downstream activator after
cleavage by an upstream DNAzyme. The SCS can be activated by various
upstream DNAzymes, can be coupled to DNA strand-displacement devices, and
is highly resistant to interference from background DNA. This work enables the
rational design of synthetic DNAzyme regulatory networks, with potential
applications

in

biomolecular

computing,

biodetection,

and

autonomous

theranostics.
4.2 Body of Manuscript
Cells use enzymatic signaling pathways for a number of critical functions,
including detection of environmental stimuli, signal amplification, and regulated
information propagation through the intracellular environment. Cells typically
implement these functions using proteins, but the complexity of protein folding
makes the rational design of protein-based signaling cascades infeasible1.
Although prior work on biocomputing devices using naturally occurring proteins
shows promise2-6, this approach is limited by the possible protein-protein
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interactions. DNA, on the other hand, is an ideal alternative engineering material
for de novo design of synthetic enzymatic cascades, thanks to predictable
Watson-Crick base pairing and secondary structure formation. Synthetic analogs
of some basic cellular processes have been implemented in DNA, including
computation,7-9 self-assembly,10,11 locomotion,12-17 small molecule sensing,18-22
and

catalysis23-25.

Here

we

focus

on

DNAzymes26

(also

known

as

deoxyribozymes), which are single-stranded DNA molecules that can catalyze
many of the same reactions as protein enzymes27-30 and have been used for
computation in parallel gate arrays.9,31,32 We report a DNAzyme cascade system
that uses structured, single-stranded substrates to sequester activating
sequences and to propagate an activating signal to a downstream DNAzyme
when cleaved by an upstream DNAzyme. We have developed multi-layer
signaling cascades and logic circuits, in which a conformational change in a
molecule propagates information downstream, mimicking biological systems that
rely on modifications such as phosphorylation of downstream enzymes to
propagate information.
We based our designs on the most widely used family of DNAzymes:
RNA-cleaving DNAzymes. With appropriate metal cation cofactors, these
DNAzymes cleave RNA or chimeric DNA/RNA substrates in a multiple-turnover
reaction, providing built-in signal amplification capabilities. For a given catalytic
motif, DNAzyme-substrate pairs can be designed by simply choosing appropriate
complementary sequences for the substrate and the substrate-binding arms of
the DNAzyme. This is considerably simpler than designing enzyme-substrate
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pairs de novo by protein engineering. We used the 8-17 RNA-cleaving DNAzyme
due to its compact size and efficient catalytic rate.33-35
This work is built on previous work on ribozyme circuits36,37 and on
DNAzyme signaling cascades that either sequestered the downstream effector
sequence in a partially complementary complex,38,39 or built two-layer cascades
where the downstream DNAzyme generates a colorimetric readout.40 In the first
case, the use of a multi-strand complex as the mediator increases the number of
strands and the complexity of circuit preparation. In the second case, the
downstream DNAzyme cannot propagate the signal further within the molecular
circuit. Although signal amplification has also been demonstrated using DNA
strand displacement25,41-43 and catalytic hairpin assembly,44,45 these circuits must
be specifically designed to obtain catalysis, for example, using seesaw
gates.7,8,46 We use DNAzyme displacement reactions,47 which combine the
advantages of strand displacement to program reaction pathways with the
inherent catalytic ability of DNAzymes. This reduces the number of DNA strands
needed to achieve signal amplification.
In cellular enzymatic signaling cascades, an activation signal is typically
passed from one enzyme to another through chemical modifications. In this work,
information propagation between enzymatic units through the covalent
modification of a structured chimeric substrate (SCS). The SCS uses a
metastable dual stem-loop design48,49 (Figure 4.1a) and comprises several
domains that make up interchangeable input and output modules. The use of a
modular intermediary simplifies the design process by removing the need for
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direct enzyme-enzyme interactions, which are often found with protein-based
cascades, such as phosphorylation in the MAPK pathway.50 The inner 7bp stem
and 8bp loop constitute the output module, whose secondary structure weakly
sequesters a downstream activator. The outer 7bp stem and 6bp loop stabilize
the structure and protect the activator toehold in the outer loop, thus preventing
unwanted interactions with the downstream DNAzyme before cleavage. The
outer stem and loop also constitute the input module, with a substrate-binding
and -cleavage domain for an upstream DNAzyme. We minimized the size of the
outer loop to better protect the toehold, which led to a 5bp overlap between the
upstream DNAzyme binding arm and the downstream inhibitor toehold
sequences. As shown in Figure 4.1b, an upstream DNAzyme interacts with the
SCS when one of the 8bp substrate binding arms hybridizes with the 4bp
outermost toehold and opens the outer stem via a toehold-mediated strand
displacement reaction.42 The second arm binds the outer loop, linearizing the
substrate domain and correctly positioning the SCS cleavage site opposite the
catalytic core of the DNAzyme. The subsequent cleavage reaction causes the
outer stem to dissociate as waste, freeing the protected toehold in the outer loop
of the SCS, which can now hybridize to its complement more effectively. The
relatively weak secondary structure in the activator released by SCS cleavage
allows it to interconvert between hairpin and linear structural forms. Thus,
downstream interactions are not impeded by secondary structure in the activator.
This mechanism is particularly suited for use with our previously reported
DNAzyme displacement logic gates,47 in which DNAzyme catalysis is controlled
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using toehold-mediated DNA strand displacement reactions.42 The activator
released by SCS cleavage binds to the toehold of the downstream DNAzymeinhibitor complex and undergoes branch migration to displace a catalytically
active DNAzyme strand, producing an inert waste complex (Figure 4.1c). The
displaced DNAzyme refolds into a catalytically active conformation and can then
cleave its own substrate. Thus, activation of one DNAzyme species causes the
activation of a second DNAzyme species, implementing signal propagation.
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Figure 4.1 - SCS design and mechanisms for SCS cleavage and DNAzyme
displacement. a) Design of an SCS to enable signaling between DNAzymes. The
SCS consists of an outer stem and loop, which make up the upstream DNAzyme
binding domain (red), and an inner stem and loop, which sequester a
downstream activator sequence (blue and black). The cleavage site is located
towards the inner end of the outer stem. The grey cage sequence is chosen to
fold into the desired structure, producing a topological constraint on the
downstream reaction kinetics that is undone when the SCS is cleaved by the
upstream DNAzyme. b) Mechanism of cleavage of the SCS by an upstream
DNAzyme (Dz). The upstream DNAzyme binds to the outer stem and loop by
toehold-mediated strand displacement. The cleavage reaction produces a waste
strand and an activator strand (Act). In the activator structure, the outer loop has
been released from the topological constraint previously imposed by the outer
stem, making the downstream toehold in the outer loop available to bind with a
downstream circuit element. c) DNAzyme displacement reaction mechanism.
The catalytic activity of the downstream DNAzyme strand (Dz2) is inhibited by
hybridization to a partially complementary inhibitor strand (Inh) with a short
overhanging toehold. Activation occurs by a toehold-mediated strand
displacement reaction: An input strand (Act) binds to the complex (Dz2-Inh)
through the toehold. The input initiates a branch-migration reaction that
eventually displaces a catalytically active downstream DNAzyme strand (Dz2),
leaving an inert waste complex (Act-Inh). The DNAzyme strand then folds into a
catalytically active conformation and proceeds to bind to substrate molecules (S)
and cleave them, producing shorter cleavage products (P1 and P2). The cleavage
reaction causes separation of the fluorophore-quencher pair attached to the two
ends of the substrate, which isobserved as an increase in bulk fluorescence due
to a loss of fluorescence resonance energy transfer (FRET).
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For correct behavior in synthetic multi-enzyme systems, each enzyme
must interact with its intended substrate with high specificity. In protein-based
enzymatic cascades, specificity is derived from complex interactions between the
secondary and tertiary conformations of both enzyme and substrate, rendering
rational design of such interactions infeasible. DNAzyme-based cascades
achieve specificity through sequence-specific hybridization to substrates. We can
modify the SCS input and output modules to enable signaling between
DNAzymes with different substrate binding arms while keeping the SCS structure
intact. As the SCS does not need to be redesigned for each subsequent layer,
this enables rapid construction of two-, three-, four-, and five-layer linear
DNAzyme signaling cascades, each initiated by the addition of active top-layer
DNAzymes (Figure 4.2). Each cascade uses the same reporter layer (layer 1),
with layer n+1 added upstream of layer n to extend the cascade. This naming
system reflects the sequence commonality between each n layer, irrespective of
cascade length. Our five-layer cascade is the longest DNAzyme signaling
cascade implemented to date. The development of extended catalytic signaling
cascades with a high signal-to-noise ratio is challenging because unwanted
signal generated in the absence of input (leakage) is also amplified by
downstream circuit elements. Kinetic traces of multi-layer cascades (Figure
4.2b) show that the time taken for cascade execution increase with the number
of layers (Supplementary Discussion in Sections A2.2.11-13). Lower DNAzyme
concentrations reduce leakage at the expense of activation speed by relying on
multiple-turnover cleavage for signal amplification (Figure A2.1). In particular,

64

using lower concentrations in the upstream layers of the cascade with increasing
concentrations in each downstream layer can reduce leakage without affecting
the maximum output level or a significant sacrifice in speed (Figure 4.2c).
Additional controls using uncleavable SCS molecules demonstrate that cleavage
is necessary for signal propagation (Figure 4.2). Therefore, we have
demonstrated that chemical modification of a structured substrate by a DNAzyme
can be used to propagate information in a signaling cascade.
As DNA interactions are sequence-specific, the SCS can interact with any
upstream or downstream circuit components with the correct sequence. We
implemented signaling cascades between a variety of DNA logic components in
both the upstream and downstream positions, including various DNAzyme logic
gates and a strand displacement reporter gate (Figure A2.3). This demonstrates
the flexibility of DNAzyme-based interactions via the SCS, which enables
development of hybrid DNA circuits comprising components from multiple
architectures, which is currently a significant challenge.
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Figure 4.2 - Demonstration of DNAzyme signaling cascades. a) Multi-layer
DNAzyme signaling cascades using DNAzyme displacement reactions. Initial
species for each layer of the cascade are highlighted in grey boxes. In each
layer, an active DNAzyme cleaves the corresponding SCS, producing an
activator that releases the downstream DNAzyme from its catalytically inactive
enzyme-inhibitor complex via a DNAzyme displacement reaction, thereby
propagating the activating signal to the next layer of the cascade. b) The mean
fluorescence signal (solid lines) from two-layer (blue), three-layer (red), four-layer
(green) and five-layer (orange) linear DNAzyme signaling cascades with
equimolar (100 nM) DNAzyme concentrations in each layer. The dashed line
represents the same reaction without the top-layer active DNAzyme, which
measures the non-specific activation (leakage) of the downstream circuit. The
dotted lines represent the 95% confidence interval from three replicate
experiments. c) Kinetic traces for multi-layer linear DNAzyme signaling cascades
with increasing DNAzyme concentrations in each layer (25 nM in fourth layer, 50
nM in third, 75 nM in second, and 100 nM in first) to demonstrate signal
amplification. In both plots, dotted lines represent the 95% confidence interval
from three replicate experiments.

66

Multi-layer synthetic DNAzyme logic cascades offer a route to increasing
the sophistication of biomolecular logic circuits, with the long-term aim of
enabling robust, isothermal detection of disease states via sequence-specific
nucleic acid detection40,51-55 or aptamer-based detection of small molecules.18-20
Incorporating logic into enzymatic cascades enables the integration of multiple
input signals, which can reduce false positives in bioassays and enable detection
of disease states where a single target is insufficient for an accurate diagnosis.
To illustrate the potential of DNAzyme logic cascades for detecting multiple
pathogenic targets in extracted DNA, we implemented multi-layer circuits for
typing representative pathogen signatures from all four dengue virus serotypes
(DEN1-4). Dengue is a major global health concern,56 and accurate serotyping
isimportant because sequential infection with different serotypes is a risk factor
for dengue hemorrhagic fever and dengue shock syndrome, both of which can be
fatal.57
We exploited the modularity of the SCS to design a two-layer, three-input
AND circuit template, in which two DNA oligomers derived from conserved
sequences within the ssRNA dengue genomes and a serotype-specific DNA
oligomer must be present to produce a fluorescent output. As shown in Figure
4.3a, each layer of the circuit is an AND gate activated by two inputs in a
cooperative displacement reaction.58 The use of mismatches in the inhibitor is
required for rapid release of the DNAzyme, because the catalytic core is not
displaced by either input.47 One of the inputs of the downstream gate is released
upon cleavage of the SCS. We replicated this template, modifying the highlighted
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parts of the upstream AND gate and the SCS, to produce four circuits, each
sensitive to a different serotype-specific target sequence (Figure A2.4). We
observed strong positive responses from all four circuits in the presence of all
three signatures, at least 2.5 times the maximum response seen in the absence
of one or more signatures (Figure 4.3b). Higher leakage is seen in the presence
of the downstream DengueB input, suggesting that there is some interaction
between the SCS and the downstream AND gate prior to SCS cleavage.
Misfolding of SCS or enzyme strands reduced system performance (Figure
A2.5), showing that optimization of the predicted secondary structure is important
for efficient circuit operation.

68

Figure 4.3 – Exemplary application of the SCS in a multi-layer diagnostic logic
circuit. a) Design of multi-layer diagnostic logic circuits for detection of sequences
from the genomes of all four dengue serotypes. The circuit template for serotype
DEN-k (k=1,2,3,4) requires the presence of two conserved sequences from the
dengue viral genome (DengueA and DengueB) and one sequence specific to the
serotype of interest (DEN-k). This is implemented by DNAzyme displacement
“AND” gates with mismatched inhibitors,[47] which are connected by a SCS
molecule. When both upstream inputs are present, the active upstream
DNAzyme cleaves the SCS, producing an activator that serves as one input to
the downstream gate. If the second input to the downstream gate is also present,
the downstream DNAzyme will be activated, which is observed by a loss of FRET
following substrate cleavage. The upstream AND gate uses the three-mismatch
design, characterized in our previous work,[47] whereas the downstream gate
uses an asymmetric pattern of mismatches because the activator produced by
the SCS only partially displaces the catalytic core. We derived detection circuits
for all four dengue serotypes (DEN1-4) by modifying only the domains
highlighted in yellow. b) Demonstrations of serotyping circuits for DEN1-4, which
show correct operation of all four instantiations of the three-input AND circuit
template. Each serotyping circuit was characterized using all eight combinations
of the two conserved sequences and the correct serotype-specific sequence.
Variations in the normalized fluorescence levels (i.e., different levels of activation
and leakage) may be attributed to variations in the stability of the corresponding
SCSk structure in each case. Error bars represent the 95% confidence interval
from three replicate experiments.
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To test our approach in a minimal biological background, we implemented
a two-layer DNAzyme cascade using the SCS with increasing amounts of
random background DNA (Figure A2.6). This models a common detection
scenario in which all the nucleic acids have been extracted from a sample for
analysis. We showed that the SCS design is sufficient for this minimal assay
detection environment. Furthermore, all experiments described herein were
performed using minimal oligonucleotide purification techniques, which is
essential for the development and use of low-cost bioassays. Therefore, we have
demonstrated two key properties for a practical bioassay: robust operation in
background and straightforward preparation.
In summary, we have developed a method to design extended DNAzyme
signaling cascades that exhibit many of the functionalities of cellular cascades:
integration of multiple input signals, signal amplification, transduction, and
propagation. The combination of DNAzymes, strand displacement and rationally
designed, structured chimeric substrates enabled us to implement synthetic
signaling cascades compatible with a variety of DNA logic gates, including the
longest DNAzyme signaling cascade demonstrated to date. These DNAzyme
cascades hold promise for practical applications such as pathogen detection. We
illustrated this by demonstrating that our circuits resist background interference
and can implement multi-input, multi-layer detection of multiple pathogen
signatures.
Future work will explore the operation of DNAzyme cascades in
physiologically relevant conditions59 such as cell lysate60 or serum, which may be
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challenging due to the presence of nucleases that may degrade circuit
components, or because of insufficient concentrations of the metal ion cofactors
required for efficient DNAzyme catalysis.61,62 Furthermore, the modular design of
the SCS should allow the implementation of increasingly complex synthetic
DNAzyme signaling networks, incorporating network motifs such as feedforward
and feedback cycles.63 These circuits could exhibit non-trivial dynamic behaviors
to enable more sophisticated decision-making for diagnostic and therapeutic
applications, possibly connected to alternative readout technologies such as gold
nanoparticles64-67 or paperfluidic devices.51,68
4.3 Materials and Methods
4.3.1 Description of Materials
All oligonucleotides were purchased from Integrated DNA Technologies
(Coralville, IA). Oligonucleotide sequences are listed in Tables A2.1-A2.8.
DNAzymes and inhibitors were purchased with standard desalting whenever
possible, with the exception of oligonucleotides that exceeded 60 base pairs in
length (which were PAGE purified by the manufacturer, in accordance with the
manufacturer’s recommended procedures). All DNA/RNA chimeric substrate
molecules (SCS molecules and fluorescent reporter substrates) were purified by
RNase-free HPLC by the manufacturer. The fluorescent reporter substrates were
labeled with a 5’ FAM quenched by a 3’ TAMRA fluorophore. Oligonucleotides
were resuspended in RNase-free H2O (Sigma-Aldrich) in accordance with the
manufacturer-provided specifications at a stock concentration of 50 µM. Working
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stocks were made by adding 50 µL of the resuspended oligonucleotide solution
into 950 µL buffer.
4.3.2 Preparation of DNAzyme-inhibitor complexes and SCS molecules
DNAzyme strands and inhibitor strands were pre-complexed by heating the
DNAzyme and inhibitor strands together at 95 °C for 3 minutes on a heat block,
and subsequently annealing by cooling to room temperature over a minimum of
90 minutes. In many cases, an excess of inhibitor relative to DNAzyme was
used, to ensure complete inhibition of the DNAzymes – in these cases, the
resulting solution of DNAzyme-inhibitor complexes and excess free inhibitor
strands was used without further purification. Single-stranded SCS molecules
(and loop-inhibited DNAzymes) were prepared using the same heating and
annealing protocol.
4.3.3 Assay conditions and instrumentation
All assays were performed at room temperature (23 °C) in a buffer of 1M NaCl,
50 mM HEPES, 1 mM ZnCl2, pH 7.0. Fluorescence was read either on a
Quantamaster 40 fluorimeter (PTI, Binghamton, NJ) in a 300 µL reaction volume
or Spectramax M2e fluorescent plate reader (Molecular Devices, Sunnyvale, CA)
in a 200 µL reaction volume. In all cases, fluorescein emission was monitored at
492 nm excitation and 518 nm emission wavelengths. Full details of assay
conditions for individual experiments are listed in Appendix 2.
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Chapter 5.
Design Principles of DNAzyme Cascading
5.1 Introduction
The innate ability of DNAzymes to catalyze a variety of reactions1-4 makes them
an attractive candidate to make molecular-scale decisions about the biochemical
environment5; as such, use of DNAzymes for molecular logic has been well
represented in the scientific literature6-16. Despite a few notable exceptions17,18,
the RNA-cleaving family of DNAzymes remains the most widely used and best
characterized, due to their small size, rapid turnover rate, and potential
therapeutic interest16,19. While these DNAzymes make excellent individual logic
gates, their catalytic mechanism hinders the development of more complex
circuits that require the interaction of multiple logical elements.
For multiple RNA-cleaving DNAzyme logic gates to interact, the cleavage
of one DNAzyme (referred to as the upstream position) must result in the
modulation of activity of a second DNAzyme (downstream position). However,
this is a difficult engineering challenge, as the cleavage of a DNAzyme substrate
results in the formation of two shorter product strands. Thus, the longer, precleaved substrate must be prevented from interacting with the downstream
DNAzyme, while the shorter, cleaved product must rapidly initiate this reaction.
While several groups have sought to address this problem, they require high
input concentrations, additional strands (which increase circuit complexity), or are
unable to further propagate a logic signal, each of which are undesirable for use
in biodetection assays13,20,21.
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The approach to implementing a DNAzyme cascade was detailed in
Chapter 4. Briefly, we used the 8-17 DNAzyme22-24, regulated by DNAzyme
displacement25, as the logical element. To connect two of these gates, we
rationally designed a structured chimeric substrate (SCS) to act as a signal
intermediary between the two DNAzymes. This chapter focuses on the
engineering challenges and rational design approach employed to construct an
efficient, modular SCS design for DNAzyme displacement gates.
5.2 Results
5.2.1 Definition of Initial Objectives and Constraints
The first step in DNAzyme communication was to outline the desired objectives,
identify associated constraints imposed by these objectives, and propose
structural features that could theoretically satisfy these constraints. The
overarching objective was to create a mechanism by which DNAzyme-based
logic gates could be easily scaled into complex decision networks. The
performance of these networks must also be suitable for biodetection; this
required circuits to operate at equimolar component concentrations and to be
amenable to low input and gate concentrations (nM, pM) with little to no loss in
circuit performance. This prevented a reliance on concentration effects to force
binding interactions, instead forcing the design of the system to handle these
interactions. The design of a system capable of executing these two main
objectives required a careful balance of interacting components; therefore we
decided to create a separate molecule capable of transmitting information
between one DNAzyme and another. While other systems were amenable to
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direct modification of the DNAzyme gate structure, this would make the task of
scaling up much more difficult6,7,9. However, by designing each interaction
separately, the identification of a mechanism that achieved productive interaction
should lend itself to rapid scaling, so long as each interaction satisfied the same
basic structural and mechanistic constraints. Thus, we removed the emphasis on
specific sequences and thermodynamic stability, increasing the potential
interactions that could be successfully employed by this regime.
After we designed the DNAzyme displacement method of regulating
DNAzyme activity to be compatible with these larger objectives (detailed in
Chapter

3),

we

identified

the

specific

objectives

necessary

for

the

communication of two DNAzyme displacement gates. As the inhibitor of the
downstream DNAzyme gate is removed by a complementary activator sequence
through strand displacement, we decided to sequester the activator sequence
using the secondary structure of the intermediary. This intermediary molecule
also had to contain an RNA base and a complementary sequence to the
substrate binding arms of an upstream DNAzyme. Binding and cleavage by the
upstream DNAzyme to our intermediary molecule then had to result in a
structural change that released the activator sequence, making it available to
now bind the downstream gate. Hence, we named this intermediary a structured
chimeric substrate (SCS), reflecting the nature and function of this molecule.
The first two objectives for the SCS design were mechanistic: an upstream
DNAzyme must cleave the SCS and this cleavage product must activate a
downstream DNAzyme. The third objective was to optimize the kinetic rates
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corresponding to these mechanistic objectives with regards the interaction with
the downstream gate: the pre-cleaved SCS should bind at a low kinetic rate
(leakage), while the post-cleaved SCS product should bind at a high kinetic rate
(activation). These rates are determined by the relative thermodynamic stability
of the hybridization interactions. Before SCS cleavage, the retention of the
secondary structure of the SCS via intramolecular interactions should be
thermodynamically favorable. After cleavage, the interaction of the SCS product
and the downstream inhibitor should be thermodynamically favorable. Therefore,
the SCS structure was designed to balance the thermodynamic stability of the
pre-cleaved state to minimize leakage and the post-cleavage state to maximize
activation.
However, these rates are not mechanistically symmetrical (Figure 5.1).
The rate of activation is complex, multi-step process, initiated via a binding step
between the upstream DNAzyme and the SCS. After the DNAzyme is stably
bound, it must then hydrolyze the RNA base. This is the rate of cleavage by the
DNAzyme, which is affected by many factors, such as the type of DNAzyme
used, buffer conditions, and orientation of the DNAzyme-substrate complex, as
detailed in Chapter 7. The DNAzyme must then dissociate from the cleaved
products, a rate dependent on the length of the DNAzyme binding arms.
Rebinding of these sequences after dissociation is highly unlikely, due to the
short product hybridization lengths and relatively low concentration in solution.
Finally, the activator is now available to hybridize to the toehold of the
downstream inhibitor and undergo strand displacement. After this DNAzyme is
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released, there is a subsequent binding, cleavage, and product dissociation step
of the FRET substrate. The rate of substrate cleavage of the activation pathway
reflects the combined rate from all of these steps and can be treated as a single
rate of activation.
Opposite the rate of activation is the rate of gate leakage, defined only by
the relative thermodynamic stability of the SCS secondary structure and its ability
to bind to the downstream inhibitor toehold. If fluctuations or imperfections in the
SCS structure were to expose the toehold, the activator sequence would be able
to displace the downstream inhibitor (Dz/INH), leading to the productive release
of the downstream DNAzyme (Dz). Although the individual rates of each of these
steps correspond to the same steps in activation, the lack of SCS cleavage
means the entire sequence remains intact during this process. As the additional
sequence and structure likely ensures a different rate constant than with the
cleavage product, this interaction may not occur in exactly the same manner.
Although binding to the toehold remains the most likely mechanism for inhibitor
displacement, invasion through the core sequence from DNA breathing may also
occur. The rational design process to obtain the structure that best satisfies these
constraints is detailed below. This chapter characterizes major design iterations;
detailed modifications of each version can be found in Appendix 3.
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Figure 5.1 – A schematic mechanism depicting the physical processes
associated with both activation (right side) and leakage (left side) rates derived
from the SCS structure. Although the SCS structure is drawn as the dual stem
loop in this figure (Design 8), reflecting the most successful structure, the actual
structure varies according to each specific design. The activation rate is defined
as the kinetic rate of signal activation, beginning with the addition of the upstream
DNAzyme (red). The leakage rate is defined as the kinetic rate of spurious
activation of the downstream gate by the SCS in the absence of the upstream
DNAzyme. In both cases, the activator is sequestered in the SCS and can
hybridize to the downstream inhibitor in the inactivate DNAzyme complex (Inh)
which releases the downstream DNAzyme. This DNAzyme can now hybridize
and cleave the reporter substrate, leading to a loss of FRET and an increase in
fluorescence. The rational design process is employed in this chapter to optimize
these rates, to achieve maximum activation while minimizing leakage.
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5.2.2 Rational design of SCS structure for DNAzyme displacement gates
The rational design process of the SCS structure was to determine the most
efficient way to sequester the activator sequence, while also enabling cleavage
to release the activator. Initially, the activator sequence was 24 bases long, made
up of a 5bp toehold, an 8bp substrate binding arm, and an 11 bp core sequence.
The first two major design iterations used this activator sequence. Subsequent
optimization of DNAzyme displacement gates reduced the necessary length of
the activator to 20 bases, removing 4 bases from the core displacement
sequence. As the DNAzyme displacement gates are regulated by toeholdmediated strand displacement, the availability of the activator toehold was
identified as the most likely method for designing the SCS structure that satisfied
all prior objectives.
The first attempt to design an SCS for communication between two
DNAzyme gates used a stem loop structure, with a 26 bp loop and a 13 bp stem.
Using the 24bp activator, the toehold, along with a significant portion of the
activator, was sequestered in the stem. The remainder of the activator continued
into the loop. The loop also contained the RNA cleavage site and substrate
binding arms of the upstream DNAzyme (Design 1, Figure 5.2A). The
postulated mechanism for this SCS structure was for the upstream DNAzyme to
bind to the loop and cleave the RNA base in the loop. This would split the stem
loop into two strands, which could then dissociate and diffuse away from each
other. Once the strands unbound, the toehold of the activator was free to
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hybridize to the downstream Dz-Inh complex and displace the inhibitor, releasing
an active DNAzyme.

Figure 5.2 – Representation of the activation and leakage mechanisms can be
found in Figure 5.1. (A) This SCS design was a stem loop design, in which the
upstream DNAzyme bound to the loop of the SCS. The target structure (left) was
implemented with the given sequence (center) producing the MFE structure
(right). The red circle denotes the beginning of the activator toehold; the end of
the activator sequence is denoted by the red square. The red star marks the
cleavage site. (B) Response of Design 1 over 60 min. Although activation was
achieved, the rate is very slow, likely due to the inefficiency of stem loop
cleavage and the stability of the long stem.
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Although this design did result in successful cascading (Figure 5.2B), the
rate of activation was far too slow for practical applications and modifications
yielded no appreciable improvement on cascade response (Appendix A3.2).
We surmised this was due to slow rate of product dissociation due to the high
stability of the long SCS stem length. Although the SCS structure was likely
being cleaved, evidenced by the positive results, the protected toehold was not
available to bind to the downstream inhibitor, as the complementary stem
sequence remained bound even after cleavage. The next major design tested
this by shortening the stem loop to 5 base pairs. The activator was tested in a
reverse orientation in SCS structure; the enzyme binding arm and core sequence
of the activator was left single-stranded, extending from the 5’ side of the SCS
while the toehold remained bound in the stem (Design 2, Figure 5.3A). Since
the complementary sequence on the inhibitor is normally complexed with the
downstream DNAzyme, we hypothesized that having the activator single
stranded for these domains would not result in much activation, as the toehold
binding is still required to initiate the reaction. However, this did not significantly
improve the cascade signal (Figure 5.3B).
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Figure 5.3 - Representation of the activation and leakage mechanisms can be
found in Figure 5.1. (A) This SCS design was a stem loop design, in which the
upstream DNAzyme bound to the loop of the SCS. The main difference between
this and the previous design is the orientation of the activation sequence, which
is now at the 5’ end of the SCS. The target structure (left) was implemented with
the given sequence (center) producing the MFE structure (right). The red circle
denotes the beginning of the activator toehold; the end of the activator sequence
is denoted by the red square. The red star marks the cleavage site. (B)
Response of Design 2 over 50 min. Although activation was achieved, the rate is
very slow, likely due to the inefficiency of stem loop cleavage. The shorter stem
decreased SCS stability, resulting in the increase in gate leakage over time.
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Due to the relatively poor performance of both the long and short stems of
Designs 1 & 2, we refocused our design efforts on the location of the cleavage
site. The two original designs placed the cleavage site in the middle of the loop,
which required the DNAzyme to bind to a structured substrate, as opposed to the
typical unstructured FRET substrate. As discussed in depth later in Chapter 7,
the efficacy of the DNAzyme-catalyzed RNA hydrolysis reaction is highly
dependent on the DNAzyme holding the RNA base in a specific conformation to
rapidly facilitate the base catalysis. We hypothesized that the torsional strain of
the loop likely alters this natural conformation and interaction of the RNA base.
Binding of the DNAzyme directly to the loop also likely altered the DNAzyme’s
ability to properly orient the RNA base. Thus, we redesigned the SCS structure to
utilize the principle of strand displacement to release the activator (Design 3,
Figure 5.4A). Here, the 3’ binding arm of the upstream DNAzyme hybridizes to a
5’ toehold extending from the SCS stem. The substrate binding arm now acts as
an invasion strand, displacing the stem loop. The loop then opens and the
second binding arm is able to bind to its complementary sequence in the loop,
creating a linear substrate properly oriented for RNA cleavage. The cleavage
site, now much closer to the stem, can now be efficiently cleaved.
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Figure 5.4 - Representation of the activation and leakage mechanisms can be
found in Figure 5.1. (A) This SCS design was a stem loop design, in which the
upstream DNAzyme displaced the stem through hybridization and the activator is
located on the 3’ side of the SCS. The main difference between this and the
previous design is the use of strand displacement for binding of the upstream
DNAzyme to its complementary substrate sequence. The target structure (left)
was implemented with the given sequence (center) producing the MFE structure
(right). The red circle denotes the beginning of the activator toehold; the end of
the activator sequence is denoted by the red square. The red star marks the
cleavage site. (B) Response of Design 3 over 25 min. Although rapid activation
was achieved, the rate of leakage also increased dramatically over previous
versions, indicating the protection of the toehold was insufficient. This is likely
due to the short stem and large loop.
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This design, however, now introduces some sequence constraints into the
system, through overlap between the upstream and downstream gates. The stem
sequence now performs two functions: it protects the downstream toehold and
serves as the binding arm displacement sequence for the upstream enzyme.
Thus, these two domains must contain the same sequence, which restricts the
design of this SCS structure. Overall, this was viewed as a small but necessary
restriction. As the downstream toehold and substrate binding arms are normally
free to vary, this was determined to be an acceptable constraint as such
sequences pose little restriction on the system as a whole.
This design also resulted in successful cascading. However, the response
of this system was completely different from the original designs (Figure 5.4B).
The system activated extremely quickly compared to Design 1, the leakage of
the system was also extremely high. Clearly, this new structure provided a
significant rate enhancement of downstream gate activation, demonstrating the
activator could indeed be quickly released. The high rate of leakage indicated
this SCS structure design was insufficient to stably sequester the activator from
the downstream toehold. We surmised this was influenced both by the length of
the stem and the size of the loop. A 5bp stem is likely affected by DNA breathing
and a large stem (25 bp for Design 3) may make it difficult for SCS to maintain
its structure through intramolecular binding by increasing the spacing between
hybridization sequences thus reducing the probability of the ends binding and
interacting. Taken together, it is unsurprising the activator was easily deprotected
even in the absence of upstream cleavage, as these results are in line with the
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findings of Bonnet et al.26 In their paper, they demonstrated that the rate of stem
closure is highly dependent on loop size, in which bigger loops close more slowly
than smaller loops. This has important implications, as large stem loops that
spontaneously dissociate are likely to remain in an open conformation for a
significantly longer time, increasing the probability of serendipitous hybridization
to the downstream toehold.
Increasing the stem size to 7bp appeared to marginally slow leakage while
maintaining rapid activation (Design 4, Figure 5.5), but the use of these longer
stems from the previous 5bp length was incompatible with the upstream enzyme
strand displacement mechanism necessary to achieve a linear substrate. The
effects of DNAzyme binding arm length on enzyme activity has been well
characterized,27 and the optimal length for rapid product dissociation was
determined to be 8bp, which imposed an additional constraint on stem loop
design. Had the DNAzyme arms been allowed to extend further, we could have
potentially extended the stem to stabilize the structure, which would have been
easily displaced by the extended binding arms. However, an 8bp arm limit
ensures that binding, cleavage, and product dissociation can occur at optimal
rates, which is essential to achieve multiple turnover. The ability to obtain
multiple turnover is critical, as it is the main advantage of using DNAzymes for
such reactions.

89

Figure 5.5 - Representation of the activation and leakage mechanisms can be
found in Figure 5.1. (A) This SCS design was a stem loop design, in which the
upstream DNAzyme displaced the stem through hybridization and the activator is
located on the 3’ side of the SCS. The main difference between this and the
previous design is the elongation of the stem and subsequent extension of the
upstream DNAzyme binding arms. The target structure (left) was implemented
with the given sequence (center) producing the MFE structure (right). The red
circle denotes the beginning of the activator toehold; the end of the activator
sequence is denoted by the red square. The red star marks the cleavage site. (B)
Response of Design 4 over 30 min. Although rapid activation was achieved, the
rate of leakage was still very high, indicating the protection of the toehold
remained insufficient. This is likely due to the short stem and large loop.
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As the first two designs excelled at activator sequestration and the second
two designs excelled at activator release via cleavage, it was evident that a
productive design was indeed achievable, but a matter of determining the right
structure to balance each of the complex rates making up the reaction.
Therefore, we decided to test a hybrid structure for Design 5 (Figure 5.6A),
which combined the strand displacement and linear substrate alignment
mechanism of Design 3 with the reversed activator orientation of Design 2. An
earlier variant of this structure SCS-D5v2 was unsuccessful (Appendix 3.1.5), as
a single 5bp stem was deemed insufficient to prevent leakage. This stem length
is likely insufficient to properly retain the SCS structure for extended periods of
time. With such little overall structure, any isoforms would likely result in
incomplete sequestration of the toehold, and therefore would result in activation
of the downstream gate.
Positioning of the activator as a single-stranded overhang enabled the
requisite size of the loop to be significantly reduced. This increases the
probability for stem rehybridization after spontaneous dissociation due to DNA
breathing and other thermodynamic effects. As short stems were insufficient to
properly sequester the activator, Design 5 increased the overall stability of the
structure by using additional hybridization to reduce loop size and increase free
energy. The cleavage site was left unhybridized, creating a 2bp bubble, resulting
in a dual stem and loop structure. This ensured the retention of 5bp stems,
beneficial for rapid activation, while augmenting the structure with a second short
stem to increase overall structure rigidity. The separation into two stems would
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likely keep the structure intact through avidity interactions, as the degradation of
the structure would only occur after two separate stem dissociation events, the
first initiated at the toehold and the second initiated in the inner loop. After
cleavage, only the first stem dissociates, which releases the toehold domain,
while the second one can refold on itself. As this stem does not participate in the
downstream interactions, this is a desirable result. However, the DNA breathing
of each stem may also result in a faster displacement, as well as the increase of
the loop. In this design, the 5’ arm of upstream DNAzyme binds to the 3’ toehold
of the SCS, initiating displacement of the outer stem. The 3’ arm binds to the
inner loop, and displaces the inner stem (Figure 5.6B). Although significantly
more stable than previously designs, this design only moderately improved upon
gate leakage.
To further increase the stability of the structure to suppress gate leakage,
we removed the 2bp bubble in Design 6 so the cleavage site was also
hybridized. The loop size was decreased to a minimal 4bp, creating a single long
stem with a very short loop (Figure 5.7A). After binding to the toehold and
partially displacing the stem, the second arm is able to bind to the loop of the
SCS and displace the rest of the stem, with the cleavage site in the middle of the
stem. Although this design performed exceedingly well (Figure 5.7B), it was
limited in that it required the use of 10bp upstream DNAzyme binding arms. This
design would present difficulties for scaling up circuit complexity, and 10bp
binding arms also slow the rate of product release and therefore enzyme
turnover.
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Figure 5.6 - Representation of the activation and leakage mechanisms can be
found in Figure 5.1. (A) This SCS design was a dual stem loop design, in which
the upstream DNAzyme displaced the stem through hybridization and the
activator is located on the 5’ side of the SCS. The main difference between this
and the previous design is the protection of the inner loop with a second stem.
The target structure (left) was implemented with the given sequence (center)
producing the MFE structure (right). The red circle denotes the beginning of the
activator toehold; the end of the activator sequence is denoted by the red square.
The red star marks the cleavage site. (B) Response of Design 5 over 30 min.
This design slightly decreased both the activation and leakage rates from the two
previous designs, but there was still insufficient distinction between the two
traces.
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Figure 5.7 - Representation of the activation and leakage mechanisms can be
found in Figure 5.1. (A) This SCS design was a single stem loop design, in which
the upstream DNAzyme displaced the stem through hybridization and the
activator is located on the 5’ side of the SCS. The main difference between this
and the previous design is the removal of the 2bp bubble at the cleavage site,
instead ensuring that sequence was also hybridized. The target structure (left)
was implemented with the given sequence (center) producing the MFE structure
(right). The red circle denotes the beginning of the activator toehold; the end of
the activator sequence is denoted by the red square. The red star marks the
cleavage site. (B) Response of Design 6 over 30 min using DNA only strands.
This design was among the best designs in terms of kinetic rate differences
between activation and leakage, although certain design constraints made
scaling up somewhat problematic.
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Design 7 moved the activator sequence back to the 3’ side of the SCS,
ensuring the activator sequence was now bound back into a loop. In this design,
each of the stems were 5bp, which formed two loops – an inner loop which
contained the activator sequence, and an outer loop, which separated the two
stems (Figure 5.8A). The cleavage site was placed in the middle of the outer
stem. Here, the upstream substrate binding arm hybridizes to the toehold on the
3’ side of the stem loop and initiates strand displacement of the outer stem. The
other substrate arm binds the outer loop and displaces through the inner stem.
Cleavage renders the outer stem as a waste product, while the inner stem
containing the toehold remains intact. This design relies on the relative instability
of the inner stem and loop, so that after the cleavage and dissociation of the
outer stem, the inner stem will still activate the downstream gate, despite the
toehold theoretically being protected in the stem loop.
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Figure 5.8 - Representation of the activation and leakage mechanisms can be
found in Figure 5.1. (A) This SCS design was a dual stem loop design, in which
the upstream DNAzyme displaced the stem through hybridization and the
activator is located on the 3’ side of the SCS. The main difference between this
and the previous design was the orientation of the activator, which reinstated the
dual stem and loop design. The target structure (left) was implemented with the
given sequence (center) producing the MFE structure (right). The red circle
denotes the beginning of the activator toehold; the end of the activator sequence
is denoted by the red square. The red star marks the cleavage site. (B)
Response of Design 7 over 30 min. This design had a good activation rate and a
much decreased leakage rate compared to Designs 3-5, but further optimization
was still required.
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Once again, although this design yielded moderate improvement of
leakage (Figure 5.8B), further optimization was required. We tested several
variants of this design, including alterations to the inner and outer stem length,
outer loop, upstream toehold, and upstream DNAzyme substrate binding arms.
Details of these potential variants and their accompanying results can be found in
Appendix 3.3.1, listed as variant designs of Design 8. This design (Figure 5.9A)
was a further derivative of Design 7, optimizing the structure to maximize many
of the kinetic rates listed in Figure 5.1. One of the main iterations, Design 8v1,
was tested as in its DNA form as well as its RNA form (Figure 5.9B), a process
discussed in detail in Section 5.2.3. Although the rate of activation was
somewhat slow after 30 min, this design retained good signal-to-background over
120 min (Figure 5.9C). We examined the effect of substrate binding arm length;
shorter arms resulted in a significantly increased activation rate, consistent with
the findings of other groups on the optimal binding arm length for maximal
product release rate. Therefore, we targeted the final optimization to ensure each
DNAzyme used 8bp binding arms.
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Figure 5.9 - Representation of the activation and leakage mechanisms can be
found in Figure 5.1. (A) This SCS design was a dual stem loop design, an
optimized version of the previous design. The main difference between this and
the previous design was the length of each stem, which also resulted in longer
DNAzyme substrate binding arms. The target structure (left) was implemented
with the given sequence (center) producing the MFE structure (right). The red
circle denotes the beginning of the activator toehold; the end of the activator
sequence is denoted by the red square. The red star marks the cleavage site. (B)
Response of Design 8v1 over 30 min using DNA only strands. This design
significantly decreased the leakage rate at the expense of activation. (C)
Optimization of the upstream DNAzyme substrate binding arms (RNA SCS),
demonstrating the effect on activation rate, likely through the rate of product
dissociation.
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The final structure and sequence of Design 8 is depicted in Figure 5.10A,
and had several modifications from the other variants. Most notable was the
placement of the cleavage site into the outer stem similar to Design 6. This had
several notable effects. First, the position of the cleavage site fixed the DNAzyme
binding arms at 8bp each, which is critical for rapid product dissociation, as
previously discussed. Second, this enabled the size of the outer loop to be
minimized, ensuring high structural stability to reduce leakage. Third, this also
enabled the use of the longer 7bp stems, which were found in this design to be
optimal to stabilize the structure to ensure low leakage. Lastly, the hybridization
of the cleavage site in the outer stem also served to protect the RNA base from
degradation, which could have also been a contributing factor to gate leakage.
Using a DNA form of a pre- and post-cleaved SCS molecules offered a good
approximation of the performance of the RNA form and upstream DNAzyme
cleavage, as seen in Figures 5.10B and 5.10C. Thus, the design of an SCS
structure to facilitate DNAzyme communication through a two layer cascade was
finally achieved, producing a robust activation response in the presence of an
upstream DNAzyme and minimal gate activation (leakage) in the absence.
This design also benefitted from a 3bp extension of the inhibitor further
into the core while retaining the length of the sequestered activator. This
extension acts as a clamp, which had been shown to reduce gate leakage by
preventing blunt end stacking of the activator and inhibitor in the core region.28
By not fully displacing the inhibitor, we achieved a much improved circuit
response.

99

Figure 5.10 – Cartoon representation of the activation and leakage mechanisms
can be found in Figure 5.1. (A) This SCS design was a dual stem loop design,
an optimized version of the previous design, and the final design and sequence
of the two layer DNAzyme cascade. The main difference between this and the
previous design was the length of each stem, which was optimized by moving the
RNA cleavage site into the outer stem. The target structure (left) was
implemented with the given sequence (center) producing the MFE structure
(right). The red circle denotes the beginning of the activator toehold; the end of
the activator sequence is denoted by the red square. The red star marks the
cleavage site. (B) Response of Design 8 over 30 min using DNA only strands.
This design showed a marked improvement in activation rate while retaining a
low rate of leakage. (C) Implementation of the DNA analysis using the RNA form
and upstream DNAzyme to active the SCS. Although the shapes of the curves
are slightly different, the lag time of the RNA form likely corresponds to the rate
of UE binding and cleavage, while the DNA form provides activator directly to the
system. The similarity between the two graphs demonstrates the costeffectiveness of this approach; approximation of RNA cleavage by a “precleaved” DNA form provides a reliable qualitative assessment of the performance
of the circuit.
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5.2.3 NUPACK Coding and Structural Predications
The

primary

motivation

for

utilizing

an

SCS

molecule

for

DNAzyme

communication was the ability to design a single structure and replicate that
structure between each two DNAzymes that must be connected in a signaling
cascade. As evidenced by Chapter 4, this was a sound strategy, enabling the
construction of a five layer cascade, with the opportunity to extend it further.
However, after the minimal success of Design 1 and the focus on structure
rather than sequence, it became immediately apparent that there was a large
solution set to each stem loop design. As upstream DNAzyme substrate binding
arms were free to vary in sequence, there are many such base pair combinations
that would allow us to achieve the desired structures. Each of these potential
sequence solutions may influence the overall stability of the structure and fold
into unproductive isoforms that could negatively affect the cascading reaction.
Hence, we used the Nucleic Acids Package (NUPACK) folding program29,30 to
code for the desired structure, which would then provide sequences that would
satisfy the constraints. Codes for each of the stem loop variants can be found in
Appendix 3.2.
To program NUPACK to solve individual SCS structures, we input several
sequences, including the downstream DNAzyme, the downstream inhibitor, the
SCS stem loop, the SCS activator, and the upstream DNAzyme. The SCS stem
loop is the desired SCS structure, whereas the SCS activator is the sequence
available to the system after SCS cleavage and product dissociation. We found it
was critical to specify both structures to ensure that both folded properly.
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Because the SCS for Design 8 folded into a dual stem and loop, the cleavage
product of this would have two single-stranded domains from both the 5’ and the
3’ side. Specifying the structure of the SCS activator structure post-cleavage
ensured a constraint was placed on the sequence so that these overhangs would
not hybridize to each other. As the 3’ domain contains the sequence
complementary to the downstream toehold, any hybridization to the 5’ sequence
would block this toehold from binding, drastically slowing the reaction. This can
be observed in the structural optimization figure from Appendix 2.5.
Use of this activator sequence significantly sped up iteration time for each
stem loop design while also significantly decreasing cost. While early designs
were purchased directly as a DNA structure with RNA cleavage site,
necessitating a surcharge for RNAse-free purification nearly three times the cost
of the strand itself, later iterations and designs were tested using a DNA only
form of both the SCS and ACT (SCS post-cleavage). In this way, we were able to
assess the hypothetical minimum and maximum circuit response, where gate
response in the presence of the SCS would be a measure of leakage, and the
ACT would be the positive response, assuming all SCS molecules are cleaved.
This was a reasonably good approximation of SCS behavior, and helped rule out
nonviable structures before they were purchased with the RNA base. That it was
both time and cost effective as well was highly beneficial, and this approach
significantly sped up the testing time for each new stem loop.
After the initial coding of the NUPACK program, we used a custom Python
script written by M. Leigh Fanning to analyze all of the potential candidate
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sequences, comparing such parameters as structural metrics, activation, and
leakage31. The calculation of activation and leakage is the relative percent of
binding between the SCS or ACT to the downstream inhibitor, in the presence of
the downstream DNAzyme. For a well-protected SCS structure, there will be
minimal interaction with the inhibitor, as it is more favorable to bind to the
downstream enzyme. For an optimal ACT structure, there will be significant
interaction between the inhibitor, resulting in a high percentage of free
downstream DNAzyme. These two parameters were viewed as relative percent
of downstream DNAzyme released, with optimal SCS structures yielding nearly
<1% DNAzyme release, while good ACT candidates yielded roughly 40-60%
DNAzyme release and excellent ACT candidates yielded around 60-80%.
It is important to note here some of the potential shortcomings of this
approach. First, NUPACK calculates all binding interactions at equilibrium
conditions32-34. As upstream DNAzyme binding, cleavage, ACT folding and
DNAzyme displacement are all dynamic processes, it was difficult at times to
assess the relation between equilibrium predictions and in vitro circuit responses.
Although the majority of experiments followed closely to predicted responses,
deviations from expected results occurred frequently enough that to suggest
there are additional complexities not accounted for by NUPACK. Second, while
looking at relative binding rates between the SCS/ACT and downstream inhibitor
was beneficial, they do not take into account the downstream DNAzyme and
inhibitor existing in a pre-formed complex. Equilibrium predictions assume all
strands are separate. This can introduce error in our predictions, as
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complementary sections of the downstream DNAzyme and inhibitor are normally
unavailable for binding, leaving just the toehold single-stranded. This fact may
result is some of the aforementioned deviations between prediction and behavior.
Third, despite proper NUPACK coding, some of the sequences generated still
failed to fold into target structures. Therefore it was important to check each
potential sequence set for structural integrity. Even in sequences that folded
properly, certain sequences (particularly the presence of A-T pairs, especially at
the ends of the stems) resulted in weakened structures or indications that
isoforms could be present at significant percentages. As nature is not without a
sense of irony, the most successful SCS structure for the original two-layer
cascade was actually a misfolded structure from the original code, found in
Appendix 3.3.9. Due to the excellent performance of this structure, all
subsequent layers (Appendix 3.3.10-12) were modeled off this structure, thus
requiring a slightly modified code from the original Design 8 version.
Because of the high cost and time of synthesis of the normal FRET
substrate, we fixed our output/reporter layer, adding additional layers upstream
via SCS molecules. Because of this, our downstream DNAzyme sequence was
always fixed while the upstream DNAzyme was free to vary. This imposes a
constraint on the SCS sequence, and some DNAzyme sequences result in more
viable SCS sequence candidates than others. While the optimized design of an
entire cascade is highly desirable, this comes at a significant computational cost,
as the number of potential interactions increases with each additional strand. For
each additional layer, the upstream DNAzyme sequence from the previous layer
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was used as the new downstream DNAzyme, allowing the next layer to be
optimized to the DNAzyme ahead of it. While this clearly worked, given the
performance of the five layer cascade, there was no optimization between
DNAzymes, inhibitors, and SCS molecules of different layers. As the number of
potential interactions is enormous, we focused on designing efficient interactions
such that they would be the favored thermodynamic pathways. However, all
inhibitors share a common DNAzyme core binding sequence. As each inhibitor is
present in solution at a 25 nM excess, the addition of five enzyme ensures a
significant (125 nM total) amount of free inhibitor. This may be the reason that
the five layer cascade has very little leakage, even though the third and fourth
layers have significantly more leakage. Further testing will be required to better
understand this phenomenon, for instance, using of streptavidin-coated magnetic
beads to remove excess inhibitor (described in Chapter 6).
5.3 Conclusions
The rational design process we followed in search of an SCS structure for the
DNAzyme-based cascades sought to balance the complex kinetic rates making
up the activation and leakage processes. Due to the minimal gate structure and
toehold availability of the DNAzyme displacement gates, the desired kinetic rates
were optimized through the thermodynamic favorability between the pre- and
post- cleavage secondary structure of the SCS molecule. This approach is in
contrast to the SCS design for the modular gate cascades, in which the structure
is built into the gate itself, which relieved many of the design constraints on the
SCS.
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Overall, the design process was illuminating in several facets. First, this
demonstrated the number of potential design variants available. Although many
of them displayed only moderate success, the individuality of each design
demonstrates that there is a highly diverse potential structure space that even
small sequences can adopt, resulting in a wide variety of behaviors. Second,
although several design had large structural differences, their performance was
quite comparable, indicating that thermodynamic interactions can be achieved
through many different pathways. This also shows the need for granularity in the
design process: small alterations often resulted in large changes to the structural
stability and therefore the kinetic rates of subsequent reactions. Finally,
development of a five layer cascade demonstrated the success of the rational
design approach for the dynamic modification of DNA nanostructures. By heavily
focusing on the structure itself to execute the thermodynamic pathways, we were
able to successively iterate the design to rapidly scale up the size and complexity
of DNAzyme cascading interactions.
5.4 Future Directions
The success of the rational design for SCS structure, both with the DNAzyme
displacement gates and the modular gates, holds significant promise for the
future development and use of DNAzyme signaling cascades. The continued
development of DNAzyme cascades may serve as a basis to construct synthetic
enzymatic cascades as well as more complex computational architectures. This
represents a significant development in the development of catalytic molecular
logic devices, which can now implement serial interaction of logic gates rather
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than solely parallel arrays in a reliable, predictable, and reproducible manner.
This enables the integration of many input signatures into a single DNA circuit,
anticipated to be one of the primary advantages over existing biomedical
diagnostic devices.
The process of rational design is critical for the continued development of
DNA nanostructures. Although modeling and predictive software can aid
process29,30,35-37, such software is currently incapable of predicting complex
structure formation, dynamic multi-strand interaction, and deviations from
traditional

Michaelis-Menten

enzyme

kinetics

using

DNAzymes;

typical

interactions are generally modeled in a static, low salt, equilibrated biochemical
environment29,30,33,34. Many DNA nanostructures contain dynamic interactions,
such as self-assembly processes or molecular motors and walkers, and rational
design may be useful when modeling software is insufficient for the prediction of
such complex behaviors. Importantly, the rational design process for the SCS
structure relied heavily on the modularity of the system and the matching of
structural components to kinetic rates. In this way, we could optimize the
structure for specific kinetic steps and identify rate-limiting steps solely with
experimental characterization. Thus, this work shows that a robust design
process capable of manipulating complex DNA nanostructures is feasible in the
absence of appropriate in silico modeling software and holds promise for the
integration of circuit response cascades and dynamic interactions into static DNA
nanostructures such as DNA origami38,39.
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5.5 Materials and Methods
5.5.1 Materials
All oligonucleotides were purchased from Integrated DNA Technologies
(Coralville, IA). Substrate molecules (DNA-RNA chimeras) were purified using
RNAse-free HPLC. Sequences for all oligonucleotides used herein are presented
in Table S1 in the Supporting Information. ATP was purchased from SigmaAldrich (St. Louis, MO). DNA strands purified using standard desalting were
resuspended in RNAse-free H2O (Sigma-Aldrich, St. Louis, MO) at a stock
concentration of 50 µM. These original stocks were diluted to working stocks of
2.5 µM, by diluting 50 µL stock DNA into 950 µL assay buffer (Section 5.5.3).
RNAse-free HPLC strands were resuspended directly at 2.5 µM in RNAse-free
H2O.
5.5.2 Gate preparation
Typically, 60 µL of DNAzyme and 75 µL inhibitor (25% excess inhibitor) of 2.5 µM
working stock solutions were added together and heated together at 95 °C for 3
minutes on a heat block, and subsequently annealed by cooling to room
temperature over a minimum of 90 minutes. All other strands that required an
initially hybridized state, including all SCS and ACT molecules, were also
annealed using the same protocol.
5.5.3 Assay conditions and instrumentation
All assays were performed at room temperature (23 °C) in a buffer of 1M NaCl,
50 mM HEPES, 1 mM ZnCl2, pH 7.0. Order of strand addition was as follows:
Substrate, Dz/INH, SCS or ACT, depending on the experiment. Upstream
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DNAzyme (UE) was added last to SCS designs with an RNA cleavage site.
Fluorescence was read on either a Spectramax M2e fluorescent plate reader
(Molecular Devices, Sunnyvale, CA) in a 200 µL reaction volume or
Quantamaster 40 fluorimeter (PTI, Binghamton, NJ) in a 300 µL reaction volume.
Fluorescence was monitored at 492 nm excitation and 518 nm emission
wavelengths.
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Chapter 6.
A Versatile, Modular DNA Biosensor
6.1 Introduction
Development of low cost bioassays is an important goal of research and medical
diagnostics. The total cost of an assay comes from reagents, readout equipment,
sample preparation, and research and development required to alter assay
parameters for different targets. This makes construction of a universal biosensor
a significant challenge as the number of bioassay targets can vary widely, as with
the detection of multi-strain pathogen sequences or even by type (i.e. DNA, RNA,
or small molecules). These factors necessitate the development of a modular,
scalable biosensor that uses common protocols, reagents, and analytical output
methods easily customized to detect different targets. Recent advances in DNA
nanotechnology have enabled the construction of nucleic acid devices that use
the predictable nature of Watson-Crick hybridization to perform complex
decisions1-4 and to detect target sequences with high specificity5,6. These
properties, together with inherent biocompatibility and rapidly decreasing
synthesis costs7, make DNA an attractive engineering material for the
development of low-cost bioassays.
Detection of multi-strain pathogens is an important problem in many areas
of medical and agricultural science and represents a significant challenge for
biosensor design and implementation. Many viral and bacterial pathogens occur
in multiple strains, whose genetic differences can be exploited to design strainspecific tests. Depending on the application, it may be important for a test to
identify a particular pathogen strain, or it may be sufficient to produce a generic
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response to a range of pathogen signatures. It is also important that new sensing
devices can be designed quickly and straightforwardly to detect newly discovered
pathogen signatures. For example, Shiga-toxin bearing E. coli (STEC) is a major
public health concern that has been associated with several outbreaks of
gastrointestinal disease8. However, there are more than 100 STEC strains 9, and
although O157 is the most prevalent, non-O157 STEC have also been implicated
in human infections9-11. Simple, low-cost field tests that determine whether any of
the STEC strains is present would allow contaminated meat or produce to be
identified and removed from the food chain at an early stage to reduce the risk to
public health are highly desirable. However, design and construction of such a
biosensor is challenging. The simultaneous detection of large numbers of strains
requires a highly modular design, capable of rapidly exchanging one strain
detection design for another.
Here we present a versatile, modular DNA-based sensor design,
expanding our previously characterized mechanism of DNAzyme displacement12
(Chapter 3). This combines toehold-mediated strand displacement with
DNAzyme-catalyzed cleavage of substrate molecules. Toehold-mediated DNA
strand displacement13 (TMSD) is a specific and powerful DNA computing
technique that has been used to implement digital logic circuits2,14, neural
networks3, enzyme-free catalytic networks15,16, hairpin assembly systems17-20 and
molecular walkers21,22. The kinetics and thermodynamics of strand displacement
reactions can be controlled based on the lengths of the toeholds that nucleate
the binding reactions23; this makes them ideal for programming detection
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pathways for targets at low concentrations. DNAzymes24 (also known as
deoxyribozymes) are single-stranded DNA enzymes that can catalyze a variety
of chemical reactions25-32, in particular, cleavage of an RNA or chimeric
DNA/RNA substrate molecule33,34. DNAzymes provide isothermal signal
amplification via multiple turnover reactions. DNAzyme-based logic gates are
DNAzymes whose catalytic activity is conditional on the presence (or absence) of
one of more target species. Large-scale parallel DNAzyme gate arrays have
been constructed for molecular decision-making1,4,35-38. Several alternative
methods have been used to turn DNAzymes into logic gates, such as loop-based
inhibition1,4,35-38 and triggered assembly of multi-component DNAzymes39-44.
However, these approaches require high concentration gradients to drive the
forward

inter-molecular

reaction,

to

overcome

the

kinetically

favorable

intramolecular reactions in the case of loop-inhibition or the entropic penalty of
assembling multiple components into an active DNAzyme. In the case of multicomponent DNAzymes, this may be overcome at the cost of additional circuit
complexity45-48.
The continued use of DNAzyme displacement enables our circuits to have
high input specificity, low input concentrations, and kinetically controllable
reactions, while retaining a simplified gate design through the inherent catalytic
ability of a DNAzyme. Although a new, more versatile and modular gate design is
detailed in this chapter, it is also important to retain the principles discovered in
the previous chapters. Thus, this chapter has two foci, the first being gate design
and performance for use in bioassay implementation, and the second being gate
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design for use in multi-layered cascades. The combination of these principles
should lead to the development of more sophisticated biodetection algorithms,
capable of integrating multiple inputs in large-scale decision networks.
6.2 Results
6.2.1 Modular gate design, structure, and behavior
Figure 6.1 depicts our modular sensor design, which consists of a catalytically
inactive DNAzyme-inhibitor complex that can be divided into two orthogonal
modules: a detection module (DM) and a reporter module (RM). When the
correct target sequence is present, it binds to the DM toehold and branch
migration occurs up to the beginning of the RM. This partially displaces the
DNAzyme strand and opens up the RM toehold, which was previously
sequestered in a 5-nucleotide (nt) bulge between the two modules. A fuel strand
then binds to the free RM toehold and displaces the remainder of the DNAzyme
strand. The free DNAzyme then folds into a catalytically active conformation and
cleaves its complementary fluorogenic substrate, producing an increase in
fluorescence due to loss of FRET. If substrate is present in excess, each
DNAzyme catalyzes the cleavage of many substrate molecules in the multipleturnover kinetic regime. This provides isothermal signal amplification in the
readout module. Here, we base all designs on the 8-17 DNAzyme34 because of
its small size and high catalytic efficiency49.
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Figure 6.1 – Mechanism of the modular gate utilizing an advanced version of
DNAzyme displacement. Here, an 8-17 DNAzyme is sequestered in an
DNAzyme-inhibitor complex, rendering the DNAzyme inactive. This complex is
sequentially separated into two orthogonal domains – a detection domain which
binds the desired target sequence and a reporter domain which contains the
DNAzyme and binds the fuel strand. The two domains are separated on the
inhibitor by a toehold sequestered in a loop, which reduces the favorability of fuel
strand binding while in complex form. Activation of the gate is a two-step
process. First, the target strand binds to the external toehold of the inhibitor
strand and removes it from the detection domain, which releases the looped
toehold. This results in a linearization of the internal toehold, which now favorably
binds the fuel strand present in solution. The fuel displaces the inhibitor from the
reporter domain, which results in the release of an active DNAzyme, now able to
cleave a FRET substrate.
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6.2.2 Optimization of Gate Structure to Reduce Non-specific Activation
Sequestering the inner toehold in a loop reduces the thermodynamic favorability
of binding between the fuel and inhibitor strands relative to the linear
conformation. This constraint alone is insufficient to prevent non-specific
activation of the gate; that is, the fuel is able to displace the RM allowing
substrate cleavage, even in the absence of the target (Figure 6.2A), an effect
that varies in a concentration dependent manner (Figure A4.1). While the rate of
non-specific activation (leakage) was relatively low over short times, this signal is
problematic for extended time courses. Our DNAzyme displacement AND gate
contained mismatches (Figure 6.3) sufficient to destabilize the interaction
between the DNAzyme and inhibitor; therefore, we systematically looked at the
addition of mismatches to destabilize the binding of the fuel strand to the inhibitor
in the absence of target, taking care to ensure that we retained activation in the
presence of target. Single mismatches were introduced at the first, second, and
third positions (P1, P2, P3) from the DM in the loop and compared to the
response without any mismatches. Double mismatches were added in the first
and second positions (P1, P2) and were tested using a 5bp loop as well as an
8bp loop (8L). (Figure 6.2). Experiments were run at typical gate concentrations
(100 nM) over a short, 20 min time course. Compared to the control with no
mismatch (Figure 6.2A) each addition of a mismatch showed significant
improvement on leakage. The best options appeared to be a single mismatch in
the second position (Figure 6.2C), and the double mismatches in the first and
second positions, both in the five and eight base pair loops (Figures 6.2E and
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6.2F, respectively). In each of these three cases, the leakage of the gate was the
lowest over background.
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Figure 6.2 – The effect of mismatches on modular gate performance. (A)
Rational mismatches were introduced to destabilize the binding of the free singlestranded fuel and the corresponding toehold on the inhibitor, sequestered in a
loop. The position of the mismatch plays an important role in leakage and
activation profiles. (B) Modular gate response with no mismatches results in high
leakage. (C-E) The addition of a single mismatch significantly reduces this
leakage. (F) The addition of two mismatches eliminates leakage, at the cost of
activation rate. (G) Alternatively, activation rate can be increased through a larger
loop, added more bases for the fuel to bind to the inhibitor. Insets for graphs
depict the specific location for each mismatch.
However, experiments are often run on much longer time scales. Thus, it was
critical to determine which mismatch profile best performed over extended time
courses. To observe this effect, we ran the same gate concentration (100 nM) for
12 hours. (Figure 6.3). Over this time course, we found that the rate of leakage is
quite significant over such extended time durations, the best performing gate
being the double mismatch of the 5 bp loop. Although gate activation is very fast
compared to the leakage, high leakage profiles indicate further optimization was
necessary to ensure these gates were suitable for longer experiments. However,
we previously found that reducing gate concentrations was sufficient for the
reduction of gate leakage (Figure A2.1). To see whether these gates followed a
similar profile, we reduced the gate concentration to 40 nM and ran them for 12
hours. Here, we found that leakage was indeed reduced, without a significant
reduction in activation. Again, the double mismatch of the 5 bp loop showed the
lowest level of leakage over 12 hours, although the activation is noticeably slower
than the other three gates. The reduction of concentration showed a marked
reduction in leak over time, which is important for the determination of values like
limit of detection (LOD), a critical parameter for real bioassay sample detection. A
detailed discussion in Section 6.2.4 will examine these parameters more closely.
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Figure 6.3 – Extended time profiles at 100 nM gate concentration, comparing the
four best performing gates, labeled based on the position of their mismatch. (A)
P2 gate (B) P3 gate (C) P1, P2 and (D) P1, P2, L8 gate.

Figure 6.4 - Extended time profiles at 40 nM gate concentration, comparing the
four best performing gates, labeled based on the position of their mismatch. (A)
P2 gate (B) P3 gate (C) P1, P2 and (D) P1, P2, L8 gate.
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As the addition of two mismatches at a reduced concentration still resulted in
a robust activation signal, we explored the addition of an additional mismatch to
each of the existing versions to see if even lower leakage over 12 hours could be
obtained.

All previous mismatched bases between the fuel and the inhibitor

strand had been placed in the toehold region, which destabilized the binding
interaction but likely had little effect on the displacement of the inhibitor strand.
Here, the additional mismatch was placed at the last position in the doublestranded region of the DM (denoted P0), immediately adjacent to the first position
of the loop. Thus, for the double mismatch versions, this third mismatch would
result in three consecutive mismatches, two in the loop and one in the hybridized
region of the inhibitor. With the addition of a mismatch as the P0 position, we
looked at two versions of this. The first was a full mismatch, replacing an adenine
with a cytosine, to mismatch with the paired thymine. We also explored a
pseudo-mismatch, in which the adenine was replaced with a guanine, thus
creating the opportunity for a wobble base pair with the thymine. As shown in
Figure 6.5, the leakage was drastically reduced, even without a mismatch in the
loop (Figure 6.5A). There were several notable observations with the addition of
this new mismatch. The most striking feature is the reduction in activation. In
Figure 6.4, all activation times using the DNA oligonucleotide (oligo) target input
were on the order of minutes, with complete activation being achieved in less
than one hour. As the P1 mismatch now likely slows the rate of strand
displacement initiation, activation rates are now on the order of hours.
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Figure 6.5 – Effect of an additional mismatch, at the P0 position. The mismatch
was either a full mismatch (C-T) or a wobble mismatch (G-T). Each previously
characterized gate was run with each new fuel containing either the CT or GT
mismatch. (A) No mismatch gate (B) P1 gate (C) P2 gate (D) P3 gate (E) P1, P2
gate and (F) P1, P2, L8 gate.
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Not surprisingly, the performance of the double mismatch (P1, P2) with the 5
bp loop suffered the most, reaching only half completion after 12 hours. The most
promising gates appeared to be the single mismatch gate P2 and the double
mismatch gate of P1, P2 with the 8 bp loop (8L). However, given the significant
difference in activation rate and time to completion, the gate P1, P2, 8L was
deemed the optimal choice for further experimentation.
6.2.3 Characterization of Input Adaptability (ssDNA, dsDNA, RNA, ATP)
The separation of target detection (DM) and reporter modules (RM) in our sensor
design allows the sequences of the two modules to be varied independently of
each other. This is important because the chimeric DNA/RNA oligo labeled with
both a fluorophore and a quencher is typically the most expensive single element
in our assays. Therefore, the ability to use the same substrate to report on the
presence of different detection targets is of great practical utility. This property
also makes these gates highly versatile, as the DM can be easily exchanged for
alternative inputs. As the detection of nucleic acids relies only on hybridization
principles, the structure of these gates enables straightforward detection of both
ssDNA and RNA inputs. However, DNA is typically found in double-stranded
form, making detection a challenge. Therefore, we designed gates to be used in
the development of a protocol for the detection of dsDNA.
We

developed

four

sensor

gates

to

each

detect

independent

subsequences from the pRSET emGFP plasmid (Life Technologies) by varying
the DM, while keeping the RM fixed for each gate. We characterized the
performance of each gate to the ssDNA oligomer targets corresponding to the
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four target sequences on the plasmid (Figure 6.6 A-D). Individually, the sensors
all performed similar to each other for the detection of ssDNA oligo targets. As
these sensors detect single-stranded nucleic acid targets by Watson-Crick base
pairing, they are also able to detect the corresponding RNA oligomer targets
(Figure 6.6 E,F). This property expands the versatility of these modular gates,
which could potentially be employed to detect mRNA or siRNA targets in addition
to DNA targets.

Figure 6.6 – Characterization of plasmid region gates. (A-D) Gates
corresponding four different regions of the pRSET emGFP plasmid were
designed and characterized. Each uses the P3 gate design. (E) R2 gate
performance against an RNA-only target using various concentrations of fuel. (F)
The R2 gate and RNA-only target at multiple turnover (250 nM substrate)
conditions, with 100 nM fuel.
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Although the detection of single-stranded DNA signatures is important,
many of the desired targets are typically found in double stranded form.
Detection of dsDNA requires additional processing to render targets singlestranded, so that the individual strands can activate our sensors via hybridization.
After extracting and purifying the plasmid from SCS110 E. coli cells, we used an
isothermal alkaline denaturation protocol to break apart the two strands. After
gate structure optimization (Section 6.2.2), we successfully demonstrated the
direct detection of denatured plasmid DNA with the R2 gate (Figure 6.7).
Leakage remains at a low level and activation continues even after one week
(Figure 6.7D).

Figure 6.7 – Plasmid detection by the R2 (P1, P2, L8) gate. Gate, fuel, and
plasmid concentrations were at 40 nM. (A) Fluorescence after 16 hours (B)
Fluorescence after 36 hours (C) Fluorescence after 96 hours (D) Fluorescence
after 204 hours.
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Although the size of the plasmid ensures that the two strands will not
rehybridize after neutralizing the pH, the target regions may still have local cis
binding to form secondary structure, rendering potential target sites inaccessible.
However, because our four sensors use a common readout module, we can
perform multiplexed detection of the four target subsequences from the plasmid
by using multiple sensors in parallel. This provides detection redundancy to
overcome any secondary structure in the denatured plasmid strands, as any one
of the four targets can activate the corresponding sensor. This could also provide
additional signal amplification from low concentrations of plasmid, since each
individual plasmid can activate four sensors, each capable of amplification via
multiple turnover.
In addition to detecting other nucleic acids by direct hybridization, DNA
strands can bind to small molecules, resulting in a conformational change50. We
exploited this fact to further demonstrate the modularity of our sensor design by
replacing the detection module with a partially blocked ATP aptamer sequence51.
Figure 6.8A depicts a reaction scheme whereby binding of two ATP molecules to
the aptamer displaces the blocking strand. This conformational change frees the
secondary toehold and allows the fuel strand to bind as before. As shown in in
Figure 6.8B, we observed significant signal over background in the presence of
1 mM ATP. In this experiment the leak rate was higher than in the earlier
experiments, which was most likely because the blocking sequence for the
aptamer detection module was shorter than the blocking sequence used in the
earlier DNA detection modules: 8 nucleotides as opposed to 15. This meant that

126

the DNAzyme-inhibitor complex in the ATP-sensing gate was less stable than in
the DNA-sensing gates, which would make it easier for the fuel strand to invade
the toehold in the absence of the target signal. We performed experiments with
ATP-sensing gates with longer blocking sequences (11 and 15 nucleotides) but
found that in these cases the blocking sequence sequestered too much of the
aptamer sequence, preventing the ligands from binding and activating the gate
(Figure A4.2) These limitations are imposed by the particular aptamer sequence,
and additional study of the kinetics and thermodynamics of aptamer activation
will be necessary for further optimization of this design. It is also worth noting that
these experiments were conducted using the P3 gate from Section 6.2.2, rather
than the optimized P1, P2, L8 gate. Use of this new gate structure should result
in a greatly improved response.

Figure 6.8 - Aptamer sensing using modular deoxyribozyme gates. a)
Replacement of the target detection module with a partially blocked aptamer
sequence allows the gate to be triggered by the binding of small molecules, in
this case ATP. b) Kinetic traces showing gate response to various ATP
concentrations.
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6.2.4 Multiplexed analysis of STEC strains
We demonstrated the practical applicability of our modular sensor gates by
designing six multiplexable sensor gates that each target a different STEC
serotype (O26, O45, O103, O121, O145 or O157) and that each use a common
reporter module. The target sequences were based on the PCR primers used for
O-antigen STEC detection by Paddock et al
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. These sequences are suitable for

our purposes because PCR primer sequences are typically chosen to minimize
secondary structure, which is also beneficial for TMSD reactions. We
characterized each of the six STEC serotype-specific gates individually, as
shown in Figure 6.9B. In each case, the sensor gates were prepared by
annealing deoxyribozyme strands at 100 nM with the corresponding inhibitor
strands at 125 nM, to account for variations in concentrations between stocks.
Each experiment also used fuel strands at 500 nM and fluorogenic substrate at
250 nM. The target strands were single-stranded synthetic DNA oligonucleotides
with the same sequences as a primer from the corresponding serotype. For the
positive traces shown in Figure 6.9B, 50 nM of the target sequence of the
particular serotype gate in question was added, and for the negative traces, 50
nM of each of the five incorrect serotype target sequences was added. In each
case, we observed a significant response in the presence of the correct serotype
target sequence, and a very low background in the presence of the other
serotypes. This demonstrates that the sensor gates are highly sequence-specific.
Variations in the activation rates between the detection gates for different STEC
serotypes may be attributed to differences in the stability of the DNAzyme-
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inhibitor complex caused by the different target sequences in the detection
modules or by different levels of secondary structure in the target strands, which
would impede the binding of the target to the toehold of the detection module.

Figure 6.9 – Modular deoxyribozyme-based sensor gates and their application to
detection of STEC target sequences. a) Basic mechanism of target detection and
deoxyribozyme activation. Binding of the target strand to the detection module by
toehold-mediated DNA strand displacement exposes the toehold in the reporter
module, allowing the fuel strand to bind and complete displacement of the
deoxyribozyme strand. The deoxyribozyme can then fold into a catalytically
active conformation and generate an amplified fluorescent output by cleaving
multiple substrate molecules labeled with a FRET pair. b) Detection of target
sequences taken from the genomes of six STEC serotypes (O26, O45, O103,
O121, O145 and O157), using sensor gates generated by fixing a reporter
module and varying the input module. Each gate was characterized separately;
the positive response in each case was obtained by adding the correct target
sequence, and the negative controls were obtained by adding all of the other five
target sequences, thereby demonstrating sequence specificity. The baseline
response that occurs when the fuel is present in solution without the target
strands was subtracted from each trace.
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Since our STEC detection gates all use a common reporter module, we can
multiplex detection of the six target sequences in a parallel gate array, with a
single fluorescent readout via a common fluorogenic substrate molecule. In this
case, a fluorescent signal is observed if any of the target sequences are present,
giving a multiplexed detection circuit that implements “OR” logic. We
demonstrated the multiplexed detection capabilities of our modular DNAzyme
displacement gates by performing a six-way assay for the detection of any of the
aforementioned six STEC serotype target sequences, as shown in Figure 6.10.
Each STEC sensor gate was prepared as outlined above, and all six were
combined along with the common fuel strands at 500 nM. This was replicated in
seven wells; a single STEC target sequence at 50 nM was added to six of the
wells, with the seventh serving as a negative control. After a 15 minute
incubation at room temperature, the common substrate strand was added at 250
nM. Endpoint fluorescence values were measured after a further 30 minutes of
incubation at room temperature. We observed a high signal to background ratio
in all cases, with the relative heights of the bars for the positive traces
corresponding roughly to the activation rates observed in the individual
characterizations (Figure 6.9B). The background was slightly higher in this
experiment, most likely due to the higher overall concentration of detector gates
causing an increase in the spurious generation of signal. These data
demonstrate that our system can simultaneously detect the STEC-specific
sequences of interest in a mock bioassay scenario. A positive response from this
six-way assay could be followed by a set of independent assays to determine the
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identity of the strain present. We have also demonstrated that the sensor gates
function well in the presence of randomized background DNA (Figure A4.3).

Figure 6.10 - Multiplexed detection of any of the six STEC serotypes of interest
(O26, O45, O103, O121, O145 and O157). The six detectors from Figure 1b
were used with a common fuel strand and a common substrate, and their
response in the presence of each serotype signature was characterized. We
observed high fluorescence values, which are similar for each of the target
sequences, and a low response when no target is present.
Detection of low input concentrations is vital in pathogen detection applications.
We investigated the limit of detection (LOD) of the O45 sensor gate by
systematically diluting the entire system down to a 100 pM gate concentration.
The left-hand axis of Figure 6.11 shows kinetic traces of the O45 sensor gate in
the presence of O45 target concentrations in the picomolar range. Lowering the
gate concentrations reduced nonspecific signal generation in the absence of
input while extending the timescale of the reactions. The right-hand axis of Figure
3 shows the LOD at various time points using the IUPAC definition of 3 standard
deviations over background, to ensure statistically significant results
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. We

observe the optimal LOD of 7.4 pM at the four hour time point (see Figure A4.4
for additional data). Thus our sensor gates are competitive with ELISA.
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Figure 6.11 - Investigating the limit of detection of the O45 sensor gate. Colored
line traces (left axis) show the response of the O45 detection circuit with various
input concentrations: 10 pM, 5 pM and 1 pM. For these experiments the system
was diluted to 100 pM gate concentration with 10 pM excess inhibitor, 100 pM
fuel and 250 nM substrate. The background signal in the absence of input has
been subtracted from all traces. Solid lines are average fluorescence values from
5 replicates, and dashed lines are one standard error above and below the mean
in each case. Red data points (right axis) are detection limits at 3σ above the
standard error of the background at various time points, calculated using the
standard IUPAC definition53.
6.2.5 Use of modular gates in DNAzyme cascades
Although characterization of modular gate behavior to this point has been
focused on the optimization and direct performance as a biosensor, the design
principles of DNAzyme cascading, outlined in detail in Chapters 4 and 5, should
be directly applicable to developing modular gate cascades. However,
modification of the gate structure from the original gates in Chapter 3 altered
several of the parameters used in the design of the original SCS. In particular,
the availability of the toehold that binds to the SCS, now sequestered in a loop, is
far more restricted in this system than its linear form in the original gates. Thus,
use of the original SCS design (Design 8, Figure 5.10) resulted in almost no
enzyme activation, likely due to the high structural stability and greater steric
hindrance. This necessitated a reassessment of the SCS design that would be
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most compatible with the modular gate structure. The increased protection of the
toehold lessens the stringency with which the activator needed to be
sequestered. Thus we revisited a previous SCS design (Design 4, Figure 5.5)
that resulted in activation in our original gates, but where the leakage was too
great to be considered a viable candidate. Here, the SCS is just a stem loop
design, with a 7bp stem and a 22bp loop, with a 4bp toehold for the upstream
DNAzyme. The mechanism of modular gate cascades remains quite similar, with
the addition of both an input and a loop being necessary to release the upstream
DNAzyme, which is then able to cleave the SCS. This cleavage product now acts
as the fuel strand (functionally identical to the activator strand in the original
DNAzyme gates) and along with Input1, is sufficient to activate the downstream
DNAzyme (Figure 6.12).

Figure 6.12 – Modular gate cascade scheme. Each enzyme requires its
respective input, with the cascade initiated by the addition of upstream fuel.
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Using the P3 gates, we designed a two layer cascade, which was activated by
the addition of a fuel strand corresponding to a potential third layer SCS
sequence. We achieved very good performance, comparable to our previous
two-layer cascade design, with only a moderate reduction in activation rate. This
is likely because the binding of its corresponding input sequence now regulates
each enzyme layer, and the increased protection of the toehold ensures that the
cleaved SCS product (Act) binds more slowly (Figure 6.13). Use of the third
layer sequences as inputs indicates the viability of constructing a three-layer
cascade, currently being implemented in the lab. This design also used a 2bp
clamp, instituted by removing the two bases on the input closest to the inner loop
toehold to prevent a full displacement of the DM, significantly reduced leakage in
the cascades. The clamp sequence was also designed to mismatch to the
activator toehold of the SCS, which resulted in reduced leakage in the cascades,
in line with NUPACK predictions of relative binding stability at room temperature.
A more detailed discussion of the design process of the P3 modular gate
cascades can be found in Section 6.2.6. A prototypical two-layer cascade was
also implemented using the P1, P2, L8 gate using a DNA-only SCS and ACT
(representing a cleaved form of the SCS), to achieve a similar kinetic profile as
the P3 gate, albeit with slightly less leakage, as would be expected from this
gate. The RNA (cleavable) version of this cascade is also currently being
implemented in the lab.
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Figure 6.13 – Performance of a two layer modular gate cascade using the P3
gate design. In the negative control (blue), Dz1/Inh and Dz2/Inh, SCS, and Inputs
1&2 are present in solution. With the addition of a DNA-only SCS, coming from
the third layer, as a sequestered fuel (brown), there is very little increase in circuit
leakage. Addition of an activator (ACT) sequence, corresponding to the
sequence derived from cleavage and dissociation of the waste product from an
RNA SCS molecule, as a released fuel, we see a positive response (green).

Figure 6.14 – Current development of a two layer cascade using the P1, P2, L8
gate design. The SCS and ACT are the DNA analog of the pre- and postcleavage of the two layer RNA SCS molecule. The RNA version is currently
being tested.
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6.2.6 Rational design of SCS structure for modular gates
The reporter module of the modular gates is identical in sequence to the first
layer of the DNAzyme displacement gates (alternatively designated as the U2
sequence); therefore we assumed that the SCS structure of Design 8 (SCS-D8)
would be sufficient to activate these gates. Here, the SCS activator would serve
as the fuel strand, which are functionally equivalent. The addition of the input
would release the target domain, and the cleaved SCS (ACT) sequence would
displace the rest of the DNAzyme, resulting in signal. By using common
DNAzyme sequences such as U2 for the basis of all experiments, different
advances in cascading or gate structure would still be compatible with each
other.
Unfortunately, the increased stability of the modular gate structure was
incompatible with the pseudostable SCS-D8, and we observed no activation
through cascading of the downstream modular gate using this SCS structure.
This is not wholly unsurprising, as SCS-D8 was based on the availability of a free
downstream toehold, and thus the activator required significant protection to
ensure optimal sequestration. However, the introduction of mismatches to the
fuel strand resulted in very little signal leakage of the gate, even in its singlestranded form. This likely resulted in a significant steric hindrance between the
ACT and the loop toehold and overhanging DNAzyme detection domain strand.
The retention of the inner stem of the SCS-D8 may have also contributed,
making displacement even more unfavorable. With the failure of this structure, it
became apparent that successful cascading no longer required a highly
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protected fuel strand. Therefore, we revisited our earlier SCS design that were
deemed nonviable due to high leakage, indicative of poor sequestration. As
these designs still resulted in successful cascading, their weak protection of the
activator strand was likely to be a good fit for the modular gate cascades.
As Design 4 (Chapter 5) was one of the most straightforward of the original
designs, requiring a minimal secondary structure as it consists of merely a single
stem and loop (Figure 5.5), we explored this design for modular gates cascades.
Because the structure of the cascades is now primarily contained within the gate,
the development of a viable stem loop structure was trivial compared to the
design of the original SCS cascades. The design process focused around minor
alterations of the toehold interactions, specifically the incorporation of
mismatched bases similar to the linear fuel strand detailed in Section 6.2.2. By
sequestering the respective fuels into the SCS Design 4 structure, we were able
to generate productive SCS designs two different gate structures (P3 and P1, P2,
L8). Performance of these gates is shown in Section 6.2.5.
6.2.7 Modular Gate Cascades for Advanced Circuit Behaviors
Although the development of modular gate cascades is still being explored and
optimized, together, the performance of modular gates as biosensors and the
regulation of each gate by its corresponding input hold significant potential for the
utilization of modular gates in complex decision-making networks. We defined
several advanced circuit behaviors to be conceptually implemented that would
serve as individual components capable of being integrated into larger networks,
with wet lab implementation occurring in the near future. The modularity of each
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gate allows for the rapid development of such components, as each process can
be designed independently. For example, the interaction of multiple enzymes
through a single SCS intermediary represents the first step for complex network
regulation and input integration. For this, the demonstration of both fan-in and
fan-out capabilities is critical, each concept should be easily implemented using
modular gates. Here, we can implement fan-in by altering the DM of the
upstream DNAzymes while keeping the DM fixed (Figure 6.15). Because each
upstream DNAzyme (Dz2 and Dz3) has the same DM, they are able to cleave
the same SCS sequence, which releases the fuel (activator) for Dz1. Note that
although the fuel for both Dz2 and Dz3 is shown as a single-stranded input, it can
also be derived from another upstream SCS molecule as well. Additionally, the
upstream regulation by separate inputs functionally acts as an OR gate, in which
either Input2 OR Input3 is sufficient to activate the downstream DNAzyme.
Additionally, we can construct a fan-out circuit, in which a single upstream
DNZzyme is able to activate two downstream DNAzymes (Figure 6.16). In the
figure below, Dz3 cleaves a single SCS, which can in turn activate either Dz1
and/or Dz2, depending on the availability of Inputs 1 & 2. Although each
downstream enzyme has one substrate binding arm in common, the second,
unhybridized arm, is free to vary. We previously observed that this is sufficient to
prevent cleavage of the same substrate sequences. Thus, we can split the initial
signal into two DNAzymes, each able to cleave their respective substrates, which
can be either FRET substrates labeled with different fluorophores or SCS
molecules themselves, able to propagate the signal further.
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Figure 6.15 – Depiction of modular gate cascades executing fan-in. Two
upstream DNAzymes (Dz2 and Dz3) contain the same reporter domain
sequence (blue) and are therefore able to cleave the same SCS molecule after
activation by their respective fuel and input. This acts as fuel for the downstream
DNAzyme (Dz1) and activates in the presence of Input1. Dz1 is then able to
cleave a FRET substrate or another SCS to propagate the signal further.
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Figure 6.16 – Depiction of modular gate cascades executing fan-out. A single
upstream DNAzyme (Dz3) cleaves the SCS molecule, after activation by its
respective fuel and input. This SCS is now able to activate two DNAzymes (Dz1
and/or Dz2) depending on the availability of Inputs 1&2 in the system. By
changing the second binding arm between DNAzymes 1&2, we can ensure each
DNAzyme binds to a unique substrate. These two substrates can be FRETlabeled outputs or additional SCS molecules, to propagate the reaction further.
Although the integration and separation of signals is important for building more
complex decision networks, the modular gate design also enables the execution
of more advanced circuit behaviors, such as DNAzyme cycles as demonstrated
in Figure 6.17. Here, we have two inhibited gates (Dz1 and Dz2), although with
two corresponding SCS molecules. With the addition of a fuel strand to initiate
the reaction, a small amount of Dz2 is released, capable of cleaving SCS1. This
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acts as fuel for Dz1, which, upon cooperative binding with Input1, is released.54
The active Dz1 is then able to cleave SCS2, which releases more of Dz2 and the
cycle continues. The activity of Dz1 can then be monitored by the addition of a
substrate, which will be cleaved more rapidly in a cycle where increasing
amounts of Dz1 can be generated. By matching the corresponding sequences,
any two DNAzymes can be linked, enabling the engineering of more complex
interactions such as three-DNAzyme cycles.

Figure 6.17 – Depiction of modular gate cascades executing a DNAzyme cycle.
As Inputs 1&2 are available in the system, the addition of fuel to the upstream
DNAzyme activates Dz2, which cleaves SCS1 to produce Act1. In conjunction
with Input1, Dz1 becomes active and cleaves SCS2 to produce Act2. As more
fuel becomes available, each enzyme becomes more active, increasing the rate
at which substrate is cleaved. The addition of a FRET substrate and its
subsequent rate of cleavage is a relative indicator of the amount of DNAzyme
present, which should be higher for positive feedback cycles such as this one.

141

6.3 Conclusions
The gate design presented herein is a major advance in modularity and
versatility compared with the original DNAzyme displacement gates. By
separating the reporter modular from the detection module, each gate is capable
of detecting unique arbitrary sequences. The gate structure was designed
specifically for biosensor performance, and optimized for fast activation with low
leakage, even over extended time durations. The gate itself has been designed
to detect a wide variety of single-stranded target DNA sequences, as well as
RNA, small molecules, and plasmid DNA.
The purely nucleic acid-based approach to various target types and
oligonucleotide sequences presented here has the advantage of simplicity and
robustness compared with approaches for sequence specific detection based on
protein enzymes, such as the polymerase chain reaction (PCR), strand
displacement amplification55, rolling circle amplification56,57, or other isothermal
nucleic acid amplification approaches58,59. Our approach is also distinct from
other approaches that have used DNAzymes selected to provide fluorescent
signals in response to bacteria based on affinity for the products excreted by the
bacteria60-62. Our aim is to provide a simple, isothermal assay platform that is
more sensitive, versatile, and cost-effective than alternative antibody-based
approaches, such as the enzyme-linked immunosorbent assay (ELISA), and that
can be performed with less expertise and less expensive lab equipment than
PCR. Although PCR remains the gold standard for nucleic acid detection in terms
of sensitivity, it is not isothermal and uses proteins, which require sophisticated
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lab equipment and therefore limit its use in low cost field assays. All experiments
were run with minimal purification of the strands and complexes, as this is
important for reducing the cost of practical assay implementations. Sequestering
the reporter module toehold in a bulge rather than in a duplex allowed us to
implement a two-stage strand displacement reaction using a two-strand complex
rather than the usual three, which further simplified the preparation of our
sensors.
In addition, this work addresses the practical need for straightforward
assays capable of identifying a large range of target strains with high sequence
specificity. This versatile DNA-based sensor gate is well suited for isothermal,
amplified detection and typing of multiple pathogen signatures. This allows new
gates to be designed to target emerging pathogen strains easily and quickly. We
demonstrated multi-strain detection capability using target sequences analogous
to six different STEC strains, and we achieved a limit of detection of 7.4 pM after
four hours. Target hybridization and strand displacement of the DM also confer
high specificity, easily discriminating between gate specific targets and other
targets sequences or a randomized DNA background.
The principles demonstrated here also show the expanded circuit design
capabilities using the modular gate infrastructure. Having a true input control
point for each DNAzyme improves both gate and circuit regulation, bringing this
approach one step closer in approximating protein-based cascade functionality.
The modular gate design lays the groundwork for truly complex decision trees
and networks, capable of simultaneously integrating many different input
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signatures. This capability is essential for the diagnosis of complex disorders and
infections, the detection of multi-strain pathogens, hybridized biodetection and
decision-making of pathogen serotyping, and the eventual construction of
theranostic devices.
6.4 Future Directions
Although the O-antigen specific gates from Section 6.2.4 performed well, each of
these gates used the P3 mismatch version (as did the ATP gate from Section
6.2.3). This version was extensively characterized for leakage, mismatch
response, sensitivity, and toehold size (Appendix 4.2, Figures A4.5 and A4.6),
and it showed an excellent signal to background ratio against single stranded
targets. However, the P1, P2, L8 gate in Figure A4.7 shows a reduced activation
response from direct detection of plasmid DNA compared with the short, singlestranded target sequences. To detect this low signal over background, it is
important to minimize gate leakage. While single-stranded targets are relatively
small and diffuse easily and can provide a robust signal, plasmid DNA and
genomic DNA targets are massive in comparison, meaning gate and target
hybridization are likely diffusion limited. In addition, the formation of secondary
structure and steric hindrance of these large targets may also have a effect on
the rate of gate activation. Repeated testing of the O-antigen gates with the P1,
P2, L8 structure is required. Although each individual gate generates a relatively
low positive signal, the overall response may be improved by the addition of
multiple gates, an option discussed above. In the specific case of STEC
detection, this approach seems especially viable. Many target sequences have
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been implicated in STEC infection (i.e. Stx1, Stx2, EAE, HlyA),8,63,64 although
there is some debate in the literature, especially in regards to the virulence
plasmid,64,66-70 as to the use of these sequences for positive STEC identification.
Several of these sequences are inserted into the genome at multiple loci.65 Thus,
gates may be able to bind a single genome copy at multiple locations of a single
sequence and across multiple sequences, and with each gate capable of multiple
turnover, this may be an excellent approach for isothermal generation of a large
output signal in the presence of low input concentrations. As additional gates
also increase the overall leakage (Figure 6.11), testing of low leakage gate
structures will be required if the approach of using multiple gates over long time
durations is to be a viable option.
A complementary approach to improve gate performance in preparation
for real-world biological sample detection is to remove excess inhibitor present in
solution. As we are working under low-cost conditions, using minimal purification,
we overcome strand impurities and concentration variation for each DNAzyme
gate through the addition of excess inhibitor, typically on the order of 10-25%.
This serves to effectively suppress any spurious DNAzyme signal, which may
occur either through incomplete inhibition or through leakage reactions due to
imperfect sequestration of the activator sequence in the SCS structure. However,
the inhibitor strand also serves as the detection strand, binding directly to the
target strand. Thus, the presence of excess inhibitor serves as a sink for the
target strand, as it is thermodynamically more favorable for the target to bind free
inhibitor than inhibitor complexed to the DNAzyme. To achieve the lowest
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possible limit of detection, each target should bind and release a DNAzyme, but
excess inhibitor effectively imposes a threshold on this lower limit. To overcome
this, we are pursuing various methods of purifying out the excess inhibitor. One
promising strategy appears to be the use of streptavidin-coated magnetic
microspheres. Here, a capture strand is bound to the magnetic microspheres
through a biotin-streptavidin conjugation, which contains the complementary
sequence to the reporter domain of the inhibitor. As this region is unavailable
when properly complexed with the DNAzyme, only the free inhibitior is able to
bind the capture strand, and is subsequently removed when the beads are
magnetically removed from solution (Figure 6.18)

Figure 6.18 – Purification strategy to remove excess inhibitor from DNAzyme
gates. Beads are streptavidin-coated magnetic microspheres. A biotinylated
capture strand is added to the beads and the bead complex is mixed with the
Dz/Inh complex. The capture strand is able to bind to the substrate binding arm
and core of the inhibitor strand, which is only available with free inhibitor strands,
as the DNAzyme for the bound inhibitor blocks that sequence. Magnetic removal
of the beads ensures that most Dz/Inh complexes are recovered at the
concentration is minimally altered.
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Initial experiments using bead purification appear to have successfully removed
excess inhibitor. Using the strand displacement DNAzyme/inhibitor FRET labeled
complex from Figure A2.3c, we were able to test the response of this complex to
increasing amounts of activator (Figure 6.19). By using a strand displacement
(non-amplified) response, rather than a DNAzyme displacement, we were able to
observe a more sensitive response to low input concentrations. Testing
conditions of unpurified DNAzyme/inhibitor (25% excess), DNAzyme/inhibitor
without capture, and DNAzyme/inhibitor with capture, we found that we achieved
a robust response to low concentrations of activator in solution only with the
captured inhibitor. We hope to further characterize this method for improved
response to low concentrations of input, such as plasmid detection, and test how
this purification can improve gate LOD. As excess inhibitor may also assist in
rebinding spuriously activated DNAzymes to suppress leak, we will also
characterize whether purification increases the signal from leakage over time.
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Figure 6.19 – Magnetic bead purification of FRET Dz/Inh complexes. Each
complex was originally incubated with 25% excess inhibitor, and each strand of
the Dz (FAM) and Inh (TAM) complex was labeled with a fluorophore. The
negative control (black dash) had no purification steps, while the bead control
(orange) incubated the Dz/Inh complex with the beads, but lacked the capture
strand necessary to bind the free inhibitor. Black dash and orange traces should
be similar in response. The purified sample (blue) incubated the beads and
capture strand with the Dz/Inh complex for 30 min. 100 nM Dz/Inh complex was
added to each well, and respective concentrations of activator strand was added.
As activator binds to the inhibitor to form a waste complex, it removes FRET
between the Dz and Inh strand, and the Dz strand can fluoresce. (A) 5 nM
activator. (B) 10 nM activator. (C) 25 nM activator. (D) 50 nM activator. (E) 100
nM activator. (F) 200 nM activator. Purified complexes had increased signal at
low concentrations of activator (A-C). The signal from the unpurified complexes
approaches the purified response only at high concentrations of activator (F,G).
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Another important future direction is the experimental implementation of
alternate designs for more complex DNA circuits using modular gate cascades.
Some work has already been done on the characterization of optimized gate
design vs. SCS structure, but more work is still necessary. Although we have
characterized the P3 and the P1, P2, L8 gates with cascades, other gate designs
that had good performance should be tested as well. Gates such as P2 and P1,
P2 gates also had reduced levels of leakage (Figure 6.3) compared to the P3
gate and should be investigated, as the design of an SCS-inhibitor interaction
that contains three mismatches (including one G-T wobble) may impose design
constraints on large circuits. Gates using this design may also have more
variable activity profiles, which will make them unreliable in circuits. The use of
modular gates for single nucleotide polymorphism (SNP) detection is detailed in
Appendix 4.3. Alternative designs are detailed in Appendix 4.4.
A major advantage of the modular gate design is the ability to modify the
reporter module to cleave a different substrate for each target sequence, a
feature we have not yet explored in detail. If different fluorogenic readout
substrates were conjugated to different fluorescently dyed beads, a large number
of different strains could be detected in a single flow cytometry assay by gating
on the bead fluorescence of the different bead populations. Finally, our sensor
designs may also be integrated with a range of other readout technologies, such
as lateral flow devices,71,72 microfluidics,73 and colorimetric readouts.74,75
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6.5 Materials and Methods
6.5.1 Materials
All oligonucleotides were purchased from Integrated DNA Technologies
(Coralville, IA). Substrate molecules (DNA-RNA chimeras) were purified using
RNAse-free HPLC. Sequences for all oligonucleotides used herein are presented
in Table S1 in the Supporting Information. ATP was purchased from SigmaAldrich (St. Louis, MO). DNA strands purified using standard desalting were
resuspended in RNAse-free H2O (Sigma-Aldrich, St. Louis, MO) at a stock
concentration of 50 µM. These original stocks were diluted to working stocks of
2.5 µM, by diluting 50 µL stock DNA into 950 µL assay buffer (Section 6.5.7).
RNAse-free HPLC strands were resuspended directly at 2.5 µM in RNAse-free
H2O.
6.5.2 Gate preparation
Typically, 60 µL of DNAzyme and 75 µL inhibitor (25% excess inhibitor) of 2.5 µM
working stock solutions were added together and heated together at 95 °C for 3
minutes on a heat block, and subsequently annealed by cooling to room
temperature over a minimum of 90 minutes. All other strands that required an
initially hybridized state, including all SCS molecules, were also annealed using
the same protocol.
6.5.3 Strand addition for modular gate experiments
General order of addition for each experiment is as follows: DNAzyme/inhibitor
complex first, followed by SCS, fuel and input (for biosensing assays, the input is
either a target strand, plasmid DNA, or ATP). The FRET substrate was added to
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initiate the reaction. All experiments, with the exception of Figure 6.10 was
monitored and plotted as a kinetic trace. For Figure 6.10, input (here, the
respective target strand) was added to initiate the reaction. After 15 minutes,
substrate was added and monitored for 30 minutes. Final fluorescent values
were reported as a bar graph.
6.5.4 Plasmid Extraction and Denaturation Protocol
pRSET emGFP (Life Technologies, Grand Island, NY) was transformed into
SCS110 cells (Agilent Technologies, Santa Clara, CA). Cells were thawed on ice
for roughly 30 min until liquid. One ng plasmid DNA was added to 100 uL cells,
and incubated on ice for 30 min. Cells were then heat-shocked at 42°C for 45
seconds, and placed back on ice for 2 min. Cells were the incubated at 37°C for
10 min. After incubation, 20 uL cells were pipetted onto LB plates containing 50
ug/mL carbenicillin (Sigma Aldrich, St. Louis, MO) and incubated overnight at
37°C. Individual colonies were selected from this plate and grown in a 5 mL
starter culture containing LB media + 50 ug/mL carbenicillin. After an overnight
incubation, cells were added to 250 mL LB + 50 ug/mL carbenicillin and grown
overnight. After incubation, cells were pelleted by centrifugation at 20,000 x g
and lysed using a Maxiprep kit (Qiagen, Venlo, Limburg, Netherlands). Pelleted
DNA was resuspended in RNAse free water. To denature the plasmid, 20 uL 1M
NaOH was added to 90 uL plasmid DNA in RNAse free water. After 10 min, 20
uL 1M HCl was added to the solution to bring the pH back down.76 Plasmid
added to wells with DNAzyme gates comprised a maximum of 10% of the total
volume.
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6.5.5 Preparation of background DNA experiments
Herring sperm DNA (Promega, Madison, WI) was used as a control for a random
DNA background. The herring sperm DNA was prepared several different ways.
First, 1 µg/mL dsDNA was added to a well containing O157 P3 gate + substrate
(Table A4.7, Figure A4.3B). The O157 gate was annealed separately. In Figure
A4.3C, Dz O157, Inh O157, and herring sperm DNA were annealed together,
that is, heated to 95°C for 3 min and cooled to room temperature over a minimum
of 2 hours. In Figure A4.3D, herring sperm DNA was heated to 95°C and cooled
rapidly on ice to prevent rehybridization. This was then added to a well containing
O157 P3 gate + substrate.
6.5.6 Magnetic Bead Separation
Quantity of excess inhibitor of 135 µL Dz-Inh complexes (Section 6.5.2) was
calculated to be 37.5 picomoles. Binding capacity of streptavidin-coated
magnetic microspheres (Promega, Madison, WI) was determined from product
information, which was estimated at 750-1250 pmol of biotinylated-oligo per mg
of beads. Using the lower 750 pM capacity estimation, 66.6 µL beads (1mg/mL)
corresponding to 50 pmol binding capacity were used. Beads were washed once
by a 5 min magnetic separation and resuspended in assay buffer containing 200
pmol biotinylated capture strand. After incubation for 30 min on a rotator, beads
were washed 2X in assay buffer. 135 µL Dz-Inh complex was added to the beads
and incubated for 60 min with rotation. Beads were magnetically separated, and
the purified Dz-Inh solution was removed. An activator strand was added to each
well and fluorescence was monitored over 30 min.
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6.5.7 Assay conditions and instrumentation
All assays were performed at room temperature (23 °C) in a buffer of 1M NaCl,
50 mM HEPES, 1 mM ZnCl2, pH 7.0. Fluorescence was read on a Spectramax
M2e fluorescent plate reader (Molecular Devices, Sunnyvale, CA) in a 200 µL
reaction volume (492 nm excitation, 518 nm emission).
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Chapter 7.
High Throughput DNAzyme Screening
7.1 Introduction
Biological systems catalyze chemical reactions primarily through the use of
protein enzymes. These enzymes are exceedingly efficient, selected by evolution
over billions of years, and catalyze a vast and diverse range of reactions within
the cell. The pressure of natural selection has ensured that protein structure,
protein-protein interactions, and cofactor activation have developed to an optimal
point, rendering further improvement using artificial selection methods infeasible.
Though prior work on biocomputing devices using naturally occurring proteins
shows promise1-5, the complexity of protein folding, non-physiological stability,
and the available repertoire of existing protein-protein interactions limits the use
of proteins in the design of synthetic molecular computation circuits and devices6.
The discovery of a group of catalytic RNA molecules, known as
ribozymes, dramatically altered this landscape. The single-stranded nature of
RNA enables it to function as a biological catalyst, and it has since been found to
catalyze many reactions previously thought to be restricted to proteins. This
discovery led to the “RNA world” hypothesis, in which RNA molecules catalyzed
the chemical reactions in the prebiotic and protobiotic Earth7,8, with the discovery
of RNA self-replication providing a mechanism for Darwinian evolution. In
addition to RNA-only catalysis, RNA can also complex with other molecules,
such as in the ribosome, where mRNA, tRNA, and rRNA all interact within the
protein scaffold.
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Due to the biochemical similarity between RNA and DNA, it followed that
DNA could potentially behave as a biological catalyst as well. Although DNA is
almost exclusively double-stranded in nature, functioning as an information
carrier in genomic or plasmid form, the advent of solid-state DNA synthesis and
artificial selection processes such as SELEX (Systematic Evolution of Ligands by
Exponential Enrichment) enabled the discovery of DNA enzymes, also known as
DNAzymes or deoxyribozymes9-11. After this initial finding, DNAzymes have been
subsequently selected as catalyzed to a wide variety of chemical reactions, just
like its RNA equivalent12-17.
Despite the continually expanding capabilities of these nucleic acid
enzymes, catalysis rates of individual reactions remain orders of magnitude lower
than protein enzymes18,19. This is widely presumed to be the result of the larger
biochemical diversity available to proteins through their more numerous and
more chemically varied amino acid composition. In the case of RNA
transesterification, the enzyme-catalyzed rate enhancement by 8-17 is achieved
through the use of two catalytic mechanisms, which involves the deprotonation of
the 2’ hydroxyl group through base catalysis20 and the arrangement of the
structure to an in-line conformation (Figure 7.1)21. However, there are two
alternative mechanisms, which involve the protonation of a non-bridging
phosphate ion and the protonation of the 5’ oxygen, both of which are specific
acid catalysis19. While protein-based enzymes such as RNAse A likely engage all
four of these mechanisms22,23, it appears that many well-studied ribozymes and
DNAzymes make use of only two of these. However, there does not appear to be

158

a hard limitation preventing DNAzymes from engaging the alternative transfer
mechanisms19. By making use of these additional strategies, nucleic acid
enzymes could achieve rate enhancements on the order of protein enzymes.

Figure 7.1 – Proposed RNA transesterification mechanism utilized by the 8-17
DNAzyme for RNA base hydrolysis. This DNAzyme appears to make near
perfect use of two different catalytic strategies. First, the 2’ hydroxyl group is
deprotonated through base catalysis, shown in step 1. This group then
participates in a nucleophilic attack on the phosphate center (step 2), resulting in
a pentacoordinate species. The efficiency of this nucleophilic attack is also
enhanced with an in-line orientation of the nucleophile, electrophile center and
leaving group, which facilitates this process. This is highlighted by the green
elliptical in step 3. After the leaving group is protonated, the reaction is complete.
(Figure adapted from Emilsson, 2003)
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Selection of catalytically active DNAzyme sequences is achieved through
the SELEX process. Thus, enzymatic activity is determined by the specific setup
and conditions of the selection procedure. The 8-17 DNAzyme, named for
selection round (8) and the clone number (17), was originally selected under the
following conditions: 1M NaCl, 10 mM MgCl2, 50 mM Tris, pH 7.510.
Characterization of additional mutations by Li found a rate enhancement with 817 in the presence of ZnCl2 instead of MgCl224. In both cases, selection
conditions were fixed with limited reactants available for DNAzyme utilization. In
light of the potential rate enhancements described by Emilsson and Breaker18,19,
DNAzymes appear to be intriguing candidates for small molecule high throughput
screening.
While inhibitor compounds may be useful, our main interest lies in the
discovery of activating compounds. The 8-17 DNAzyme was chosen for
screening, due to its small size and high catalytic activity, as well as its extensive
use in related experiments in our lab. The discovery of activators has numerous
potential benefits. It has been shown the DNAzymes similar to 8-17 appear to
have perfected the use of two different catalytic mechanisms18. Therefore,
compounds able to increase the rate of 8-17 substrate cleavage would likely
engage an additional transfer mechanism, such as acid catalysis, not yet
observed in nucleic acid enzymes. This would have a substantial effect on our
understanding of ribozyme and DNAzyme catalysis, potentially shedding light on
the RNA world hypothesis and the origins of RNA enzyme complexes with
peptides and other small molecules. Additionally, activators could also be of
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significant importance in areas where DNAzymes are used14,25-28, such as our
DNAzyme displacement gates and cascades29. Improved performance of
enzyme catalysis could speed up decision times by orders of magnitude, which
could bring DNA circuit performance closer to electronic circuits. Improving
decision times would also advance their capabilities as biosensor elements,
making them more competitive with protein-based assays.
7.2 Results
7.2.1 Preparation of DNAzyme assay conditions for HTS compatibility
Development of a protocol for high throughput screening for the 8-17 DNAzyme
required the refinement of assay parameters. These included a positive control, a
negative control, and a “mid-control” to be quenched at the end of the experiment
to assess the relative increase or decrease in enzyme activity in the presence
effector compounds. The AllX library of compounds was chosen for this
screening effort30,31, due to its wide compound and scaffold variability. Each well
contains an entire scaffold library, that is, a single base compound with all
possible substitutions at each position on the compound. Scaffolds can be small
molecule- or peptide-based. This library was tested in a 96 well format.
Several controls were necessary to determine compatibility between
typical buffer conditions (1M NaCl, 50 mM HEPES, 1mM ZnCl2, pH7) and the
AllX scaffold library, which is stored in dimethylformamide (DMF), as well as to
define assay parameters. As other potential libraries contained dimethylsulfoxide
(DMSO) rather than DMF, we also examined the effect of DMSO on DNAzyme
performance. (Figure A5.1) Parameters tested included buffer conditions,
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enzyme purification, enzyme concentration, and EDTA quenching concentration
(Figure 7.2).
Prior experiments in this dissertation focused on the use of DNAzymes for
bioassay development, thus it was desirable to minimize additional purification
steps to reduce cost. To ensure DNAzyme performance was optimized for
performance to reliably assess compound interaction, we tested DNAzyme
response through PAGE purification. We found that using PAGE purified
DNAzyme strands resulted in a more robust enzyme performance, in line with the
findings of other groups (Figure 7.2A)32,33. To characterize a suitable quencher
for the mid-control reaction, we tested various concentrations of EDTA.
Consistent with expected results for a buffer containing a 1mM metal cation
concentration, the reaction was only quenched by the addition of at least 1mM
EDTA (Figure 7.2B). As the concentration of EDTA did not affect the fluorescent
response, a final concentration of 0.1M EDTA was used for the screening
protocol.
After reaction initiation and quenching conditions were established.
Initially, we explored the use of DNAse I for a positive control, to cleave the
chimeric substrate strand, but that failed to produce the requisite fluorescent
response (Figure A5.2). We found that the addition of a significant excess of 817 DNAzyme was sufficient for the positive control, rapidly cleaving all available
substrate (Figure 7.2C). As with previous experiments, the negative control
remained the reaction without input, in this case the DNAzyme strand. Here, this
was the substrate by itself. To ensure the screening ran long enough to evaluate
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compound effects, the enzyme concentration was chosen to produce 50%
maximum fluorescence after 20 minutes. With the use of PAGE purified
DNAzyme strands, which were already shown to have increased activity
compared to standard desalting, the optimal DNAzyme concentration was found
to be 15 nM (Figure 7.2C). All three controls (positive, negative, and mid),
conducted with 8 replicates and accompanying error bars. These replicates were
essential to ensure consistency across a 96 well plate, and our results showed
exceptional reproducibility. Figure 7.2D demonstrates the mid control with
quenching by EDTA. Final experimental conditions and assay parameters are
detailed in the materials and methods (Section 7.4). Additional parameters were
also examined and are reported in Appendix 5.
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Figure 7.2 – Determination of scaffold library screening parameters. (A) The use
of PAGE purification resulted in an increased DNAzyme performance (n=3). (B)
DNAzyme activity quenching via EDTA after 10 min, requiring a minimum of 1
mM EDTA for complete quenching. (C) Relative performance at the final
concentrations of DNAzyme for negative (0 nM), mid (15 nM), and positive (200
nM) controls (n=8). (D) Mid control performance with and without quenching
(n=3).
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Plate Layout

A
B
A
B
C
D
E
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G
H

% of midCntrl

B
C
A
B
C
D
E
F
G
H

loCntrl
loCntrl
loCntrl
loCntrl
hiCntrl
hiCntrl
hiCntrl
hiCntrl

1

1
0.4
F0.1
F0.1
F0.2
216.0
202.0
218.7
215.0

2
67.4
83.9
83.1
74.4
86.4
63.8
76.4
66.0

2
1169
1170
1171
1172
1174
1275
1276
1319
1"mg/ml,"10%"DMF/water
3
4
62.1
72.6
62.4
71.7
84.6
48.1
69.4
54.6
63.9
78.4
70.2
68.0
56.4
81.3
57.7
80.7

1"mg/ml,"10%"DMF/water
3
4
1324
1420
1343
1421
1344
1422
1345
923
1346
924
1347
1455
1418
1456
1419
1477

5
65.0
15.0
84.6
79.1
86.1
85.5
90.9
77.2

6
88.4
58.2
82.7
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83.9
88.8
93.3
89.4

5
6
1481
882
1433
531
1295
914
1277
506
1387
886
1409 sc_1mg/ml
1509 sc_1mg/ml
1002 sc_1mg/ml

7
73.5
84.5
90.4
80.4
92.9
69.1
84.0
75.7

7
1169
1170
1171
1172
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0.5"mg/ml,"5%"DMF/water
8
9
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71.4
68.1
71.9
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54.4
77.0
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69.3
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90.6
63.5
86.7

0.5"mg/ml,"5%"DMF/water
8
9
1324
1420
1343
1421
1344
1422
1345
923
1346
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1347
1455
1418
1456
1419
1477

10
59.2
14.8
89.2
83.4
86.7
90.0
91.4
85.7

11
85.8
59.5
82.2
63.4
90.6
92.3
94.5
91.0

10
11
1481
882
1433
531
1295
914
1277
506
1387
886
1409 sc_0.5mg/ml
1509 sc_0.5mg/ml
1002 sc_0.5mg/ml

12
95.4
98.6
103.9
92.3
98.4
102.1
110.0
99.3

12
midCntrl
midCntrl
midCntrl
midCntrl
midCntrl
midCntrl
midCntrl
midCntrl

Table 7.1 – Results from AllX scaffold library screening against the 8-17 DNAzyme. (A) Well layout, including all four
controls. High control (4X, Column 1, Rows E-H) contains 200 nM DNAzyme. Mid control (8X, Column 12) contains 15 nM
DNAzyme. Lo control (4X, Column 1, Rows A-d) contains 0 nM DNAzyme. Solvent control (3X, Column 6, Rows F-H)
contains buffer with DMF, with no compounds added. Compound reference numbers are listed in respective wells. (B)
Relative fluorescent values, based off of the averaged results of all 8 mid control replicates establishing a baseline of
100% activity. No activators were found. The top two inhibitors are highlighted in yellow and green.
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Upon determination of final assay parameters, the AllX library was
successfully screened. Table 7.1A shows the well layout of the library screen on
a 96 well plate. Scaffold libraries were screened at two different concentrations, 1
mg/mL listed under the yellow column and 0.5 mg/mL listed under the blue
column. Table 7.1B contains the relative fluorescent response of each well
displayed as a percent of activation compared to the mid-control samples (15 nM
DNAzyme, no compound, EDTA quenched after 20 minutes). Although no
activator compounds were discovered, we found two promising inhibitors - a
nitrosamine-based compound being a very strong inhibitor (85% inhibition) and a
N-methyltriamine being a decent inhibitor (52% inhibition), (Figure 7.3).

[A]
R3

R2
N
NO

NO
N
R1

R2

[B]
N
NO

R3

N
H

H
N

NH
R1

Figure 7.3 – Structures of two inhibitors of 8-17 DNAzyme activity. R groups
indicate positions of modification. (A) Nitrosamine (B) N-methyltriamine.
7.3 Conclusions
In the work presented here, we screened the 8-17 DNAzyme against the AllX
scaffold library. We discovered one scaffold based on nitrosamine that resulted in
excellent inhibition (~85%) and several others that resulted in ~50% inhibition,
the best one being N-methyltriamine. The inhibition mechanism for these
compounds is currently unknown and would require further experimentation.
Although no activators were found in this study, the work here presents a path for
additional screening, either using different compound libraries such as the Torrey

166

Pines (TPIMS) combinatorial library or different DNAzymes such as 10-23. Newly
discovered DNAzymes, such as the DNA-cleaving I-R3, may employ alternative
hydrolysis strategies and would therefore be exciting candidates. Additionally,
DNAzymes that catalyze reactions other than RNA transesterification may also
be screening candidates for their respective chemistries, allowing them to be
more kinetically competitive with RNA-cleaving DNAzymes.
7.4 Materials and Methods
7.4.1 Oligonucleotide Sequences
Oligonucleotide sequences for the enzyme and substrate are listed 5’-3’, and
substrate binding regions are color-coded. All oligonucleotides were purchased
from Integrated DNA Technologies (Coralville, IA). DNAzymes, inhibitors, and
input strands were ordered purified with standard desalting. DNA/RNA chimeric
FRET reporter substrates were ordered purified using RNase-free HPLC. All
sequences are listed in Appendix 5, along with their respective concentrations in
each experiment. Oligonucleotides were resuspended in RNase-free H2O
(Sigma-Aldrich) in accordance with the manufacturer-provided specifications at a
stock concentration (50 µM). Working stocks were made by adding the
resuspended oligonucleotide solution (50 µL) into buffer (950 µL). All reactions
were run in a buffer of NaCl (1M), HEPES (50 mM), and ZnCl2 (1mM), at pH 7.0,
unless otherwise noted (through the addition of DMSO, DMF, or the quenching
by EDTA).
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7.4.2 Parameter Control Experiments
DNAzyme sequence #1 (Dz1) and its corresponding substrate (Sub1) were used
for the actual screening assay, and Figures 7.2 and A5.2-A5.4 controls for
activity and fluorescent response. Figure A5.1 and A5.5 demonstrate the
fluorescent response of Dz2 and Sub2 in the presence of DMSO and DMF and
varying pH, although these sequences were ultimately not used in the screening.
In each case, the reaction was initiated through the addition of the corresponding
DNAzyme. Enzyme performance was characterized on a PTI (Birmingham, NJ)
Quantamaster-40 fluorimeter at an excitation wavelength of 492 nm and an
emission wavelength of 518 nm for Sub1 and an excitation wavelength of 648 nm
and an emission wavelength of 668 nm for Sub2.
7.4.3 Scaffold Library Screening
Screening was performed against the AllX scaffold library. Compounds were
initially at a stock concentration of 20 ug/mL and 10 ug/mL in DMF; addition to
DNAzyme and substrate-containing wells diluted these compounds to a final
concentration of 1 ug/mL and 0.5 ug/mL, respectively. Each control contains only
enzyme and substrate, the low control containing 0 nM enzyme, the mid control
containing 15 nM enzyme, and the high control containing 200 nM enzyme, as
determined in Figure 7.2. The reaction was initiated with the addition of
substrate, to a final concentration of 500 nM. The reaction was quenched by 10
mM EDTA after 20 min and immediately read out on a 1420-040 Victor 3V
multilabel fluorescent plate reader (Perkin-Elmer).
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Chapter 8.
Surface-based Conjugation for DNA and Protein
Compartmentalization
8.1 Introduction
Solution-based DNA computation has generated significant interest, and many
groups have developed molecular logic gates based on DNA. The principles
have been utilized to construct circuits of impressive scale. However, the
continued development of complex computational interactions will likely require a
more efficient method for scaling up while minimizing spurious interactions.
Although significant work has gone into inhibition and sequestration of active
sequences in solution-based assays, including our own efforts in DNAzyme
cascading, the lack of physical separation of circuit components ensures that
leakage through cross-reactivity will continue to hinder circuit development and
growth. Work on the physical separation of circuit components has been limited;
to our knowledge, only two instances of direct conjugation of DNA logical
elements to microspheres have been reported to date1,2. This represents a field
with significant future potential.
As flow cytometry excels in the analysis of many separate populations, it
appears ideally suited for the development of multi-analyte computational
analysis. There are many different modalities available for the coupling of
computational elements to microspheres suitable for analysis by flow cytometry,
each with application-specific advantages. Given the nascence of this field,
characterization of different attachment methods to microspheres would fill an
important need.
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Direct attachment of DNA strands and logic gates to microspheres has
been used in prior studies1,2. This method has obvious advantages for design
simplicity and preparation and fulfills one of the key constraints for use in
biosensor devices. For certain applications, this approach is highly beneficial and
warrants further characterization. In other cases, such as DNA-substrate
interactions, immobilization of circuit elements may be problematic. To address
this issue, the exploration of alternative modalities that can provide element
mobility to facilitate component interactions, such as biological membranes,
would be highly beneficial.
Membranes have been demonstrated in several new areas of DNA
nanotechnology, including lipid vesicles3,4, planar bilayers5,6, and mammalian cell
lines7. The latter case was an important demonstration both for the performance
of DNA computation on a cell surface as well as the use of flow cytometry
analysis of computational systems. Although direct cellular analysis is of high
interest, cells are complex systems composed of many different molecular
species and cell culture work can be expensive and time-consuming. These
limitations indicate the necessity of a model system capable of both DNA and
protein interaction and amenable to flow cytometry analysis. One promising
platform is supported lipid bilayers (SLB)8, in which a pure lipid bilayer is coated
on the surface of silica microspheres, or “cushioned” bilayers for polystyrene
particles9. These SLBs have been shown to retain natural lipid fluidity, ensuring
that elements associated with the SLB are able to freely diffuse in a 2D plane.
This approach has been demonstrated for the sequestration and release of
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dye10, chemotherapeutic compounds11 and interfering oligonucleotides12, along
with integration of transmembrane proteins13.
The use of SLBs may be of use for DNA computational architectures that
include proteins, potentially enabling the discovery of new circuit behaviors. This
system may also have use in the continued development and characterization of
synthetic transcriptional circuits14-16. For these reasons, it is important to
characterize the use of microspheres and SLBs for both proteins as well as DNA,
which may be of use to the wide variety of DNA computation implementations
currently being explored. One of the aspects we explored in depth was the use of
supported lipid bilayers for the stable and specific attachment of hexahistidinetagged proteins. This is a commonly used protein tag for the purification of
proteins, and would be highly desirable for use in bioassay development and the
2D constraint of proteins on the surface of SLBs, which has important
implications for surface-based synthetic circuit designs. However, reports on the
use of histidine-tag immobilization of proteins on microspheres have been mixed.
8.2 Background on histidine tags for assay development
Immobilized metal affinity chromatography (IMAC) is one of the most
widely used technologies for protein purification. The small hexa- or decahistidine tags have significant advantages over other affinity tags, due to their
lack of steric hindrance and ease of use. These benefits have made histidine
tags attractive targets for use in protein-based biological assays. The histidine
tag has a relatively weak (~µM Kd) monovalent binding affinity for any of its
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receptors17. This results in a relatively rapid equilibration of bound and unbound
states, which is useful for protein chromatography.
However, the weak binding affinity of his-tags for their known partner receptors
has made the development of biomimetic surfaces, which require stable and
directional binding of proteins, problematic. While several groups have reported
stable his-tag binding on supported surfaces17-20, others have shown that his-tag
binding is insufficient for biological assays demonstrated discrepancies between
binding on different surfaces21-23. Previous studies on large, planar systems have
proposed two mechanisms for achieving stable protein binding: rebinding and
avidity. The model of rebinding proposes that upon dissociation from its receptor,
a ligand will instead rebind to the surface with a different receptor, rather than
diffuse from the surface24,25. Thus, rebinding is highly dependent on surface
receptor density. Rebinding effects were first described for the Ni-NTA system
using surface plasmon resonance to measure the binding of polyhistidine tagged
proteins a high density of Ni-NTA groups in a porous dextran layer17. In this
study, the high receptor density found on the dextran layer was postulated to
increase the apparent affinity of his-tagged proteins. This model was also the
proposed mechanism of another low affinity tag (glutathione-S-transferase) that
was effective for protein immobilization on the surface of microspheres with high
receptor density, despite its low monovalent affinity for its surface bound
receptor26. Microsphere studies with Ni-NTA have reported his-tagged binding to
be insufficient for use in assay development21.
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Multivalency of his-tags has also been proposed as a mechanism to
achieve stable protein binding via avidity effects derived from simultaneous
molecular binding interactions with multiple Ni-NTA groups on a surface27. The
use of mobile receptors in supported lipid bilayers28, can improve avidity. Mobility
allows for receptor rearrangement, increasing the apparent affinity of his-tagged
proteins. Supported lipid bilayers have been shown to provide an excellent
platform for directionally oriented protein binding via histidine chelator lipids29,30,
especially at high densities31,32. Stable binding has been reported using 1% NiNTA incorporated into lipid bilayers supported on a silica chip27. Similar attempts
were made to transfer such bilayers to microsphere surfaces, however, the
bilayer proved to be unstable in these efforts21.
8.3 Results
8.3.1 Direct Attachment to Microspheres
The standard of DNA computation on microspheres has been the use of direct
non-covalent attachment through conjugation via biotin-streptavidin. To provide a
reference point for our surface-based DNAzyme characterizations, we sought to
implement direct attachment to observe DNAzyme cleavage off of streptavidincoated polystyrene microspheres (Spherotech, Lake Forest, IL). Using a
biotinylated chimeric substrate labeled with FAM (a fluorescein derivative), we
attached the substrate to the surface of the microsphere (Figure 8.1A). With the
addition of the E6 DNAzyme, we observed a loss of fluorescence from the bead
surface over the course of 24 hours (Figure 8.1B). Although this demonstrated
the feasibility of direct attachment in agreement with earlier studies, this differed
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from the implementation by Stojanovic2, which also attached the DNAzyme to the
surface of the microsphere. In our characterization, the E6 DNAzyme was added
to the solution and could freely diffuse to the bead surface. Thus, this effort was a
first step in the binding and substrate cleavage with a microsphere/flow
cytometry-based format; additional circuit element development for the
implementation of DNA logic and computation is currently underway.

Figure 8.1 – Chimeric substrate cleavage from a microsphere with an E6
DNAzyme, measured by a loss of fluorescence.
8.3.2 Covalent attachment of DNA to SLBs
Although the direct, non-covalent attachment of DNA directly to microspheres is
of interest due to its simplified set up, many elements of DNA logic and
computation could benefit from a mobile yet 2D constrained interaction. Although
circuit elements would be topologically constrained in the same manner and
orientation as with direct attachment, they would have a significant advantage in
their ability to interact with other circuit elements attached to the same surface
outside of their local attachment area. To implement this mobility, we attached
the chimeric DNAzyme substrate to supported lipid bilayers. The fluidity of the
lipid leaflets ensures that the DNA elements would have the mobility to interact
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with multiple circuit elements. While the biotin-streptavidin attachment method
has potential use, it also may be problematic. For SLBs, this approach requires a
biotinylated lipid, with the attachment of the streptavidin followed by the
attachment of a biotinylated DNA oligonucleotide. Although possible using
tetrameric streptavidin, this can result in ostrich quenching of the fluorescein
labeled DNA substrate strand33, in which fluorescein can associate with the
biotin-binding pocket of streptavidin, resulting in altered fluorescence. This may
prevent access of the DNAzyme to its substrate. Given the flexibility of singlestranded DNA, this interaction should be avoided. To avoid this self-quenching,
we explored an alternative method of conjugation, adapting a previously
established method for coupling a thiolated DNA strand to a maleimide lipid
(Avanti Polar Lipids, Alabaster, Alabama) through a thioether linkage
reaction34,35. This results in a covalent attachment of DNA to the surface, which
can then be read out on the flow cytometer (Figure 8.2).

Figure 8.2 – Coupling of a chimeric substrate to supported lipid bilayers through
a covalent thioether conjugation. (A) Cartoon representation (B) Flow cytometry
analysis of labeled (blue) vs. unlabeled (red) beads.
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After the demonstration of successful coupling, free E6 DNAzyme was added to
the solution and allowed to freely diffuse to the bead surface where it cleaved
substrate. This cleavage was measured as a loss of fluorescence (Figure 8.3).
This is the first successful demonstration of DNAzyme substrate cleavage from
supported lipid bilayers.

Figure 8.3 – (A) Attachment of a chimeric substrate to supported lipid bilayers
and cleavage using an E6 DNAzyme. (B) Loss of fluorescence measured by flow
cytometry, indicative of substrate cleavage (red) from the negative control (black)
without the addition of E6.
8.3.3 Non-covalent attachment of proteins to SLBs
The attachment of proteins to supported lipid bilayers is also of high importance,
due to their use in various synthetic DNA circuits14-16,36. One of the most
commonly used tags is the 6xHis tag, a repeat of six consecutive histidine amino
acids that chelates nickel ions complexed with nitrilotriacetic acid (Ni-NTA), due
to its small size and simple purification techniques. We explored the use of a
mobile lipid bilayer for the rearrangement for Ni-NTA receptors for the
development of stable his-tagged proteins to microspheres, which has not been
previously demonstrated in the literature21. Using high concentrations of Ni-NTA
added to an EggPC lipid bilayer, we were able to demonstrate stable attachment
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of GFP to microspheres, even over several days (Figure 8.4A), and elution with
imidazole resulting in <1% non-specific binding (Figure 8.4B).

!
Figure 8.4 – High percentages and long pre-incubation times yield low
dissociation rates and highly specific binding. (A) High percentages of Ni-NTA
MSLBs demonstrate a biphasic dissociation rate and retain stably bound histagged GFP for 120 hours. (B) Addition of 250 mM imidazole after 72 hours
shows non-specific binding is less than 1%.

To ensure that this attachment strategy would be sufficient to retain multiple
populations, we attached GFP to a single population of beads under various
conditions (Figure 8.5) and mixed this with an unlabeled population. Several time
points were taken to monitor whether the GFP dissociated from the surface of the
bound population and associated with the unlabeled population. Optimal results
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occurred under a 50% labeling density after a 20 hour incubation with GFP,
which showed that populations remained distinct, even after a day (20 hours).

!
Figure 8.5 - Fluorescence transfer between unlabeled and GFP labeled
microsphere populations. Low receptor density incubation times yields
populations that rapidly converge, while increasing receptor density and
incubation time significant stabilizes bead fluorescence, reducing crosstalk. (A)
1% Ni-NTA labeling density, 2hr incubation time (B) 1% Ni-NTA labeling density,
20hr incubation time (C) 50% Ni-NTA labeling density, 2hr incubation time (D)
50% Ni-NTA labeling density, 20hr incubation time.
8.3.4 Direct peptide insertion into SLBs
As transmembrane signaling is a critical mechanism for the cellular
compartmentalization of signaling, we sought to characterize the use of
supported lipid bilayers for the direct insertion of a transmembrane peptide and
the interaction with a synthetic protease construct37. After solubilizing the bilayers
using a mild detergent, the peptide was added to supported lipid bilayers and the
hydrophobic sequence spontaneously inserted into the bilayer. After removing
the detergent, the fluorescent tag was cleaved from the peptide upon addition of
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the protease (Figure 8.6). This demonstrates the viability of monitoring
enzymatic reactions on the surface of supported lipid bilayers.
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Figure 8.6 – Cleavage of a transmembrane peptide from the surface of a silica
microsphere supported lipid bilayer. Loss of fluorescence was observed with the
addition of 500 nM (blue) or 1 µM (green) protease.
8.3.5 Multiplex analysis of SLBs
The use of flow cytometry for monitoring surface compartmentalization of DNA
computational elements holds considerable promise for monitoring the
interactions between multiple bead populations simultaneously. While this is
easily done with hard-dyed polystyrene beads, the use of silica microspheres for
supported lipid bilayers makes multiplexing a significant challenge. Here, we
explored the development of multiplexable supported lipid bilayers with the use of
multiple fluorescence lipids. The use of a pyrene-labeled lipid (Ex: 350, Em: 405)
along with a carboxyfluorescein-labeled lipid (Ex: 488, Em: 530) allowed the
discrimination of multiple separate populations, which can be gated on each
fluorescent channel respective to the concentration of lipid added to each bead
population (Figure 8.7). With the use of different fluorophores, such as one in the
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far red channel, biochemical reactions can be analyzed off of a multiplexed
supported lipid bilayer platform.

Figure 8.7 – Multiplexed supported lipid bilayers with the addition of pyrene (xaxis) and carboxyfluorescein (y-axis). Flow cytometry analysis (using a Mo-Flo
cytometer) was able to discern separate populations of beads with a low (0%),
medium (0.01%), and high (1%) of labeled lipids.
8.4 Conclusions
The work demonstrated here shows the feasibility of surface-based attachment
methods for potential use in DNA computation. We have repeated the
demonstration of direct microsphere attachment and DNAzyme activity shown
previously2. We have also demonstrated a significant amount of work towards
the characterization of supported lipid bilayers for attachment of elements that
could be used in DNA computing circuits, including DNA, proteins, and peptides.
SLBs offer a wide variety of attachment chemistries, including covalent, noncovalent, and direct insertion mechanisms. The use of multiple fluorescent lipids
provide a mechanism for the multiplexing of supported lipid bilayers, ensuring
that this technology can still be used to monitor multiple populations
simultaneously.
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8.5 Future Directions
Successful demonstration of multiple attachment strategies opens the prospect
of coupling and interaction of multiple DNA computing elements to form a
communicating network. Work is underway in our laboratory to develop strand
displacement and DNAzyme displacement for direct microsphere attachment as
well as for supported lipid bilayers. Although we saw promising results for
monitoring cleavage reactions, both DNA and protease, on the surface of SLBs,
optimization to improve these reactions would be essential for the generation of
robust and responsive DNA circuits. Additional coupling strategies, such as click
chemistry,38 should also be explored.
8.6 Materials and Methods
8.6.1 General experimental conditions
Unless otherwise noted, all experiments were conducted on an Accuri C6 flow
cytometer (Becton-Dickinson, San Jose, CA) using a 488 nm laser for excitation
and 530/30 filter for emission.
E6 sequence: CTCTTCAGCGATGGCGAAGCCCACCATGTTAGTGA
E6 substrate sequence (Direct attachment): /5-BiosG/ TTT TCA CTA TrAG GAA
GAG TTT /36-FAM/
E6 substrate sequence (Thiol attachment): /5ThioMC6-D/ TCA CTA TrAG GAA
GAG /iSpC3 /36-FAM/
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8.6.2 Synthesis of supported lipid bilayers
The microspheres were prepared as previously described39. Briefly, 1 mM NiNTA lipids were added in a mol/mol% ratio to generic EPC lipids (Avanti Polar
Lipids). The chloroform solution was dried out and reconstituted in PBS buffer,
and the lipid solution was then extruded or sonicated until clear to form vesicles.
Vesicles were vortexed for 45 min with 10 um nanoporous silica microspheres
with 100 Å pores (GFS Chemicals), surface treated to be hydrophilic.

The

microsphere supported lipid bilayers (MSLB) were then washed three times in
buffer.
8.6.3 DNA-SLB covalent attachment
Vesicles contained 10% MBP-PE (Avanti Polar Lipids, Alabaster, Alabama) in
DOPC were prepared in VP buffer (20 mM citric acid, 35 mM Na2PO4, 108 mM
NaCl, 1 mM EDTA, pH 4.5) and sonicated until clear using a bath sonicator.
Reducing buffer (20 mM citric acid, 35 mM Na2PO4, 108 mM NaCl, 1 mM EDTA,
20 mM DTT, pH 5.0) was degassed under argon for 90 min. 5 uL of 1 mM thiolated
DNA was added to 0.5 mL reducing buffer for a 10 µM final concentration. This
solution was eluted on a Nap-5 column after equilibration with VP buffer. DNA was
added in a 1000X excess of MBP concentration and mixed under a constant argon
stream for up to 8hrs with stirring.

8.6.4 GFP experiments
Microspheres were incubated for various times with a thermostable GFP protein
containing a C-terminal hexahistidine tag, expressed from the pET-CK3-sfGFP40.
This allowed for all protein assays to be run at room temperature to monitor
bilayer stability while minimizing protein denaturation.
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Chapter 9.
Conclusions and Future Directions
9.1 Conclusions
9.1.1 Development of DNAzyme displacement gates
We have demonstrated the successful regulation of DNAzyme activity by strand
displacement for the construction of molecular logic gates. This combines the
advantages of both technologies: the use of DNAzymes can provide DNA circuits
with a rich diversity of biochemical reactions and innate catalysis without the
need

for

additional

strands

and

hybridization

reactions,

while

strand

displacement offers a sensitive and specific mechanism for programming
molecular

interactions.

Each

has

been

extensively

but

independently

characterized, and unifying these biochemical concepts can have far-reaching
implications for the potential development of DNA circuits and computers. We
also demonstrated the introduction of mismatches for the release of a DNAzyme,
which furthers the understanding of strand displacement interactions and
capabilities. This represents an important first effort in creating robustly regulated
DNAzymes for molecular logic and for the development of hybrid logic circuits.
9.1.2 Multi-layer DNAzyme cascades
Using the DNAzyme displacement logic gates, we developed a structured
chimeric substrate (SCS) that enabled a DNA signal to be propagated from one
DNAzyme logic gate to another. This was a major advance for the development
of DNAzyme cascades; there had only been minor success in this area1,2, which
had not been broadly applicable to the DNA computational community at large.
The rational design process for the SCS structure was described in detail,
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demonstrating both the wide variety of structural changes and the large effects
they can have on signal propagation. The success of the SCS demonstrates the
efficacy of this approach for the design of dynamic DNA nanostructures;
however, the granularity at which alterations were made implies a large potential
structure-space, even for the design of sequences that contain multiple design
constraints.
The SCS molecule served as an effective communication module between
two DNAzyme displacement gates, which enabled the construction of a five layer
DNAzyme cascade, the longest to date. This molecule can interact with
molecular logic gates outside of the 8-17 DNAzyme displacement gates used in
the cascade, yet another step in the creation of hybrid DNA circuits. These
cascades are also amenable to use in bioassays, as they are resistant to
background and do not require additional purification. The potential of this
system was demonstrated in a representative three-input Dengue serotyping
assay, in which the circuit responded with a positive output response only in the
presence of all three targets. This has implications both for molecular logic and
computation as well as the understanding and development of synthetic enzyme
cascades, which may aid in the understanding of complex signal propagation and
transduction networks.
9.1.3 A versatile, modular DNA biosensor
We have designed a new DNA biosensor structure that couples each reporter
DNAzyme to an input recognition domain, which we call the detection domain.
These domains are orthogonal to each other and therefore can vary
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independently, which gives this sensor a broad flexibility both for the input as well
as the output. We have extensively characterized this biosensor structure,
optimizing it for low leakage while retaining high activation even in the continuous
presence of the fuel strand. As with the cascades, this biosensor is highly
specific and performs well in a random DNA background under minimal
purification. This biosensor was shown to perform well with the detection of many
different targets of a multiplex assay, with a limit of detection below 10 pM. Given
its modularity, we altered the detection domain to show response against a
variety of inputs, including RNA, ssDNA, dsDNA, and small molecules such as
ATP. We also demonstrated initial success to in cascading this new gate
structure. This has significant implications for the combination of biosensing with
molecular logic for higher order computation and the development of intelligent
biosensors.
9.1.4 High-throughput screen of the 8-17 DNAzyme
The 8-17 DNAzyme was screened against a scaffold library to look for molecular
cofactors that could lead to catalytic rate enhancement. As DNAzymes are
artificially selected under specific conditions, the use of high-throughput screens
for testing large numbers of randomized compounds has the potential to uncover
new and unique catalytic behaviors. Although no activating compounds were
discovered, two strongly inhibitory scaffolds were identified. These compounds
could have potential for establishing a threshold for in vitro assays or regulating
the in vivo activity of therapeutic DNAzymes.
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9.1.5 Surface-based DNA and protein attachment
We have established a baseline characterization of several different modalities
for surface-based DNA computation. The compartmentalization of DNA circuit
units provides a straightforward method to standardizing circuit components via
physical separation, which is a critical step towards rapid scaling of circuit size
and complexity, allowing circuits to integrate more inputs and leading to the
development of intelligent biosensors. Due to their ease of use, we have
demonstrated the attachment and cleavage of chimeric substrates from
polystyrene beads, which holds promise for the development of hybrid beadsolution interactions. However, to overcome the limitations of previous work
using direct attachment to beads3,4, we have characterized the binding of both
DNA and proteins to supported lipid bilayers5, which have the potential to create
mobile DNA logic elements constrained on bead surfaces. We have explored
several different attachment strategies, such as covalent thioether attachment of
DNA, non-covalent 6xHis-tag/Ni-NTA of proteins, and direct peptide insertion.
Although further characterization is necessary, each of these shows considerable
promise for the potential use of supported lipid bilayers for surface-based
interactions.
9.2 Future Directions
Taken as a whole, the work presented in this dissertation expands the
understanding of the underlying principles of DNA computation for use in
biodetection applications. These principles establish a comprehensive framework
with which the continued development of more sophisticated computational tools
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and circuits can be carried out. Outlined below are some of the most promising
directions that can now feasibly be achieved through the knowledge gained
through this work. Conceptualization and implementation for many of these ideas
are currently underway.
9.2.1 Modular gate cascades
Our laboratory is currently in the process of continuing work and development on
the modular gate cascades. Successful implementation of a two-layer cascade
using the modular gate framework has been demonstrated in Section 6.2.5. This
gate design has already shown considerable promise as a direct biosensor, with
a low limit of detection (LOD) and high specificity, sensitivity, and modularity. The
development of cascades using the modular gate designs offers an apparent
method for the construction of multi-layer DNAzyme cascades capable of
performing molecular logic. Most importantly, the design ensures each DNAzyme
is regulated by a corresponding input; thus, the inclusion of multiple modular
gates into a single circuit also ensures the integration of multiple inputs, a key
parameter for the development of complex computation. This can give rise to
advanced circuit behaviors, examples of which are described in Section 6.2.7.
Given the performance of individual gates as biosensors, the addition of complex
logic will be a crucial next step for the development of a next-generation
biosensor and ultimately, intelligent biosensors.
9.2.2 Optimization of modular gate design
Although much improvement has already been made regarding the performance
of the modular gates through the introduction of mismatches into the loop toehold
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for fuel strand displacement, further optimizations are highly desirable. In
particular, the rate of activation against double-stranded DNA targets such as
whole plasmid DNA is very slow (full activation is achieved after several days of
incubation). Improving this activation rate while retaining low leakage will be a
major advancement in the performance of a biosensor and open up many new
target opportunities currently out of reach due to the long sensing times.
Optimization of modular gate performance will likely also target the
removal of excess inhibitor, as its presence currently acts as a sink for target
inputs, negatively affecting the attainable limit-of-detection of the gate. While new
data indicates that magnetic bead purification hold promise for fast, isothermal
removal, the excess inhibitor may not be benign as currently presumed, but may
play a role in the suppression of gate leakage or the reinhibition of activated
DNAzymes. Thus, while the removal of inhibitor may result in a lower detection
limit, it may also increase spurious gate activation. Further characterization of
these effects is warranted.
9.2.3 Detection of biological samples
Although much effort has been made toward the development of DNAzyme
displacement gates, cascades, and modular gates for biological applications,
including their performance in a random DNA background, their performance
against real world biological sample targets has not yet been demonstrated.
Efforts are currently underway to explore their use against multi-strain targets
such as Dengue (a single-stranded RNA target) and Shiga-toxin producing E. coli
(a double-stranded DNA target). One of the major concerns is the low
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concentration of nucleic acid targets, likely in the low picomolar to femtomolar
range, which is currently below our characterized LOD for a ssDNA target input.
9.2.4 Additional screening targets for DNAzymes
Although the screen of the 8-17 DNAzyme was unsuccessful in finding catalytic
cofactors, the demonstration of the first successful high throughput screen of a
DNAzyme holds considerable promise for the potential success of future targets.
Although the AllX scaffold library contained a significant amount of diverse
compounds, the screening of other small molecule libraries may yet yield
activating compounds. Additionally, there are DNAzymes known to contain
alternative mechanisms of RNA-cleavage outside of exclusive αγ catalysis, such
as 10-23 or X-motif6. The difference in RNA catalysis may yield activation in the
presence of certain compounds that could amplify or accelerate these
mechanisms. Additionally, newly discovered DNA-cleaving DNAzymes7 are of
significant interest due to the use of an all-DNA substrate, and their selection
under physiologically relevant conditions would make the transition to in vivo use
a realistic goal.
9.2.5 Development of theranostic circuits
Although the work in this dissertation focused predominately on the development
of the input/detection methods, the demonstration of DNAzyme cascading was a
major advance for the extension of a signal cascade through the output of a DNA
strand. This approach may offer a straightforward method for the development of
theranostic circuits, in which the release of a DNA strand could be an active
DNAzyme capable of cleaving RNA strands in vivo8-10. In this way, the

193

mechanism of interpreting inputs of a logic circuit developed herein could be
coupled to the release of an output capable of affecting cellular functionality.
Alternatively, there has been significant work and interest in the use of supported
lipid bilayers for the targeted delivery of therapeutic compounds or nucleic acids
to cancer cells11-14. If the release of these compounds could be triggered by the
computational decisions of a DNA logic circuit, this would be a major step
towards the development of theranostic devices.
9.2.6 In vivo DNA computation
The promising long-term future of DNA computation lies with the continued
progress toward an in vivo biological computer. While there have been several
key demonstrations of this concept, overall the sophistication of in vivo DNAbased computation is still in its infancy. Although some progress has been made
as to the performance of strand displacement logic gates in cells15, the location
and availability of these gates outside endosomal compartments remains
unclear. The use of DNAzymes in vivo has a similarly conflicted scientific record.
While there have been several promising studies8-10,16, there are also concerns
about the efficacy and performance in cells17-21 and these systems did not
employ any molecular logic. Taken as a whole, one of the most anticipated
advances in the field DNA computation will be the improved design and
performance of autonomous, multi-component circuits under non-pristine
conditions, particularly in vivo diagnostics.
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Appendix 1
Section A1.1. Oligonucleotide sequences and concentrations
All oligonucleotide sequences are listed 5’ to 3’. Functional domains have been
color-coded to match the corresponding domains in the figures, domain junctions
are indicated by a space, and strand names have been annotated with the
corresponding labels from the figures. The dinucleotide junctions that are cleaved
in the substrate strands have been highlighted using a yellow background, and
mismatched bases in AND gate inhibitors are shown as single red letters. The
RNA base at the cleavage site in each substrate strand is represented as rA, and
the fluorophore (fluorescein) and quencher (TAMRA) are represented as FAM
and TAM respectively.
Table A1.1. Oligonucleotide sequences and concentrations for Figures 3.2A and
A1.2.
Strand
Input
DNAzyme (Dz)
Inhibitor (Inh)
Substrate

Sequence
GCCGGTCGAA AACTAAGA TACAT
GAACTATC TCCGAGCCGGTCGAA AACTAAGA
ATGTA TCTTAGTT TTCGACCGGC
FAM-TCTTAGTT rAG GATAGTTC AT-TAM

Conc. (nM)
100
100
125
250

Table A1.2. Oligonucleotide sequences and concentrations for Figure 3.2B.
Strand
Input
DNAzyme (Dz)
Substrate

Sequence
ATGTA TCTTAGTT TTCGACCGGC
GAACTATC TCCGAGCCGGTCGAA AACTAAGA
FAM-TCTTAGTT rAG GATAGTTC AT-TAM

Conc. (nM)
125
100
250

Table A1.3. Oligonucleotide sequences and concentrations for Figures 3.2C and
A1.1.
Strand
Input1
Input2
DNAzyme (Dz)
Inhibitor (Inh)
Substrate

Sequence
CGGTCGAA AACTAAGA TGGAG
GACCT GAACTATC TCCGAGC
GAACTATC TCCGAGCCGGTCGAA AACTAAGA
CTCCA TCTTAGTT TTCGACCGGCTCGGA GATAGTTC AGGTC
FAM-TCTTAGTT rAG GATAGTTC AT-TAM

Conc. (nM)
100
100
100
125
250

Table A1.4. Oligonucleotide sequences and concentrations for Figure 3.3.
Strand
Input1
Input2
DNAzyme (Dz)

Sequence
AACTAAGA TGATGTGGAG
GAGGTTGATG GAACTATC
GAACTATC TCCGAGCCGGTCGAA AACTAAGA
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Conc. (nM)
100
100
100

Inhibitor
n=0
Inhibitor
n=1
Inhibitor
n=2
Inhibitor
n=3
Substrate

(Inh),
(Inh),
(Inh),
(Inh),

CTCCACATCA TCTTAGTT TTCGACCGGCTCGGA
CATCAACCTC
CTCCACATCA TCTTAGTT TTCGACCAGCTCGGA
CATCAACCTC
CTCCACATCA TCTTAGTT TTCAACCGGCTAGGA
CATCAACCTC
CTCCACATCA TCTTAGTT TTCAACCAGCTAGGA
CATCAACCTC
FAM-TCTTAGTT rAG GATAGTTC AT-TAM

GATAGTTC 125
GATAGTTC 125
GATAGTTC 125
GATAGTTC 125
50

Table A1.5. Oligonucleotide sequences for Figure 3.4.
Strand
Input1
Input2
DNAzyme AND gate
strand
Inhibitor for AND gate
Substrate for AND gate
Input3
DNAzyme NOT gate
strand
Substrate for NOT gate

Sequence
AACTAAGA TGATGTGGAG
GAGGTTGATG GAACTATC
GAACTATC TCCGAGCCGGTCGAA AACTAAGA

Conc. (nM)
100
100
100

CTCCACATCA TCTTAGTT TTCAACCAGCTAGGA
GATAGTTC CATCAACCTC
FAM-TCTTAGTT rAG GATAGTTC AT-TAM
CGGCTCGGA TCTATCCA CATTC
TGGATAGA TCCGAGCCGGTCGAA AACTAAGA

125

FAM-TCTTAGTT rAG TCTATCCA AT-TAM

50

50
125
100

Section A1.2. Further investigation of AND gate controls
In Figure 3.2C we observed that our DNAzyme displacement AND gate showed
slightly different behavior upon the addition of Input2. While addition of Input1
showed no increase in signal compared to the control comprising the inhibited
gate complex and the substrate, the addition of Input2 lead to a reproducible
initial increase in fluorescence, as shown in Figure A1.1A (which is a
reproduction of Figure 3.2C, included here for ease of comparison).
We investigated this effect by running additional controls with just the substrate
and the individual input strands, as shown in Figure S1B. We observed an
identical response to that seen in the presence of the inhibited gate complex. We
conclude that Input2 interacts directly with the reporter substrate, which has a
direct effect on the observed fluorescence. This is likely due to additional
undesired complementarity between Input2 and the 3’ end of the substrate
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molecule, near the quencher. Binding of the activator this close to the quencher
may interfere with the FRET efficiency. Alternatively, activator binding to the
substrate strand may result in a straightened helix, which could increase the
distance between the FRET pair, again reducing quencher efficiency. This effect
also may sequester a significant fraction of the second input that, when
combined with the slower kinetics of cooperative hybridization, yields the
significantly slower rates than was observed for the YES gates.
Therefore the different behavior of the input control can be attributed not to
incomplete inhibition of the DNAzyme (which makes sense given that the
fluorescence trace does not rise following the initial “burst”), but to undesired
interactions between Input2 and the substrate. We believe that further sequence
optimization could enable us to eliminate this effect, producing a similar response
in the presence of just Input2 as was seen in the presence of just Input1.
The initial burst phase seen in Figure A1.1B was not observed in Figure A1.1A,
likely due to different dead time between the two experiments. Concentrations
are given in Table A1.3.

Figure A1.1. Investigation of activator-substrate interactions in the DNAzyme
displacement AND gate. A) Data from main text illustrating action of DNAzyme
displacement AND gate. B) Control experiments consisting of just activator
strands and substrate in solution, in the absence of DNAzymes.
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Section A1.3. Investigation of concentration effects and input thresholding
by excess inhibitor strands
Preparation of DNAzyme-inhibitor complexes is a crucial part of our experimental
procedure. Any DNAzymes that are not inhibited will be free to cleave substrates
regardless of whether input strands are present, producing an unwanted leakage
signal that gradually rises over time due to the multiple-turnover action of the
DNAzyme. Therefore, it is important to ensure that all DNAzymes are fully
inhibited.
One way to achieve this is to purify DNAzyme-inhibitor complexes after
annealing by gel electrophoresis; however, this is both time- and labor-intensive,
and therefore costly. Therefore we investigated the effect of annealing the
DNAzyme-inhibitor complexes in the presence of a stoichiometric excess of
inhibitor, to account for concentration and purity variations between stocks. We
used different concentrations of activator and excess inhibitor in the YES gate
example from Figure 3.2A, and the results are presented in Figure A1.2. We
found that adding inhibitor strands in 10-20% excess relative to the concentration
of the DNAzyme strand produced optimal performance. We observed lower
leakage with increasing amounts of excess inhibitor, but this reduced the
system’s sensitivity and increased the response time for lower input
concentrations. This is most likely due to a thresholding effect, whereby the
excess inhibitor absorbs some (or all) of the input strands because the inhibitor
strands bind more rapidly to the input strands than to the DNAzyme-inhibitor
complexes, because the inhibitor contain a longer sequence complementary to
the input. Similar effects are observed in other systems based on strand
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displacement systems1-3. We observed a clear signal over background down to 1
nM input concentrations in certain conditions, which shows that the low input
concentrations are amplified into a larger concentration of cleaved substrate due
to the isothermal signal amplification capability of DNAzymes.

Figure A1.2. Kinetic traces of DNAzyme displacement YES gate output for
different concentrations of input and excess inhibitor. In each panel, the
concentration of the input strand (labeled “Input” in Figure 2A) varies as labeled.
The concentration of excess inhibitor in solution varies between panels, as
follows: A) 0 nM, B) 5 nM, C) 10 nM, D) 15 nM, E) 20 nM, F) 25 nM. In all cases,
the concentration of inhibited DNAzymes (labeled Dz-Inh in Figure 2A) was 100
nM and the concentration of substrate was 50 nM. As the inhibitor concentration
increases, it produces lower leakage but at the cost of increasing the limit of
detection and slowing the response to lower concentrations of input.
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Section A1.4. Thermodynamic investigation of destabilization of AND gate
inhibitor by mismatched bases in the catalytic core
In Figure 3.3, the use of three mismatches in the AND gate inhibitor produced
the optimal response in the presence of both activators, compared to the
inhibitors with 0, 1, and 2 mismatches. To investigate this further, we used
NUPACK4,5 to generate predicted structures and complexes, along with their
corresponding minimal free energies (MFEs) and the relative probability of
formation. The results of these calculations are summarized in Tables A1.6 and
A1.7.
Columns (a) and (b) of Table S6 show a trend of increasing minimum free energy
(MFE) with increasing numbers n of mismatches, for both the DNAzyme-inhibitor
complex (Dz-I) and the DNAzyme-inhibitor complex with both inputs bound (DzInh-Input1-Input2). The latter is formed when both inputs are added, and maybe
be viewed as an unwanted structure because the both activators have bound to
the DNAzyme-inhibitor complex, but the active DNAzyme has not been released
into solution. The concentration of free DNAzyme strands in solution corresponds
to the formation of an inhibitor-activator complex (Inh-Input1-Input2) without the
DNAzyme strand still bound, since the formation of this structure indicates the
displacement of the DNAzyme strand.
Column (c) of Table A1.6 presents the equilibrium concentrations of the Dz-InhInput1-Input2 complex (corresponding to unsuccessful displacement of the
DNAzyme strand by both activators) and of free DNAzyme (Dz) in solution
(corresponding to successful displacement). These concentrations do not add up
to 100 nM because of additional complexes involving the Dz strand, for instance
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the initial Dz-Inh complex and those complexes where only a single activator is
bound (Dz-Inh-Input1 and Dz-I-Input2). For clarity, we do not tabulate these
concentrations here. We see that the concentration of free DNAzyme in solution
is very low for n=0,1,2 but increases dramatically for n=3. We observe a similar,
but less pronounced, trend in column (d), where we included an additional 25 nM
of inhibitor to more accurately reflect our experimental conditions. In this case,
the additional inhibitor is able to rebind some of the displaced Dz strands, which
accounts almost exactly for the discrepancy in the concentration of free Dz (68
nM versus 97 nM). In any case, these calculations concur with the trend from our
experimental data from Figure 3.3B, where we saw low activation for n=0,1,2 but
a fast kinetic trace for n=3. This is likely due to the fact that three mismatches
ensures that the core region of the DNAzyme remains bound to the inhibitor only
by several short duplexes, which decreases the relative stability of any single
duplex. In the absence of each activator, the binding arm duplexes are sufficient
to maintain a stable complex, even in the presence of one activator (Figure
3.3C). However, with both activators present, in the catalytic core region only
duplexes of 6, 3, 3, and 6 bases remain, and DNA breathing likely accounts for
the rapid dissociation of the DNAzyme from this complex.
We observed that the MFE structure for the Dz-Inh-Input1-Input2 complexes was
not quite the idealized structure that we depicted in Figure 3.3A. As shown in
Figure A1.3, the MFE structure actually has incomplete binding of the two input
strands, which presumably leads to a more stable complex overall by extending
the length of the duplex on either side of the mismatches bases. We computed
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free energies for these idealized structures, which are listed in Table A1.8. The
results are shown in column (a) of Table A1.7, and we observed a similar trend
of increasing free energy with increasing n.
Finally, we investigated the stability of the binding between the catalytic core and
the (potentially mismatched) inhibitor strand in isolation. We used just the
catalytic core portion of the DNAzyme strand as one input sequence, and the
corresponding portion of the inhibitor strand (for n=0,1,2,3) as a second input
sequence. As shown in columns (b) and (c) of Table A1.7, we observed a similar
trend of almost complete binding of the inhibitor to the catalytic core for n=0,1
and no binding at all for n=3. Interestingly, the binding percentage for n=2 in this
experiment was lower than observed when modeling the entire complex, which
suggests that the additional flanking duplex between the DNAzyme and inhibitor
strands (see Figure A1.3) may play a role in stabilizing the complex in this case.
It is important to bear in mind the limitations of thermodynamic modeling. In
particular, NUPACK models all structures at equilibrium conditions, which may
not accurately reflect the dynamic behavior of our DNAzyme displacement
devices, which are inherently reliant on transient interactions between
catalytically active DNAzyme strands and their substrates. While we have largely
concerned ourselves with the MFE structured and energies, there will be many
additional variants of each structure present in solution. Additionally, the direct
applicability of NUPACK’s structural predictions to our experiments is limited by
the fact that the tables of thermodynamic parameters that serve as the basis of
the NUPACK prediction algorithm are only really valid within a certain range of
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salt concentrations. In particular, our reactions require Zn2+ ions in the buffer to
serve as cofactors for the DNAzyme cleavage reaction, and the effects of these
ions on the relative stability of the various DNA structures (and, indeed, on the
folding of the DNAzyme strand) are a subject of ongoing research6,7.

Figure A1.3. (A) Idealized structure of the Dz-Inh-Input1-Input2 complex with n=3
mismatches. (B) Minimum free energy structure of the Dz-Inh-Input1-Input2
complex for n=3. Note that, in the most stable structure, the two input strands are
not completely bound to the inhibitor: rather, some bases are left overhanging.
Presumably this produces a more stable structure overall by increasing the
length of the bound duplex on either side of the outermost mismatched base on
the inhibitor.
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93
93
89
2

0
0
4.2
97

100 nM inhibitor
(c) Conc. of (d) Conc. of
Dz-Inh-Input1- free Dz (nM)
Input2 (nm)

56
56
55
1.3

0
0
0.4
68

125 nM inhibitor
(e) Conc. of (f) Conc. of
Dz-Inh-Input1- free Dz (nM)
Input2 (nm)

Table A1.6. Results of thermodynamic calculations using NUPACK to assess the stability of AND gates with various
numbers n of mismatched bases in the part of the inhibitor strand that is complementary to the catalytic core. All NUPACK
calculations where performed in DNA mode at 25°C, with a maximum complex size of 4 and using the default advanced
options (dangles=”some”, Na+=1.0M, Mg++=0.0M). All sequences are presented in Table A1.4 – the sequences for the
DNAzyme strand (Dz) and the two input strands (Input1 and Input2) are the same throughout, and the sequence of the
inhibitor strand (Inh) changes with varying n as shown in Table S4. In all cases the concentrations of Dz, Input1 and
Input2 were each 100 nM. Calculations were performed with concentrations of Inh at both 100 nM and 125 nM, to assess
the effect of excess inhibitor on the predictions. In columns (c) and (d), the concentrations of Dz, Inh, Input1 and Input2
were all 100 nM. In columns (e) and (f), the concentrations of Dz, Input1 and Input2 were 100 nM and the concentration of
Inh was 125 nM.

-50.49
-44.34
-39.61
-33.46

Number
of (a) MFE of Dz- (b) MFE of Dzmismatches
Inh complex Inh-Input1in inhibitor, n
(kcal/mol)
Input2
complex
(kcal/mol)
-83.52
-77.36
-72.64
-66.49
0
1
2
3
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of
in

(a) Free energy of idealized Dz-Inh-Input1Input2 complex structure (kcal/mol)
-79.96
-73.81
-69.08
-62.93

(b) Percentage of core sequence
(100 nM) bound to inhibitor (100
nM)
100%
97%
48%
0%

(c)
Percentage
of
core
sequence (100 nM) bound to
inhibitor (125 nM)
100%
100%
55%
0%

Table A1.7. Results of additional thermodynamic calculations using NUPACK. Parameters, settings and sequences were
as described in Table S6. (a) Free energies of the “idealized” structures of the Dz-Inh-Input1-Input2 complexes. In each
case, the idealized structure assumes complete binding of the two inputs to the inhibitor strand, which completely
displaces the two substrate binding arms of the DNAzyme from the complex. These structured are presented explicitly in
Table A1.8 below. (b) and (c) Hybridization of just the core sequence of the DNAzyme strand (the black bases in Table
A1.4) were used as one input strand, with the corresponding part of the inhibitor strand (black bases and red mismatches
in Table A1.4). The maximum complex size was 2. In column (b), the concentrations of core strand and inhibitor strand
were both 100 nM, and in column (c) they were 100 and 125 nM respectively.
Number
mismatches
inhibitor, n
0
1
2
3
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of
in

(((((((((((((((((((((((((((((((((((((((((((((((((((+))))))))))))))))))+........)))))))))))))))........+))))))))))))))))))
(((((((((((((((((((((((((.(((((((((((((((((((((((((+))))))))))))))))))+........))))))).)))))))........+))))))))))))))))))
(((((((((((((((((((((.(((((((.(((((((((((((((((((((+))))))))))))))))))+........))).))))))).)))........+))))))))))))))))))
(((((((((((((((((((((.(((.(((.(((((((((((((((((((((+))))))))))))))))))+........))).))).))).)))........+))))))))))))))))))

Dot-paren-plus representation for idealized structure of Dz-Inh-Input1-Input2 complex

Table A1.8. Idealized structures for Dz-Inh-Input1-Input2 complexes for different numbers n of mismatched bases in the
inhibitor. The structures are represented in the dot-paren-plus format, which is a standard notation for the secondary
structures of multi-strand complexes. Parentheses denote paired bases, dots denote unpaired bases, and plus signs
denote strand breaks.
Number
mismatches
inhibitor, n
0
1
2
3
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Appendix 2
A2.1.1 Oligonucleotide sequences

Oligonucleotide sequences are presented in Tables 4.1-4.8. All sequences are listed 5’ to 3’. The cleavage sites in the

substrates have been highlighted in red and the catalytic cores of DNAzymes are highlighted in bold. The RNA base at

the cleavage site in each substrate (including SCS) strand is represented as rA. Fluorescein fluorophores and TAMRA
quenchers are represented as /FAM/ and /TAM/ respectively.

Sequence
GGGAGCCGTCCGAGCCGGTCGAAACTGTGGT
GCCGCTATACAAAGGTCGAAATATTTGTACCACAGTrAGCGGCTCCC
GGTAGCGCTCCGAGCCGGTCGAAATATTTGT
GTGGTACAAATATTTCGACCGGC
GCGCCTATTCCCCGGTCGAAACAGGGGAACAAATATrAGGCGCTACC
ACATGCCGTCCGAGCCGGTCGAAACAGGGGA
TTTGTTCCCCTGTTTCGACCGGC
GCCGCTAATACATGGTCGAAAGTATGTATCCCCTGTrAGCGGCATGT
ATCACGCCTCCGAGCCGGTCGAAAGTATGTA
GGGGATACATACTTTCGACCGGC
CGCCCTAATCTTAGGTCGAAAACTAAGATACATACTrAGGGCGTGATG
GAACTATCTCCGAGCCGGTCGAAAACTAAGA
ATGTATCTTAGTTTTCGACCGGC
/FAM/-TCTTAGTTrAGGATAGTTCAT-/TAM/

Table A2.1. Sequences from multi-layer cascade experiments (Figure 4.2b), concentration profile of two-layer DNAzyme
signaling cascade (Figure A2.1), and two-layer cascade experiment in DNA background (Figure A2.6).
Strand
th
5 layer DNAzyme
SCS5
th
4 layer DNAzyme
th
4 layer inhibitor
SCS4
rd
3 layer DNAzyme
rd
3 layer inhibitor
SCS3
nd
2 layer DNAzyme
nd
2 layer inhibitor
SCS2
st
1 layer DNAzyme
st
1 layer inhibitor
st
1 layer reporter substrate
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Sequence
ACCAACAACAAACACCAAA
ACACCAAATCCGAGCCGGTCGAACATCATTC
TCTGTGCCTGGAATGATGTTCAACCAGCTAGGATTTGGTGTTTGTTGTTGGT
CAAACTCCTCTTAGGTCGAAAACTAAGAGAATGATGrAGTTTGGTGT
ACTGCTCTTAACATCCTC
ACATCCTCTCCGAGCCGGTCGAACATCATTC
TCTGTGCCTGGAATGATGTTCAACCAGCTAGGAGAGGATGTTAAGAGCAGT
CCTCCTCCTCTTAGGTCGAAAACTAAGAGAATGATGrAGGAGGATGT
GTGTGCCAGTCTTCAAGC
CTTCAAGCTCCGAGCCGGTCGAACATCATTC
TCTGTGCCTGGAATGATGTTCAACCAGCTAGGAGCTTGAAGACTGGCACAC
AAGCCTCCTCTTAGGTCGAAAACTAAGAGAATGATGrAGGCTTGAAG
TATTGAAGTCAGGCCACT
AGGCCACTTCCGAGCCGGTCGAACATCATTC
TCTGTGCCTGGAATGATGTTCAACCAGCTAGGAAGTGGCCTGACTTCAATA
CACTCTCCTCTTAGGTCGAAAACTAAGAGAATGATGrAGAGTGGCCT
CATCATTCCAGGCACAGA
CATGGGCTACTGGATAGA
TGGATAGATCCGAGCCGGTCGAAAACTAAGA
CATTCTCTTAGTTTTCGACCAGCTAGGATCTATCCAGTAGCCCATG
/FAM/-TCTTAGTTrAGTCTATCCAAT-/TAM/

Table A2.2. Sequences from characterization of two-layer dengue serotyping circuits (Figure 4.3b and Figure A2.4).
Strand
DEN-1 target
DEN-1 upstream DNAzyme
DEN-1 upstream inhibitor
DEN-1 SCS
DEN-2 target
DEN-2 upstream DNAzyme
DEN-2 upstream inhibitor
DEN-2 SCS
DEN-3 target
DEN-3 upstream DNAzyme
DEN-3 upstream inhibitor
DEN-3 SCS
DEN-4 target
DEN-4 upstream DNAzyme
DEN-4 upstream inhibitor
DEN-4 SCS
DengueA target
DengueB target
Downstream DNAzyme
Downstream inhibitor
Downstream reporter substrate

Sequence
ATCACGCCTCCGAGCCGGTCGAAAGTATGTA
CGCCCTAATCTTAGGTCGAAAACTAAGATACATACTAGGGCGTGATG
CGCCCTAATCTTAGGTCGAAAACTAAGATACATACTrAGGGCGTGATG
GAACTATCTCCGAGCCGGTCGAAAACTAAGA
ATGTATCTTAGTTTTCGACCGGC
/FAM/-TCTTAGTTrAGGATAGTTCAT-/TAM/

Table A2.3. Sequences from demonstration that SCS cleavage is necessary for signal propagation (Figure A2.2).
Strand
Upstream DNAzyme
Uncleavable SCS
SCS
Downstream DNAzyme
Downstream inhibitor
Downstream reporter substrate

209

Sequence
ATCACGCCTCCGAGCCGGTCGAAAGTATGTA
CTCCTGTGCATACATACTTTCAACCAGCTAGGAGGCGTGATGATGAGTTTG
AGTATGTATGCACAGGAG
CAAACTCATCATCACGCC
CGCCCTAATCTTAGGTCGAAAACTAAGATACATACTrAGGGCGTGATG
GAACTATCTCCGAGCCGGTCGAAAACTAAGA
ATGTATCTTAGTTTTCGACCGGC
/FAM/-TCTTAGTTrAGGATAGTTCAT-/TAM/

Table A2.4. Sequences from demonstration of first SCS input-output combination (Figure A2.3a).
Strand
Upstream DNAzyme
Upstream inhibitor
Input 1
Input 2
SCS
Downstream DNAzyme
Downstream inhibitor
Downstream reporter substrate

Sequence
ATCACGCCTCCGAGCCGGTCGAAAGTATGTA
AAACATACATACTTTCGACCGGC
GGTCGAAAGTATGTATGTTT
CGCCCTAATCTTAGGTCGAAAACTAAGATACATACTrAGGGCGTGATG
TGATAGTTCATGTATCTTAGTTTTCGGAACTATCAGCGATGACTGTTTTCAGTCCACCCATGTAACTAAGA
/FAM/-TCTTAGTTrAGGATAGTTCAT-/TAM/

Table A2.5. Sequences from demonstration of second SCS input-output combination (Figure A2.3b).
Strand
Upstream DNAzyme
Upstream inhibitor
Input
SCS
Downstream DNAzyme
Downstream reporter substrate

Sequence
ATCACGCCTCCGAGCCGGTCGAAAGTATGTA
AAACATACATACTTTCGACCGGC
GGTCGAAAGTATGTATGTTT
CGCCCTAATCTTAGGTCGAAAACTAAGATACATACTrAGGGCGTGATG
/FAM/-GCCGGTCGAAAACTAAGA
ATGTATCTTAGTTTTCGACC-/TAM/

Table A2.6. Sequences from demonstration of third SCS input-output combination (Figure A2.3c).
Strand
Upstream DNAzyme
Upstream inhibitor
Input
SCS
Downstream fluorophore strand
Downstream quencher strand

!
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Sequence
TGCCAGTCTTCAAGCATG
CAAGCATGTCCGAGCCGGTCGAACATCATTC
TCTGTGCCTGGAATGATGTTCAACCAGCTAGGACATGCTTGAAGACTGGCA
CATGCTCCTCTTAGGTCGAAAACTAAGAGAATGATGrAGCATGCTTG
GTGTGCCAGTCTTCAAGC
CTTCAAGCTCCGAGCCGGTCGAACATCATTC
TCTGTGCCTGGAATGATGTTCAACCAGCTAGGAGCTTGAAGACTGGCACAC
AAGCCTCCTCTTAGGTCGAAAACTAAGAGAATGATGrAGGCTTGAAG
CATCATTCCAGGCACAGA
CATGGGCTACTGGATAGA
TGGATAGATCCGAGCCGGTCGAAAACTAAGA
CATTCTCTTAGTTTTCGACCAGCTAGGATCTATCCAGTAGCCCATG
/FAM/-TCTTAGTTrAGTCTATCCAAT-/TAM/

Table A2.7. Sequences from optimization of DEN-3 serotyping circuit (Figure A2.5b).
Strand
Initial DEN-3 target
Initial DEN-3 upstream DNAzyme
Initial DEN-3 upstream inhibitor
Initial DEN-3 SCS
Optimized DEN-3 target
Optimized DEN-3 upstream DNAzyme
Optimized DEN-3 upstream inhibitor
Optimized DEN-3 SCS
DengueA target
DengueB target
Downstream DNAzyme
Downstream inhibitor
Downstream reporter substrate

Sequence
CTCTTAACATCCTCACAG
CCTCACAGTCCGAGCCGGTCGAACATCATTC
TCTGTGCCTGGAATGATGTTCAACCAGCTAGGACTGTGAGGATGTTAAGAG
ACAGCTCCTCTTAGGTCGAAAACTAAGAGAATGATGrAGCTGTGAGG
ACTGCTCTTAACATCCTC
ACATCCTCTCCGAGCCGGTCGAACATCATTC
TCTGTGCCTGGAATGATGTTCAACCAGCTAGGAGAGGATGTTAAGAGCAGT
CCTCCTCCTCTTAGGTCGAAAACTAAGAGAATGATGrAGGAGGATGT
CATCATTCCAGGCACAGA
CATGGGCTACTGGATAGA
TGGATAGATCCGAGCCGGTCGAAAACTAAGA
CATTCTCTTAGTTTTCGACCAGCTAGGATCTATCCAGTAGCCCATG
/FAM/-TCTTAGTTrAGTCTATCCAAT-/TAM/

Table A2.8. Sequences from optimization of DEN-2 serotyping circuit (Figure A2.5d).
Strand
Initial DEN-2 target
Initial DEN-2 upstream DNAzyme
Initial DEN-2 upstream inhibitor
Initial DEN-2 SCS
Optimized DEN-2 target
Optimized DEN-2 upstream DNAzyme
Optimized DEN-2 upstream inhibitor
Optimized DEN-2 SCS
DengueA target
DengueB target
Downstream DNAzyme
Downstream inhibitor
Downstream reporter substrate
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A2.2.2 DNA sequence design
The high-level structures of the strands and complexes were designed based on
biophysical expectations of the stability of the complexes and their dynamic
interactions with the other components of the system. The conserved sequences
of the catalytic cores of the 8-17 and E6 DNAzymes were obtained from the
literature 8,9.
Sequence design for SCS molecules was performed using a custom
Python script that uses the NUPACK secondary structure prediction algorithm
and the ISO numeric representation of nucleic acid secondary structure

11

10

to find

suitable domain assignments for the SCS sequence. Randomly generated
sequences were tested using NUPACK to assess their equilibrium binding to the
downstream DNAzyme and inhibitor strands in both the pre-cleavage state (to
estimate leak rates) and the post-cleavage state (to estimate activation rates).
Sequences that passed these tests were assessed for unwanted secondary
structure using NUPACK and ISO, and candidate sequences were manually
checked and optimized. Sequences for loop-inhibited DNAzyme logic gates were
derived from the sequences of the DNAzyme displacement logic gates in the
two-layer cascade via ensemble defect optimization using the NUPACK design
tool 12.
For the dengue serotyping bioassays, we first performed a ClustalW
sequence alignment on the genomes of all four dengue serotypes. Conserved
and unconserved regions were identified manually and candidate target
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sequences were selected from these regions. These were then tested for
secondary structure using NUPACK and optimized by hand as necessary.
It is worth noting that NUPACK only models systems at thermodynamic
equilibrium, and because the SCS participates in highly dynamic, transient
interactions we can only draw limited conclusions about the behavior of our
circuits from NUPACK predictions. We were forced to approximate the ribose
base at the cleavage site by a deoxyribose base, because the available
thermodynamic tables that serve as the basis of the NUPACK structure
prediction algorithm

13

do not include parameters for DNA-RNA hybrids.

Furthermore, the thermodynamic tables are only strictly valid within a certain
range of salt concentrations. In particular, our reactions require Zn2+ ions in the
buffer to serve as cofactors for the DNAzyme cleavage reaction, and the effects
of these ions on DNA folding and on the relative stability of the various DNA
structures are subjects of ongoing research 6,7,14-16.
A2.2.3 Multi-layer cascade experiments (Figure 4.2b,c)
Sequences are listed in Table A2.1. Concentrations for Figure 4.2b: 100 nM
DNAzyme per layer, 125 nM inhibitor per layer (except the top layer), 100 nM
SCS per layer, 250 nM fluorescent reporter substrate. Concentrations for Figure
2c: 100 nM 1st layer DNAzyme, 75 nM 2nd Layer DNAzyme, 50 nM 3rd layer
DNAzyme, 25 nM 4th layer DNAzyme, 25% excess inhibitor and equimolar SCS
per layer relative to DNAzyme concentration, 250 nM fluorescent reporter
substrate. Pre-annealed DNAzyme-inhibitor complexes were added to buffer first,
then pre-annealed SCS molecules, then fluorescent reporter substrate. Input
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(active DNAzyme in the top layer) was added last to initiate the reaction. Loss of
FRET was observed over two hours. Each trace was baseline-corrected by
subtracting the initial value for that trace from each time point in that trace.
A2.2.4 Characterization of two-layer dengue serotyping circuits (Figure 4.3b,
Figure A2.4) and secondary structure optimization in dengue serotyping
circuits (Figure A2.5b,d)
Sequences for Figure 4.3b and Figure A2.4 are listed in Table A2.2. Sequences
for Figure A2.5b are listed in Table A2.7. Sequences for Figure A2.5d are listed
in Table A2.8. Concentrations: 100 nM DNAzyme (upstream & downstream),
125 nM inhibitor (upstream & downstream), 100 nM inputs (DengueA, DengueB,
DEN-k for k=1,2,3,4 as appropriate), 250 nM fluorescent reporter substrate. In
Figure A2.4, experiments using multiple serotype-specific input strands were run
using 100 nM of each serotype-specific input.
Pre-annealed DNAzyme-inhibitor complexes were added to buffer first,
then pre-annealed SCS molecules, then inputs. The system was incubated at
room temperature for 2 hours, then fluorescent reporter substrate was added,
and the endpoint fluorescence value was observed after incubation at room
temperature for a further 6 hours (2 hours for Figure A2.5b,d). All endpoint
fluorescence values were baseline-corrected relative to the corresponding
fluorescence value at the time of substrate addition. In Figure 4.3b and Figure
A2.4, the baseline-corrected fluorescence values were normalized to the
endpoint fluorescence of the positive trace, so that values between 0 and 1 could
be reported. In Figure A2.5b,d, the baseline-corrected fluorescence values were
plotted with no further data processing.
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A2.2.5 Concentration profile of two-layer DNAzyme signaling cascade
(Figure A2.1)
Sequences are listed in Table A2.1. DNAzyme concentrations (upstream &
downstream) and SCS molecules and inputs varied according to the figure
legend. In each case, downstream inhibitor was used in 25% excess relative to
the concentration of the downstream DNAzyme. 250 nM reporter substrate was
used. Pre-annealed DNAzyme-inhibitor complexes were added to buffer first,
then pre-annealed SCS molecules, then fluorescent reporter substrate. Inputs
were added last to initiate the reaction. Loss of FRET was observed over 30
minutes. Raw fluorescence values are plotted.

Figure A2.1: Concentration profile of two-layer DNAzyme signaling cascade.
Broken lines indicate response in absence of active upstream DNAzymes (-ve
control) and solid lines indicate response in presence of active upstream
DNAzymes (+ve control). Concentrations of DNAzymes, inputs and SCS
molecules vary as shown in the legend; inhibitor concentrations were also varied
to ensure a 25% excess of inhibitor with respect to the DNAzyme concentration
in each case. Concentration of the readout substrate was the same in all cases.
Reducing the concentrations of circuit elements reduced both leakage rates and
activation rates, as expected.
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A2.2.6 Demonstration that SCS cleavage is necessary for signal
propagation (Figure A2.1)
Sequences are listed in Table A2.3. Concentrations: 100 nM DNAzymes
(upstream & downstream), 125 nM inhibitor (downstream), 100 nM SCS
(cleavable or uncleavable, as appropriate), 250 nM fluorescent reporter substrate.
Pre-annealed DNAzyme-inhibitor complexes were added to buffer first,
then pre-annealed SCS molecules, then fluorescent reporter substrate. Active
upstream DNAzyme was added last to initiate the reaction. Loss of FRET was
observed over two hours. Raw fluorescence values were plotted with no
additional data processing.

Figure A2.2: Demonstration that cleavage is required for signal propagation
by the SCS in a two-layer cascade. Red traces are the response of an SCS
molecule with the rA (ribose) base at the cleavage replaced by a dA
(deoxyribose) base, both in the presence (+ve control, solid line) and absence (ve control, broken line) of the upstream active DNAzyme. The substitution of dA
for rA at the cleavage site makes the SCS molecule uncleavable. For comparison,
the blue traces are the response of a cleavable SCS in the two layer cascade,
both in the presence (solid line) and absence (broken line) of the upstream active
DNAzyme. Addition of the upstream active DNAzyme does not produce any
additional leakage in the case of the uncleavable SCS, which demonstrates that
simply opening the outer stem by strand displacement does not produce
downstream signal propagation. Hence, the cleavage step is required.

!
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A2.2.7 Demonstration of SCS input-output combinations (Figure A2.3a-c)
Sequences are listed in Tables A2.4-6. Concentrations: (a) 100 nM DNAzymes
(upstream & downstream), 125 nM inhibitor (upstream & downstream), 100 nM
SCS, 50 nM reporter substrate, 100 nM input 1, 100 nM input 2. (b) 100 nM
DNAzymes (upstream & downstream), 125 nM inhibitor (upstream), 100 nM SCS,
50 nM reporter substrate, 100 nM input. (c) 100 nM DNAzyme (upstream), 125
DNAzyme inhibitor (upstream), 100 nM SCS, 100 nM input, 100 nM fluorescent
reporter strand, 125 nM downstream inhibitor labeled with quencher.
Inhibited DNAzymes (either pre-annealed DNAzyme-inhibitor complexes or
annealed loop-inhibited DNAzyme strands) were added to buffer first, then preannealed SCS molecules, then inputs. The system was incubated for 2 hours at
room temperature, then the reporter (either a fluorescent reporter substrate or a
strand

displacement

reporter

complex)

was

added,

and

the

endpoint

fluorescence value was observed after a further 30 minutes incubation at room
temperature. Each endpoint fluorescence value was baseline-corrected relative
to the corresponding fluorescence value at substrate addition.
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Figure A2.3. Application of the SCS as a generic interface molecule. An
active DNAzyme from the input module cleaves the SCS, releasing an activator
for the output module. This shows that our SCS design enables interoperability
between different architectures, which is an important goal for future
development of DNA logic circuits. Error bars on bar charts show the 95%
confidence interval from triplicate runs of each experiment. a) Input module is a
previously reported 8-17 DNAzyme displacement (DzD) “AND” gate with
mismatched bases in the catalytic core portion of the inhibitor 17, which is
activated by two inputs in a cooperative strand displacement reaction 18. Output
module is an 8-17 DzD “YES” gate. b) Input module is an 8-17 DzD “YES” gate,
output module is a loop-inhibited “YES” gate based on the E6 catalytic motif 8.
Since the E6 DNAzyme cleaves the same dinucleotide junction as the 8-17
DNAzyme, we can use the same fluorescent reporter substrate in this case. c)
Input module is an 8-17 DzD “YES” gate, output module is a DNA strand
displacement reporter gate in which the activator released by cleavage of the
SCS simply displaces a fluorescently-labeled strand from the reporter complex.
The advantage of using a strand displacement gate as the reporter is that it does
not amplify leakage, which might be preferable for certain applications. More
generally, this reaction demonstrates that the SCS design could be used to
interface DNAzymes with arbitrary strand displacement circuits and alternative
DNAzyme catalytic motifs such as the 10-23 RNA-cleaving DNAzyme 9 and
DNA-cleaving DNAzymes 19-21.
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A2.2.8 – Dengue Biosensor Specificity
Sequences can be found in Table A2.2. Concentrations can be found in Section
A2.2.4.

Figure A2.4: Demonstration of serotype-specific response from dengue
serotyping circuits, which were presented in Figure 4.3. In each case, the
negative control (grey) is the response in the absence of all three inputs, and the
positive control (green) is the response in the presence of the two conserved
inputs and the correct serotype-specific input (DEN-1, DEN-2, DEN-3 or DEN-4).
The orange bar is the response in the presence of the two conserved inputs and
all three incorrect serotype-specific sequences. a, Serotype specificity of DEN-1
detection circuit. b, Serotype specificity of DEN-2 detection circuit. c, Serotype
specificity of DEN-3 detection circuit. d, Serotype specificity of DEN-4 detection
circuit. In all cases, we observe a significantly reduced response when the
incorrect serotype-specific sequences are present. In fact, the magnitudes of the
non-specific responses to the incorrect serotype-sequences correlate with the
background activations observed in the presence of the downstream DengueB
input sequence in Figure 4.3, so it is likely that the non-specific activation seen in
the presence of the incorrect serotype-specific sequences is in fact largely
caused by the presence of DengueB. Hence we conclude that our four dengue
detection circuits are in fact serotype-specific. Error bars represent the 95%
confidence interval from three replicate experiments.

!
219

A2.2.9 – Dengue Biosensor Structural Optimization
Sequences can be found in Tables A2.2, A2.7, and A2.8. Concentrations can be
found in Section A2.2.4.

Figure A2.5: Performance improvements from secondary structure
optimization of dengue serotyping circuit components. a) The upstream
DNAzyme derived from the initial DEN-3 target sequence was found to have
unwanted secondary structure, highlighted in red. We hypothesized that this
would cause difficulty binding to the SCS molecule in the dengue serotyping
circuit, because the two substrate binding arms of the DNAzyme were hybridized
to each other. We switched to a different DEN-3 target sequence that removed
this unwanted binding in the DNAzyme strand. b) Performance of the DEN-3
detection circuit using the initial and the optimized target sequences (and
associated upstream DNAzymes and SCS molecules). The initial circuit
produced no activation above background in the presence of all three inputs,
whereas the optimized circuit produced a significant response in this case. c)
The SCS cleavage product derived from the initial DEN-2 target sequence was
found to have unwanted secondary structure, highlighted in red. We
hypothesized that this would sequester the toehold of the downstream activator
strand even after the SCS was cleaved, leading to low activation of the circuit.
We switch to a different DEN-2 target sequence that removed this unwanted
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binding in the activator strand. d) Performance of the DEN-2 detection circuit
using the initial and the optimized target sequences (and associated upstream
DNAzymes and SCS molecules). The initial circuit produced little activation
above background in the presence of all three inputs, whereas the optimized
circuit produced a significant response in this case. This highlights the
importance of design optimization to prevent the formation of unwanted
structures. The bar charts are representative data that illustrate the performance
difference between the initial and optimized versions of the circuits.
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A2.2.10 Two-layer cascade experiment in DNA background (Figure A2.6)
Sequences are listed in Table A2.1. Concentrations: 100 nM DNAzyme (2nd and
1st layers), 125 nM inhibitor (1st layer), 100 nM SCS (SCS2), 50 nM fluorescent
reporter substrate (1st layer). Herring sperm DNA (Promega, Madison, WI) was
annealed (as described previously) and various amounts were added to 96 well
plates

containing

buffer.

Pre-annealed

downstream

DNAzyme-inhibitor

complexes were added first, then pre-annealed SCS molecules, then fluorescent
reporter substrate. Input (active upstream DNAzyme) was added last to initiate
the reaction. Loss of FRET was observed over 30 minutes. Each positive kinetic
trace was baseline-corrected by subtracting each time point observed from a
negative control (run in the same experimental conditions but no active upstream
DNAzyme present) from the corresponding time point in each positive trace.
None of the negative controls showed a significant increase in fluorescence.

Figure A2.6. Operation of DNAzyme signaling cascades in the presence of
background DNA. The two-layer cascade experiment was repeated in the
presence of the labeled concentrations of denatured herring sperm DNA,
covering six orders of magnitude from 1 ng/mL to 1 mg/mL. We observed no
systematic loss of performance caused by the presence of background DNA. We
hypothesize that the single-stranded SCS design allows rapid refolding following
interactions with the background DNA, preventing spurious activation.
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A2.2.11 - Discussion of spurious interactions in cascades
We have identified the following potential mechanisms for spurious activation in
our DNAzyme signaling cascades.
1. Unwanted activation of one of the DNAzymes in the cascade by
spontaneous dissociation of its inhibitor. The spuriously activated
DNAzyme can then proceed to cleave its substrate, which may be an SCS
molecule or a fluorescently labeled readout substrate.
2. Unwanted binding of an inhibited upstream DNAzyme to the SCS
molecule. This may open the outer stem even in the absence of a
cleavage reaction, providing a window of opportunity for the downstream
effector sequence to interact with the downstream, inhibited DNAzyme.
3. Direct binding of the downstream inhibitor toehold to the sequestered
toehold in the outer loop, leading to activation of the downstream
DNAzyme by a toehold-mediated strand displacement (TMSD) reaction.
4. Spontaneous dissociation of one or both of the duplex stems of the SCS
molecule, which reduces the topological constraint on the downstream
toehold, enabling it to more easily activate the downstream DNAzyme by
TMSD.
Our design work on DNAzyme displacement logic gates has shown that the
effect of mechanism #1 can be reduced by extending the length of the inhibitor
strands and, if necessary, introducing additional inhibitor strands free in solution
to bias the equilibrium towards continued deactivation of the DNAzymes.
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We addressed mechanism #2 by running additional controls with an SCS
molecule in which the RNA base at the cleavage site is replaced by the
corresponding DNA base. Since the 8-17 DNAzyme is RNA-cleaving, this single
base substitution suffices to make the SCS molecule uncleavable by the
upstream DNAzyme (Figure S3). These results demonstrated that stem opening
by the binding of the upstream DNAzyme is not a significant leak mechanism.
Previous studies of hairpin opening kinetics

22

have shown that the rate constant

for opening a hairpin by TMSD is several orders of magnitude slower when the
toehold is contained within the hairpin (an “internal toehold”) as opposed to
outside (an “external toehold”). This is directly relevant to the kinetics of
unwanted binding of the downstream, inhibited DNAzyme to the sequestered our
SCS molecule, as in mechanism #3, which can be thought of as opening a loop
via an internal toehold. Hence we conclude that mechanism #3 is probably not
the dominant leakage mechanism.
Therefore, mechanism #4 is most likely to be the primary source of
leakage in our cascades. The most obvious way to reduce such spurious
dissociation of duplexes in the SCS molecule would be to extend these duplexes,
in order to increase their melting temperature. However, the desire to retain
multiple turnover in the cleavage of SCS molecules by upstream DNAzymes
restricts the length of the DNAzymes’ substrate binding arms to ~8-10
nucleotides each, so that the product strands unbind rapidly from the DNAzyme
after cleavage. This, in turn, places upper limits on the lengths of the duplexes in
the SCS structure, since these must be displaced by the substrate binding arms
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via TMSD reactions. One of the substrate binding arms must also bind to the
SCS toehold, so this also had to be taken into consideration when designing the
basic SCS structure. A 4nt toehold was chosen to strike a balance between
speed of toehold binding and subsequent strand displacement, and leaving
enough of the substrate binding arm left so that the stem could be sufficiently
long to reduce leakage as far as possible.
A2.2.12 - Discussion of rate-limiting steps in DNAzyme signaling cascades
Cleavage of an SCS molecule by an active upstream DNAzyme is a complex
reaction with a number of steps that could be rate-limiting. In particular:
1. In order to cleave the SCS molecule, the upstream DNAzyme must initiate
a TMSD reaction to open the outer stem and then nucleate a second
binding event with the outer loop, so that both substrate binding arms are
bound to the SCS molecule and the catalytic core is correctly positioned
opposite the cleavage site. The second binding event is similar to a
“remote toehold” strand displacement reaction
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, in that an internal

diffusion step is required, which slows down the reaction considerably.
Furthermore, the cleavage reaction must compete with the attempts of the
SCS molecule to reform its dual-stem structure. This could cause the
upstream DNAzyme to be displaced from the complex before cleavage
takes place.
2. Post-cleavage, activation of the downstream DNAzyme involves a TMSD
reaction in which the invading strand has some secondary structure (the
short hairpin comprising the inner stem and inner loop from Figure 1a), as
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opposed to being a single strand with no secondary structure. It is well
known that secondary structure in the invader strand reduces the rate of
strand displacement reactions 24.
A2.2.13 - Discussion of SCS design parameters and circuit leakage
The design of the SCS balances a number of constraints. To minimize the rate of
leakage, that is, unwanted downstream activation caused by uncleaved SCS
molecules interacting with DNAzyme gates, stems were made as long as
possible. However, for efficient catalytic turnover the substrate binding arms of
the DNAzymes should each be at most 8 nucleotides long, constraining the
length of the stems.25 To maximize the length of the outer stem and toehold while
respecting this constraint, we place the cleavage site within the outer stem.
Finally, to reduce leakage we make the SCS as compact as possible, by using
the outer loop (part of the input module) to also serve as the toehold for the
downstream activator. Minimizing loop size makes them more difficult to invade
when in the sequestered state, reducing the potential for unwanted circuit
element interactions. This approach does not constrain the recognition
sequences of the different DNAzymes in the cascade. Overall, our SCS design
exploits the predictable, sequence-specific folding of DNA to program a favorable
reaction pathway directly into the structure of the substrate molecule.
Despite these efforts, the primary limiting factor for DNAzyme signaling cascades
using the SCS remains the rate of circuit leakage. Although constraints on the
SCS limit design space to a certain extent, a number of alternative strategies
offer the potential to overcome this challenge. These include the physical
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separation of circuit components by attaching them to the surfaces of
microspheres,26 and the rational introduction of mismatched bases27 in the SCS
design. Such strategies may be used in conjunction with one another, as physical
separation should reduce the number of interactions between inactivate circuit
components, while mismatches should reduce the conditional probability of
unwanted signal generation given that an interaction has taken place. A number
of such design alternatives are currently being explored. Additionally, while our
work has advanced DNA logic for bioassay development, several challenges still
remain. Most notable is the use of the fluorogenic chimeric substrate, which is
expensive and requires RNAse free conditions for optimal response. However,
recent work on DNA cleaving DNAzymes

19-21

may offer a path forward using

cheaper pure DNA substrates instead of chimeric DNA/RNA substrates.
A2.2.14 - Discussion of SCS sequence effect on kinetic rates
As stated in Section 5.2.1, one of the primary objectives in the SCS design
process was to optimize kinetic rates of activation vs. leakage. The modularity of
the SCS design allowed the sequence to be altered while retaining the structure
of the molecule. Each individual SCS sequence behaves identically from a
mechanistic standpoint; however, the variation between layers of the five-layer
cascade (Figure 4.2B) suggested that they do not all respond with the same
kinetic profile. Although global kinetic modeling would be required to assign
quantitative values to each of these rates, we may still be able to achieve a
qualitative understanding of these differences through a careful look into the
sequence selection process.
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In Section 5.2.3, we discussed the mechanism for choosing each
sequence. Briefly, we used NUPACK to explore the structure space of each
DNAzyme pair, keeping the downstream DNAzyme sequence fixed while
allowing

the

downstream

inhibitor

toehold,

upstream

DNAzyme,

and

corresponding SCS upstream substrate sequences to vary freely. To assess the
potential performance of a given sequence, we compared the equilibrium binding
probabilities between the pre-cleavage SCS molecule (SCS) and the postcleavage SCS molecule (ACT) in the presence of the downstream DNAzyme and
inhibitor. In this way, we would expect a low probability of the SCS binding with
the downstream inhibitor, thus favoring a low percentage of activate downstream
DNAzyme (referred to as the leak parameter). However after cleavage, the
interaction between the downstream inhibitor and ACT would be favored,
increasing the percentage of active DNAzyme (referred to as the activation
parameter). Optimally, we look to achieve the highest activation/leak ratio, while
ensuring good structural formation. In the graph below, the activation and leak
parameters are listed for each SCS used in the five-layer cascade.
Table A2.9 – Activation vs. Leak percentages for each SCS sequence
Strand
SCS2
SCS3
SCS4
SCS5

% Leak
~0
0.24
0.29
0.28

% Activation
6.7
71.55
71.57
50

Note that the SCS2 design was a misfolded structure from the original NUPACK
script it was coded from, which may explain the low activation percentage.
Additionally, the custom Python script used to search for optimal sequences was
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not used for the first SCS sequence, but was used for all three subsequent
sequences. There are two striking features from this table. First, it seems likely
that despite the good performance of the SCS2 (Design 8) demonstrated in
Figure 5.10, this structure may indeed be the rate-limiting step of the cascades.
Second, despite the third and fourth SCS sequences being nearly identical in
both leak and activation parameters, they result in vastly different kinetic
responses. While the lag phase between the two-layer and three-layer cascades
is only slightly offset, there is a significant increase in the lag phase between the
three-layer and the fourth-layer.
It remains unclear what structural differences contribute to the large
differences in activation rate, and why similar activation/leak profiles (SCS3 and
SCS4) result in very different kinetic traces in a multi-layered cascade. There are
no obvious differences with downstream DNAzyme, Dz-Inh complex, SCS
structure, or ACT-Inh complex. In Figure A2.7, we can observe the relative
differences in structural stability of the ACT structure, which is generate from the
SCS after cleavage by the upstream DNAzyme. It appears that the ACT structure
from SCS2 may have the most stable stem structure, in which all seven bases
bind at a high probability. This may offer a possible explanation as to why this is
the lowest activation rate (a stable ACT structure may slow the rate of strand
displacement of the downstream Dz-Inh complex). However, this line of
reasoning may be problematic in that the next most stable structures (SCS3,
which retains a seven base stem, albeit at a lower probability of remaining
bound; SCS4, which retains a six base pair stem at a high probability) also yield
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the highest rate of activation. Finally, the weakest ACT structure is derived from
SCS5, having only a moderate probability of retaining a five base pair stem yet
this sequence produces only a medium activation percentage, well below
seemingly more stable structures. It is possible that this activation is slowed from
the many of the unpaired bases exhibiting a lower probability, indicating that this
structure may fold up on itself to some degree.

Figure A2.7 – Comparison of ACT (post-cleavage) structural probabilities for the
four respective SCS structures.
Absent of any defining factors that could readily explain the differences in
equilibrium predictions and observed kinetic rates, it is clear that more work
needs to be done in this area. Kinetic modeling and the determination of kinetic
rates to each of the individual reactions may provide significant insight into this
mechanism. It may also be beneficial to run a global sequence interaction
program to predict cross-reactivity between layers, something that has not yet
been explored.
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Appendix 3
A3.1 Oligonucleotide sequences and concentrations

Sequence
GAACTATCTCCGAGCCGGTCGAAAACTAAGA
CTCCATCTTAGTTTTCGACCGGCT
CTCCATCTTAGTTTGGGTATTrAGGCGGACAGCCGGTCGAAAACTAAGATGGAG
GTCCGCTCCGAGCCGGTCGAAAATACCC
FAM-TCTTAGTTrAGGATAGTTCAT-TAM

Sequence
GAACTATCTCCGAGCCGGTCGAAAACTAAGA
CTCCATCTTCGTTTTCGACCGGCT
CTCCATCTTCGTTGGGTATTrAGGCGGACAGCCGGTCGAAAACGAAGATGGAG
GTCCGCTCCGAGCCGGTCGAAAATACCC
FAM-TCTTAGTTrAGGATAGTTCAT-TAM

Sequence
GAACTATCTCCGAGCCGGTCGAAAACTAAGA
CTCCATCTTAGTTTTCGACCGGCT
CTCCATCTTAGTTGGGTATTrAGGCGGACAGCCGGTCGAAAACTAAGATGGAG
GTCCGCTCCGAGCCGGTCGAAAATACCC
FAM-TCTTAGTTrAGGATAGTTCAT-TAM

Conc (nM)
100
120
100
100
50

Conc (nM)
100
120
100
100
50

Conc (nM)
100
120
100
100
50

Section A3.1.1 Oligonucleotide sequences and concentrations for each variant of SCS Design 1 for DNAzyme cascades.
The variant used in Figure 5.2 is highlighted in cyan.
Table A3.1
Strand (D1v1)
Dz
INH
SCS
UE
Substrate

Table A3.2
Strand (D1v2)
Dz
INH
SCS
UE
Substrate

Table A3.3
Strand (D1v3)
Dz
INH
SCS
UE
Substrate

!
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Table A3.4
Strand (D1v4)
Dz
INH
SCS
UE
Substrate

Table A3.5
Strand (D1v5)
Dz
INH
SCS
UE
Substrate

Table A3.6
Strand (D1v6)
Dz
INH
SCS
UE
Substrate

Table A3.7
Strand (D1v7)
Dz
INH
SCS
UE

Sequence
GAACTATCTCCGAGCCGGTCGAAAACTAAGA
CTCCATCTTAGTTTTCGACCGGCT
CTCCATCTTAGTTTTGGGTATTrAGGCGGACAGCCGGTCGAAAACTAAGATGGAG
GTCCGCTCCGAGCCGGTCGAAAATACCC
FAM-TCTTAGTTrAGGATAGTTCAT-TAM

Conc (nM)
100
120
100
100
50

Conc (nM)
100
120
100
100
50

Conc (nM)
100
120
100
100
50

Sequence
GAACTATCTCCGAGCCGGTCGAAAACTAAGA
CTCCATCTTAGTTTTCGACCGGCT
CTCCATCTAAGTTTTCGGGTATTrAGGCGGACAGCCGGTCGAAAACTAAGATGGAG
GTCCGCTCCGAGCCGGTCGAAAATACCC
FAM-TCTTAGTTrAGGATAGTTCAT-TAM

Sequence
GAACTATCTCCGAGCCGGTCGAAAACTAAGA
CTCCATCTTAGTTTTCGACCGGCT
CTCCATCTTAGTTTTCGGGTATTrAGGCGGACAGCCGGTCGAAAACTAAGATGGAG
GTCCGCTCCGAGCCGGTCGAAAATACCC
FAM-TCTTAGTTrAGGATAGTTCAT-TAM

Sequence
GAACTATCTCCGAGCCGGTCGAAAACTAAGA
CTCCATCTTAGTTTTCGACCGGCT

CTCCATCTTAGTTTTCGAGGGTATTrAGGCGGACAGCCGGTCGAAAACTAAGATGGAG

Conc (nM)
100
120
100
100
GTCCGCTCCGAGCCGGTCGAAAATACCC
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Substrate

Table A3.8
Strand (D1v8)
Dz
INH
SCS
UE
Substrate

Table A3.9
Strand (D1v4)
Dz
INH
SCS
UE
Substrate

Sequence
GAACTATCTCCGAGCCGGTCGAAAACTAAGA
CTCCATCTTAGTTTTCGACCGGCT
AGCCGGTCGAAAACTAAGATGGAGGGGTATTrAGGCGGACTAGTTTTCGACCGGCT
GTCCGCTCCGAGCCGGTCGAAAATACCC
FAM-TCTTAGTTrAGGATAGTTCAT-TAM

Sequence
GAACTATCTCCGAGCCGGTCGAAAACTAAGA
CTCCATCTTAGTTTTCGACCGGCT
CTCCATCTAAGTTTTCGAGGGTATTrAGGCGGACAGCCGGTCGAAAACTAAGATGGAG
GTCCGCTCCGAGCCGGTCGAAAATACCC
FAM-TCTTAGTTrAGGATAGTTCAT-TAM

FAM-TCTTAGTTrAGGATAGTTCAT-TAM

Conc (nM)
100
120
100
100
50

Conc (nM)
100
120
100
100
50

50

Sequence
GAACTATCTCCGAGCCGGTCGAAAACTAAGA
CTCCATCTTAGTTTTCGACCGGCT
AGCCGGTCGAAAACTAAGACGTGAGGGTATTrAGGCGGACTCACG
GAGTCCGCTCCGAGCCGGTCGAAAATACCCT
FAM-TCTTAGTTrAGGATAGTTCAT-TAM

Conc (nM)
100
120
100
100
50

Section A3.1.2 Oligonucleotide sequences and concentrations for each variant of SCS Design 2 for DNAzyme cascades.
The variant used in Figure 5.3 is highlighted in cyan. NUPACK code for this design is in Section A3.2.1.
Table A3.10
Strand (D2v1)
Dz
INH
SCS
UE
Substrate
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Table A3.11
Strand (D2v2)
Dz
INH
SCS
UE
Substrate

Sequence
GAACTATCTCCGAGCCGGTCGAAAACTAAGA
CTCCATCTTAGTTTTCGACCGGCT
AGCCGGTCGAAAACTAAGACGCCCAGGGTATTrAGGCGGACTGGGCG
CAGTCCGCTCCGAGCCGGTCGAAAATACCCT
FAM-TCTTAGTTrAGGATAGTTCAT-TAM

Sequence
GAACTATCTCCGAGCCGGTCGAAAACTAAGA
CGGGTTCTTAGTTTTCGACC
AGCCGGTCGAAAACTAAGACGCCCAGGGTATTrAGGCGGACTGGGCG
GTTTATGCTCCGAGCCGGTCGAAACCCGTTTCT
FAM-TCTTAGTTrAGGATAGTTCAT-TAM

Conc (nM)
100
120
100
100
50

Conc (nM)
100
120
100
100
50

Section A3.1.3 Oligonucleotide sequences and concentrations for SCS Design 3 for DNAzyme cascades (Figure 5.4).
Table A3.12
Strand (D3)
Dz
INH
SCS
UE
Substrate

Sequence
GAACTATCTCCGAGCCGGTCGAAAACTAAGA
GAAGTTCTTAGTTTTCGACC
GGGATGTGAAGTrAGGATGGGACGGTCGAAAACTAAGAACTTCAC
GTCCCATCTCCGAGCCGGTCGAAACTTCACATCCC
FAM-TCTTAGTTrAGGATAGTTCAT-TAM

Conc (nM)
100
120
100
100
50

Section A3.1.4 Oligonucleotide sequences and concentrations for SCS Design 4 for DNAzyme cascades (Figure 5.5).
NUPACK code for this design can be found in Section A3.2.2.
Table A3.13
Strand (D4)
Dz
INH
SCS
UE
Substrate

!
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Sequence
GGGATGTGAAGTrAGGATGGGACAATCGAAAACTAAGAACTTCAC
GGGATGTGAAGTrAGGATGGGACGGTCGAAAACTAAAGACTTCAC
GGGATGTGAAGTrAGGATGGGACAATCGAAAACTAAAGACTTCAC
GGGATGAGTGAAGTrAGGATGGGACGGTCGAAAACTAAGAACTTCACTC
GGGATGTGCCGTrAGGATGGGACGGTCGAAAACTAAGAACGGCAC
GGGATGAGTGCCGTrAGGATGGGACGGTCGAAAACTAAGAACGGCACTC

Conc (nM)
100
100
100
100
100
100

Table A3.14 Proposed variants of the SCS Design 4. Bold bases were targeted for variation, as described by the strand
name. This is an example of the granularity of the rational design process. M2 indicates the mutation of two bases, either
on the 3’ end or the 5’ end of the activator. The corresponding sequences for each SCS Design 4 variant is found in Table
A3.12. These sequences were not explicitly tested but such targeted locations for optimization were used in later variants.
Strand (D4v1)
M2-5’
M2-3’
M2-5’3’
S9
7GC
9GC

Conc (nM)
100
120
100
100
50

Conc (nM)
100
120
100
100
50

Section A3.1.5 Oligonucleotide sequences and concentrations for each variant of SCS Design 5 for DNAzyme cascades.
The variant used in Figure 5.6 is highlighted in cyan.

Sequence
GAACTATCTCCGAGCCGGTCGAAAACTAAGA
CGTATTCTTAGTTTTCGACC
GGTCGAAAACTAAGAATACGGGACTACAGTTAGTAGTrAGCGTATGAGGG
CCCTCATACGCTCCGAGCCGGTCGAAACTACTAACT
FAM-TCTTAGTTrAGGATAGTTCAT-TAM

Table A3.15 - NUPACK code for this design can be found in Section A3.2.3.
Strand (D5v1)
Dz
INH
SCS
UE
Substrate

Sequence
GAACTATCTCCGAGCCGGTCGAAAACTAAGA
GCCACTCTTAGTTTTCGACC
GGTCGAAAACTAAGAGTGGCACCAGACTrAGGCCACTCATAAA
TTTATGAGTGGCTCCGAGCCGGTCGAAAGTCTGGT
FAM-TCTTAGTTrAGGATAGTTCAT-TAM

Table A3.16 - NUPACK code for this design can be found in Section A3.2.4.
Strand (D5v2)
Dz
INH
SCS
UE
Substrate
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Conc (nM)
100
120
100
100
50

Section A3.1.6 Oligonucleotide sequences and concentrations for SCS Design 6 for DNAzyme cascades (Figure 5.7).

Sequence
GAACTATCTCCGAGCCGGTCGAAAACTAAGA
CGACCCGTCTTAGTTTTCGACCGGC
GGTCGAAAACTAAGACGTACTAGTACTACTACTAGTACGGGAA
GGTCGAAAACTAAGACGTACTAGTACTACTACTA
FAM-TCTTAGTTrAGGATAGTTCAT-TAM

Table A3.17 - NUPACK code for this design can be found in Section A3.2.5.
Strand (D6)
Dz
INH
SCS
SCS ACT
Substrate

Conc (nM)
100
120
100
100
50

Conc (nM)
100
120
100
100
50

Section A3.1.7 Oligonucleotide sequences and concentrations for each variant of SCS Design 7 for DNAzyme cascades.
The variant used in Figure 5.8 is highlighted in cyan.

Sequence
GAACTATCTCCGAGCCGGTCGAAAACTAAGA
GTAGCTCTTAGTTTTCGACC
CACGCGTAGCGGTCGAAAACTAAGAGCTACAATrAGGCGTGAGG
CCTCACGCTCCGAGCCGGTCGAAATTGTAGC
FAM-TCTTAGTTrAGGATAGTTCAT-TAM

Table A3.18 - NUPACK code for this design can be found in Section A3.2.6.
Strand (D7v1)
Dz
INH
SCS
UE
Substrate

Sequence
GAACTATCTCCGAGCCGGTCGAAAACTAAGA
TTTACTCTTAGTTTTCGACC
CCCTACGACTTTACGGTCGAAAACTAAGAGTAAAGTGCAATrAGCGTAGGGATGAA
TTCATCCCTACGTCCGAGCCGGTCGAAATTGCACTTTAC
FAM-TCTTAGTTrAGGATAGTTCAT-TAM

Table A3.19 - NUPACK code for this design can be found in Section A3.2.7.
Strand (D7v2)
Dz
INH
SCS
UE
Substrate
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Sequence
GAACTATCTCCGAGCCGGTCGAAAACTAAGA
TCTGATCTTAGTTTTCGACC
AAAGCCGTGATCGGTCGAAAACTAAGATCAGATACATrAGCGGCTTTAAC
GTTAAAGCCGTCCGAGCCGGTCGAAATGTATCTGA
FAM-TCTTAGTTrAGGATAGTTCAT-TAM

Table A3.20 - NUPACK code for this design can be found in Section A3.2.8.
Strand (D7v3)
Dz
INH
SCS
UE
Substrate

Sequence
GAACTATCTCCGAGCCGGTCGAAAACTAAGA
TCCAATCTTAGTTTTCGACC
CAAACGCTCCAATCGGTCGAAAACTAAGATTGGATAACTrAGGCGTTTGATG
CATCAAACGCTCCGAGCCGGTCGAAAGTTATCCAA
FAM-TCTTAGTTrAGGATAGTTCAT-TAM

Table A3.21 - NUPACK code for this design can be found in Section A3.2.9.
Strand (D7v4)
Dz
INH
SCS
UE
Substrate

Sequence
GAACTATCTCCGAGCCGGTCGAAAACTAAGA
ATGTATCTTAGTTTTCGACC
CACGCCTATCTTAGGTCGAAAACTAAGATTCATTTACTrAGGGCGTGATTAG
CACGCCTATCTTAGGTCGAAAACTAAGATTCATTTACTA
CTAATCACGCCTCCGAGCCGGTCGAAAGTAAATGAA
CTAATCACGCCTCCGAGCCGGTCGAAAGTAAATG
TAATCACGCCTCCGAGCCGGTCGAAAGTAAATG
FAM-TCTTAGTTrAGGATAGTTCAT-TAM

Conc (nM)
100
120
100
100
50

Conc (nM)
100
120
100
100
50

Conc (nM)
100
120
100
100
100
100
100
50

Section A3.1.8 Oligonucleotide sequences and concentrations for each variant of SCS Design 8 for DNAzyme cascades.
The variant used in Figure 5.9 is highlighted in cyan. NUPACK code for this design can be found in Section A3.2.10.
Manual adjustments were made between the original variant (D8v1) and the final variant (v4).
Table A3.22
Strand (D8v1)
Dz
INH
SCS
SCS ACT
UE 11-10
UE 11-8
UE 10-8
Substrate

!

237

Table A3.23
Strand (D8v2)
Dz
INH
SCS
SCS ACT
Substrate

Table A3.24
Strand (D8v3)
Dz
INH
SCS
UE
Substrate

Sequence
GAACTATCTCCGAGCCGGTCGAAAACTAAGA
TCCAATCTTAGTTTTCGACC
CACGCCTGTCTTAGGTCGAAAACTAAGATTCATTTACTAGGGCGTGATTAG
CACGCCTGTCTTAGGTCGAAAACTAAGATTCATTTACTA
FAM-TCTTAGTTrAGGATAGTTCAT-TAM

Conc (nM)
100
120
100
100
50

Conc (nM)
100
120
100
100
50

Conc (nM)
100
120
100
100
50

Sequence
GAACTATCTCCGAGCCGGTCGAAAACTAAGA
ATGTATCTTAGTTTTCGACC
ACGCCCTATCTTAGGTCGAAAACTAAGATTCATTACTrAGGGCGTGATT
AATCACGCCCTCCGAGCCGGTCGAAAGTAATGAA
FAM-TCTTAGTTrAGGATAGTTCAT-TAM

Sequence
GAACTATCTCCGAGCCGGTCGAAAACTAAGA
ATGTATCTTAGTTTTCGACCGGC
CGCCCTAATCTTAGGTCGAAAACTAAGATACATACTrAGGGCGTGATG
ATCACGCCTCCGAGCCGGTCGAAAGTATGTA
FAM-TCTTAGTTrAGGATAGTTCAT-TAM

Table A3.25 – This variant is used in Figure 5.10.
Strand (D8v4)
Dz
INH
SCS
UE
Substrate
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A3.2 NUPACK Codes
A3.2.1 NUPACK Code for Design 2
#
# design material, temperature, and trials
# see NUPACK User Guide for valid options for
# material, sodium, magnesium, and dangles
#
material = dna temperature[C] = 25.0 # optional units: C (default) or K
trials = 2
sodium[M] = 1.0 # optional units: M (default), mM, uM, nM, pM
dangles = some
#
# target structure using DU+ notation
#
structure stickfigure = U5D5(U25)
#
# sequence domains
#
domain core = GGTCGAA
domain cleave = TAGG
domain sub = AACTAAGA
domain U1 = N9
domain U2 = N7
domain TH = N5
#
# thread sequence domains onto target structures
#
stickfigure.seq = U1 cleave U2 core sub TH
#
# specify stop conditions for normalized ensemble defect
# default: 1.0 (percent) for each target structure
#
stickfigure.stop = 1.0
#
# prevent sequence patterns
#
prevent = AAAA, CCCC, GGGG, UUUU, KKKKKK, MMMMMM, RRRRRR, SSSSSS,
WWWWWW, YYYYYY
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A3.2.2 NUPACK Code for Design 4
#
# design material, temperature, and trials
# see NUPACK User Guide for valid options for
# material, sodium, magnesium, and dangles
#
material = dna
temperature[C] = 25.0 # optional units: C (default) or K
trials = 2
sodium[M] = 1.0 # optional units: M (default), mM, uM, nM, pM
dangles = some
#
# target structure using DU+ notation
#
structure stickfigure = U5D7(U25)
structure enzyme = U9 D3 ( U3 ) U17
#
# sequence domains
#
domain core = GGTCGAA
domain cleave = AG
domain sub = AACTAAGA
domain U1 = N11 T
domain U2 = G N7
domain TH = N7
domain corea1 = TCC
domain corea2 = GAGCC
domain coreb = GGTCGAA # NB: core = 5'-corea1-corea2-coreb-3', 15nt total.
#
# thread sequence domains onto target structures
#
stickfigure.seq = U1 cleave U2 core sub TH
enzyme.seq = U2* corea1 corea2 coreb U1*
#
# specify stop conditions for normalized ensemble defect
# default: 1.0 (percent) for each target structure
#
stickfigure.stop = 1.0
#
# prevent sequence patterns
#
prevent = AAAA, CCCC, GGGG, UUUU, KKKKKK, MMMMMM, RRRRRR, SSSSSS,
WWWWWW, YYYYYY

!

!

!
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A3.2.3 NUPACK Code for Design 5
#
# design material, temperature, and trials
# see NUPACK User Guide for valid options for
# material, sodium, magnesium, and dangles
#
material = dna
temperature[C] = 23.0 # optional units: C (default) or K
trials = 2
sodium[M] = 1.0 # optional units: M (default), mM, uM, nM, pM
dangles = some
#
# target structure using DU+ notation
#
structure stickfigure = U15D5(U2D5(U5)U2)U5
#
# sequence domains
#
domain core = GGTCGAAAACTAAGA
domain a = N5
domain b = N2
domain c = N5
domain d = N5
domain e = N4 T
domain f= AG
domain g = N5
domain h = N5
#
# thread sequence domains onto target structures
#
stickfigure.seq = core a b c d e f g h
#
# specify stop conditions for normalized ensemble defect
# default: 1.0 (percent) for each target structure
#
stickfigure.stop = 1.0
#
# prevent sequence patterns
#
prevent = AAAA, CCCC, GGGG, UUUU, KKKKKK, MMMMMM, RRRRRR, SSSSSS,
WWWWWW, YYYYYY
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A3.2.4 NUPACK Code for Design 5v2
#
# design material, temperature, and trials
# see NUPACK User Guide for valid options for
# material, sodium, magnesium, and dangles
#
material = dna
temperature[C] = 25.0 # optional units: C (default) or K
trials = 10
sodium[M] = 1.0 # optional units: M (default), mM, uM, nM, pM
dangles = some
#
# target structure using DU+ notation
#
structure stickfigure = U15D5(U10)U5
#
# sequence domains
#
domain core = GGTCGAA
domain cleave = TAGG
domain sub = AACTAAGA
domain U1 = N9
domain U2 = N7
domain TH = N5
#
# thread sequence domains onto target structures
#
stickfigure.seq = core sub TH U2 cleave U1
#
# specify stop conditions for normalized ensemble defect
# default: 1.0 (percent) for each target structure
#
stickfigure.stop = 1.0
#
# prevent sequence patterns
#
prevent = AAAA, CCCC, GGGG, UUUU, KKKKKK, MMMMMM, RRRRRR, SSSSSS,
WWWWWW, YYYYYY
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!
A3.2.5 NUPACK Code for Design 6
This variant has a 2nt clamp added to the downstream enzyme, and the inhibitor has 3nt extra at
the core end which is not displaced by the activator. This variant has a 4nt loop.
#############################################################################
################
#
#% downstream_name = U2
#% upstream_name = R
#% link_type = ASL3.2-4Loop_5prime
#% num_iterations = 1500
#% pyxis_tests = asl:50
#% max_leak_pct = 15
#% min_act_pct = 5
#% temp = 25
#% test_conc = 1e-7
#
#############################################################################
################
#
# sequence domains
#
domain u1a = N4
domain u1b = SSN
domain u1c = N
domain u2a = AN
domain u2c = N4
domain clva = A
domain clvb = G
domain d1a = GAAC
domain d1b = TATC
domain d2a = AACTAA
domain d2b = GA
domain corea1 = TCC
domain corea2 = GA
domain coreb1 = GCC
domain coreb2a = GGT
domain coreb2b = CGAA
domain clamp = SSS
# Upstream enzyme
structure u = U9 D3 ( U3 ) U14
u.seq = u1a u1b u1c corea1 corea2 coreb1 coreb2a coreb2b u2a clamp u2c
# Downstream enzyme
structure d = U12 D3 ( U3 ) U13
d.seq = clamp d1a d1b corea1 corea2 coreb1 coreb2a coreb2b d2a d2b
# Downstream inhibitor with clamp and core extension
structure d_inhibitor_clamp_extn = U25
d_inhibitor_clamp_extn.seq = coreb2a* coreb1* corea2* corea1* d1b* d1a* clamp* u2a* clva clvb
u1c*

!
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# Downstream substrate
structure d_sub = U18
d_sub.seq = d2b* d2a* clva clvb d1b* d1a*
# Communicator
structure asl = U4 D11 ( U4 ) U16
asl.seq = u2c* clamp* u2a* clva clvb u1c* u1b* u1a* u1b u1c clvb* clva* u2a clamp d1a d1b
corea1 corea2 coreb1
# Waste strand from cleavage
structure waste = U10
waste.seq = u2c* clamp* u2a* clva
# Downstream activator
structure d_activator = U36 # there will be some secondary structure due to weak hairpin and 817 core
d_activator.seq = clvb u1c* u1b* u1a* u1b u1c clvb* clva* u2a clamp d1a d1b corea1 corea2
coreb1
#
# prevent sequence patterns
#
prevent = AAAA, CCCC, GGGG, UUUU, KKKKKK, MMMMMM, RRRRRR, SSSSSS,
WWWWWW, YYYYYY
#
# design material, temperature (C), and trials
#
material = dna
temperature = 25.0
dangles = some
trials = 10
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A3.2.6 NUPACK Code for Design 7v1
This variant has 8nt arms on both upstream (U) and downstream (D) enzymes. The SCS element
has each binding arm split into a 3nt toehold and 5nt stem. The downstream enzyme is
constrained to our existing 8-17 sequence (U2) whereas the upstream enzyme can be freely
varied, but without any G in the substrate binding arms. There is a sequence constraint between
the upstream enzyme sequence and the toehold used on the downstream inhibitor strand.
# design material, temperature (C), and trials
#
material = dna
temperature = 25.0
trials = 5
#
# sequence domains
#
domain u1a = H3
domain u1b = H5 # NB: u1 = 5’-u1a-u1b-3’, 8nt total
# We must subdivide corea like this so that NUPACK accepts the design.
domain corea1 = TCC
domain corea2 = GAGCC
domain coreb = GGTCGAA # NB: core = 5'-corea1-corea2-coreb-3', 15nt total.
domain u2a = A H2
domain u2b = H5 # NB: u2 = 5’-u2a-u2b-3’, 8nt total
domain clv = AG
domain d1 = GAACTATC # 5’ substrate binding arm of U2 enzyme
domain d2 = AACTAAGA # 3’ substrate binding arm of U2 enzyme
#
# target structures, list from 5’ to 3’
#
# NB: “canonical” 8-17 core secondary structure is U1 D3 ( U3 ) U5
# So for substrate binding arms of X nt each, the whole thing is U[X+1] D3 ( U3 ) U[X+5]
structure asl = D5 ( D5 ( U15 ) U5 ) U3
structure u = U9 D3 ( U3 ) U13
#structure u_bound_to_asl = D8 ( U1 D3 ( U3 ) U5 D8 ( + U18 ) U2 )
structure d_activator = U33 # there will be some secondary structure due to weak hairpin and 817 core
#structure d = U9 D3 ( U3 ) U13
#structure d_inhibitor = U21
# thread sequence domains onto target structures, list from 5’ to 3’
asl.seq = u1b u2b coreb d2 u2b* u2a* clv u1b* u1a*
u.seq = u1a u1b corea1 corea2 coreb u2a u2b
#u_bound_to_asl.seq = u1a u1b corea1 corea2 coreb u2a u2b u1b u2b d1 u2b* u2a* clv u1b*
u1a*
d_activator.seq = u1b u2b coreb d2 u2b* u2a*
#d.seq = d1 corea1 corea2 coreb d2
#d_inhibitor.seq = u2b d1* coreb*
# specify stop conditions for normalized ensemble defect
# default: 1.0 (percent) for each target structure
#
#asl.stop = 1.0
# prevent sequence patterns
#
prevent = AAAA, CCCC, GGGG, UUUU, KKKKKK, MMMMMM, RRRRRR, SSSSSS,
WWWWWW, YYYYYY
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A3.2.7 NUPACK Code for Design 7v2
This variant has 12nt arms on both upstream (U) and downstream (D) enzymes. The SCS
element has each binding arm split into a 5nt toehold and 7nt stem. The downstream enzyme is
constrained to our existing U2 sequence whereas the upstream enzyme can be freely varied.
There is a sequence constraint between the upstream enzyme sequence and the toehold used
on the downstream inhibitor strand.
# design material, temperature (C), and trials
#
material = dna
temperature = 25.0
trials = 5
#
# sequence domains
#
domain u1a = H5
domain u1b = H7 # NB: u1 = 5’-u1a-u1b-3’, 12nt total
# We must subdivide corea like this so that NUPACK accepts the design.
domain corea1 = TCC
domain corea2 = GAGCC
domain coreb = GGTCGAA # NB: core = 5'-corea1-corea2-coreb-3', 15nt total.
domain u2a = A H4
domain u2b = H7 # NB: u2 = 5’-u2a-u2b-3’, 12nt total
domain clv = AG
domain d1 = GAACTATC # 5’ substrate binding arm of U2 enzyme
domain d2 = AACTAAGA # 3’ substrate binding arm of U2 enzyme
# target structures, list from 5’ to 3’
#
# NB: “canonical” 8-17 core secondary structure is U1 D3 ( U3 ) U5
# So for substrate binding arms of X nt each, the whole thing is U[X+1] D3 ( U3 ) U[X+5]
structure asl = D7 ( D7 ( U15 ) U7 ) U5
structure u = U13 D3 ( U3 ) U17
#structure u_bound_to_asl = D8 ( U1 D3 ( U3 ) U5 D8 ( + U18 ) U2 )
structure d_activator = U41 # there will be some secondary structure due to weak hairpin and 817 core
#structure d = U9 D3 ( U3 ) U13
#structure d_inhibitor = U21
#
# thread sequence domains onto target structures, list from 5’ to 3’
#
asl.seq = u1b u2b coreb d2 u2b* u2a* clv u1b* u1a*
u.seq = u1a u1b corea1 corea2 coreb u2a u2b
#u_bound_to_asl.seq = u1a u1b corea1 corea2 coreb u2a u2b u1b u2b d1 u2b* u2a* clv u1b*
u1a*
d_activator.seq = u1b u2b coreb d2 u2b* u2a*
#d.seq = d1 corea1 corea2 coreb d2
#d_inhibitor.seq = u2b d1* coreb*
# specify stop conditions for normalized ensemble defect
# default: 1.0 (percent) for each target structure
#asl.stop = 1.0
#
# prevent sequence patterns
#
prevent = AAAA, CCCC, GGGG, UUUU, KKKKKK, MMMMMM, RRRRRR, SSSSSS,
WWWWWW, YYYYYY
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A3.2.8 NUPACK Code for Design 7v3
This variant has a 2nt clamp for arm end of activator, 7nt outer stem and 5nt inner stem. The
downstream inhibitor toehold is 5bp.
#
# NUPACK answers (using a 3' activator/inhibitor combo):
# ASL strand: AAAGCCGTGATCGGTCGAAAACTAAGATCAGATACATAGCGGCTTTAAC (10.66 kcal/mol)
# D activator strand: AAAGCCGTGATCGGTCGAAAACTAAGATCAGATACAT
# D inhibitor strand: TGATCTTAGTTTTCGACC
# D strand (codename U2): GAACTATCTCCGAGCCGGTCGAAAACTAAGA
# U strand (codename V): GTTAAAGCCGTCCGAGCCGGTCGAAATGTATCTGA
#
# Equimolar DAct, DInh and D give ~89% free D
# Equimolar ASL, DInh and D gives ~5.5% free D
#############################################################################
################
#
# design material, temperature (C), and trials
#
material = dna
temperature = 25.0
trials = 5
#
# sequence domains
#
domain u1a = N3
domain u1b = S2 N3 S2 # NB: u1 = 5’-u1a-u1b-3’, 10nt total
# We must subdivide corea like this so that NUPACK accepts the design.
domain corea1 = TCC
domain corea2 = GAGCC
domain coreb = GGTCGAA # NB: core = 5'-corea1-corea2-coreb-3', 15nt total.
domain u2a = A N4
domain u2c = N2
domain u2b = N3 # NB: u2 = 5’-u2a-u2b-3’, 10nt total
domain clv = AG
domain d1 = GAACTATC # 5’ substrate binding arm of U2 enzyme
# We must divide d2 like this so that NUPACK accepts the design.
domain d2a = AACTAA
domain d2b = GA # 3’ substrate binding arm of U2 enzyme. NB: d2 = 5'-d2a-d2b-3', 8nt total
domain clamp = N2
# NB: “canonical” 8-17 core secondary structure is U1 D3 ( U3 ) U5
# So for substrate binding arms of X nt each, the whole thing is U[X+1] D3 ( U3 ) U[X+5]
#
# NNB: all structures and sequences are listed from 5' to 3'
# Upstream enzyme
structure u = U11 D3 ( U3 ) U15
u.seq = u1a u1b corea1 corea2 coreb u2a u2c u2b
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# ASL
structure asl = D7 ( D5 ( U13 ) U9 ) U3
asl.seq = u1b u2b clamp coreb d2a d2b u2b* u2c* u2a* clv u1b* u1a*
#asl.stop = 1.0 # (1.0 is the default)
# Downstream activator
structure d_activator = U37 # there will be some secondary structure due to weak hairpin and 817 core
d_activator.seq = u1b u2b clamp coreb d2a d2b u2b* u2c* u2a*
# Downstream enzyme
structure d = U9 D3 ( U3 ) U13
d.seq = d1 corea1 corea2 coreb d2a d2b
# Downstream inhibitor
structure d_inhibitor = U20
d_inhibitor.seq = u2b u2c d2b* d2a* coreb*
#
# prevent sequence patterns
#
prevent = AAAA, CCCC, GGGG, UUUU, KKKKKK, MMMMMM, RRRRRR, SSSSSS,
WWWWWW, YYYYYY
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A3.2.9 NUPACK Code for Design 7v4
This variant has a 2nt clamp for arm end of activator, 7nt outer stem and 7nt inner stem.
#
# NUPACK suggestions:
# ASL strand: CAAACGCTCCCATCGGTCGAAAACTAAGATTGGATAACTAGGCGTTTGATG (10.31 kcal/mol)
# D activator strand: CAAACGCTCCCATCGGTCGAAAACTAAGATTGGATAACT
# D inhibitor strand: TCCCATCTTAGTTTTCGACC
# D strand: GAACTATCTCCGAGCCGGTCGAAAACTAAGA
# U strand: CATCAAACGCTCCGAGCCGGTCGAAAGTTATCCCA
#
# Equimolar DAct, DInh and D gives ~87% free D.
# Equimolar ASL, DInh and D gives ~8% free D.
# NUPACK suggestions, modified for a better-looking ASL structure:
# ASL strand: CAAACGCTCCAATCGGTCGAAAACTAAGATTGGATAACTAGGCGTTTGATG (14.62 kcal/mol)
# D activator strand: CAAACGCTCCAATCGGTCGAAAACTAAGATTGGATAACT
# D inhibitor strand: TCCAATCTTAGTTTTCGACC
# D strand: GAACTATCTCCGAGCCGGTCGAAAACTAAGA
# U strand: CATCAAACGCTCCGAGCCGGTCGAAAGTTATCCAA
#
# Equimolar Dact, DInh and D gives ~93% free D.
# Equimolar ASL, DInh and D gives ~8% free D.
#############################################################################
################=
#
# design material, temperature (C), and trials
#
material = dna
temperature = 25.0
trials = 5
#
# sequence domains
#
domain u1a = N3
domain u1b = N7 # NB: u1 = 5’-u1a-u1b-3’, 10nt total
# We must subdivide corea like this so that NUPACK accepts the design.
domain corea1 = TCC
domain corea2 = GAGCC
domain coreb = GGTCGAA # NB: core = 5'-corea1-corea2-coreb-3', 15nt total.
domain u2a = A N4
domain u2b = N5 # NB: u2 = 5’-u2a-u2b-3’, 10nt total
domain clv = AG
domain d1 = GAACTATC # 5’ substrate binding arm of U2 enzyme
# We must divide d2 like this so that NUPACK accepts the design.
domain d2a = AACTAA
domain d2b = GA # 3’ substrate binding arm of U2 enzyme. NB: d2 = 5'-d2a-d2b-3', 8nt total
domain clamp = N2
# NB: “canonical” 8-17 core secondary structure is U1 D3 ( U3 ) U5
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# So for substrate binding arms of X nt each, the whole thing is U[X+1] D3 ( U3 ) U[X+5]
#
# NNB: all structures and sequences are listed from 5' to 3'
# Upstream enzyme
structure u = U11 D3 ( U3 ) U15
u.seq = u1a u1b corea1 corea2 coreb u2a u2b
# ASL
structure asl = D7 ( D7 ( U13 ) U7 ) U3
asl.seq = u1b u2b clamp coreb d2a d2b u2b* u2a* clv u1b* u1a*
#asl.stop = 1.0 # (1.0 is the default)
# Downstream activator
structure d_activator = U39 # there will be some secondary structure due to weak hairpin and 817 core
d_activator.seq = u1b u2b clamp coreb d2a d2b u2b* u2a*
# Downstream enzyme
structure d = U9 D3 ( U3 ) U13
d.seq = d1 corea1 corea2 coreb d2a d2b
# Downstream inhibitor
structure d_inhibitor = U20
d_inhibitor.seq = u2b d2b* d2a* coreb*
#
# prevent sequence patterns
#
prevent = AAAA, CCCC, GGGG, UUUU, KKKKKK, MMMMMM, RRRRRR, SSSSSS,
WWWWWW, YYYYYY
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A3.2.10 NUPACK Code for Design 8
This is a hybrid variant, derived from a combination of several of the earlier versions. Here we
focus on retaining 8bp binding arms for the upstream enzyme. The inner stem is 6bp and the
outer stem is 7bp, with a 4bp upstream toehold and a 5bp downstream toehold (one of which is in
the inner stem). This was also the first design to move the cleavage site into the outer stem.
#############################################################################
################
#
# ASL5.8 - trying to use upstream enzymes with 8bp binding arms
#
#############################################################################
################
#
# sequence domains
#
domain u1a = N4
domain u1b = S N2 S # NB: u1 = 5’-u1a-u1b-3’, 10nt total
domain u2a = A N4
domain u2b = N3 # NB: u2 = 5’-u2a-u2b-3’, 10nt total
# We subdivide clv like this so we can use the bases in the cleavage product strands.
domain clva = G
domain clvb = A # NB: clv = 5'-clvb-clva-3', 2nt total
# We must subdivide corea like this so that NUPACK accepts the designs for the enzyme strands.
domain corea1 = TCC
domain corea2 = GAGCC
domain coreb = GGTCGAA # NB: core = 5'-corea1-corea2-coreb-3', 15nt total.
domain dt1 = N
domain dt2 = N
domain d1 = GAACTATC # 5’ substrate binding arm of U2 enzyme
# We must divide d2 like this so that NUPACK accepts the design.
domain d2a = AA
domain d2b = CTAAGA # 3’ substrate binding arm of U2 enzyme. NB: d2 = 5'-d2a-d2b-3', 8nt
total
domain clamp = N5
# NB: “canonical” 8-17 core secondary structure is U1 D3 ( U3 ) U5
# So for substrate binding arms of X nt at the 5' end and Y nt at the 3' end, the whole thing is
U[X+1] D3 ( U3 ) U[Y+5]
#
# NNB: all structures and sequences are listed from 5' to 3'
# Upstream enzyme
structure u = U9 D3 ( U3 ) U13
u.seq = u1a u1b corea1 corea2 coreb u2a u2b
# ASL
structure asl = D6 ( D7 ( U9 ) U9 ) U4
asl.seq = u1b clva* clvb* dt2* d2b* coreb d2a d2b dt2 dt1 u2b* u2a* clvb clva u1b* u1a*
# Downstream activator
structure d_activator = U39 # there will be some secondary structure due to weak hairpin and 817 core
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d_activator.seq = u1b clva* clvb* dt2* d2b* coreb d2a d2b dt2 dt1 u2b* u2a* clvb
# Waste strand from cleavage
structure waste = U9
waste.seq = clva u1b* u1a*
# Downstream enzyme
structure d = U9 D3 ( U3 ) U13
d.seq = d1 corea1 corea2 coreb d2a d2b
# Downstream inhibitor
structure d_inhibitor = U20
d_inhibitor.seq = u2b* dt1* dt2* d2b* d2a* coreb*
#
# prevent sequence patterns
#
prevent = AAAA, CCCC, GGGG, UUUU, KKKKKK, MMMMMM, RRRRRR, SSSSSS,
WWWWWW, YYYYYY
#
# design material, temperature (C), and trials
#
material = dna
temperature = 25.0
dangles = some
trials = 10

!
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A3.2.11 NUPACK Code for Design 8 – Third Layer
#############################################################################
################
#
# ASL5.8 - trying to use upstream enzymes with 8bp binding arms
#
#% downstream_name = A
#% upstream_name = B
#% link_type = ASL8-8_3Prime_Inh3
#% num_iterations = 1000
#% pyxis_tests = asl:50
#% max_leak_pct = 10
#% min_act_pct = 30
#% temp = 25
#% test_conc = 1e-6
#
#############################################################################
################
#
# sequence domains
#
domain u1a = N4
domain u1b = N4
domain clva = G
domain clvb = A
domain u2a = T
domain u2b = N2
domain u2c = N4
domain u2d = N
domain d1 = ATCACGCC
domain d2a = AG
domain d2b = T
domain d2c = ATGTA
domain clamp = N5
domain corea1 = TCC
domain corea2 = GA
domain corea3 = GCC
domain coreb = GGTCGAA
# Communicator
structure asl = D7 ( D6 ( U10 ) U6 ) U4
asl.seq = u1b* clva* clvb* u2a* u2d* d2c* coreb d2a d2b d2c u2d u2c u2b u2a clvb clva u1b u1a
# Downstream activator
structure d_activator = U37 # there will be some secondary structure due to weak hairpin and 817 core
d_activator.seq = u1b* clva* clvb* u2a* u2d* d2c* coreb d2a d2b d2c u2d u2c u2b u2a clvb
# Waste strand from cleavage
structure waste = U9
waste.seq = clva u1b u1a
# Upstream enzyme
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structure u = U9 D3 ( U3 ) U13
u.seq = u1a* u1b* corea1 corea2 corea3 coreb u2a* u2b* u2c* u2d*
# Downstream enzyme
structure d = U9 D3 ( U3 ) U13
d.seq = d1 corea1 corea2 corea3 coreb d2a d2b d2c
# Downstream inhibitor
structure d_inhibitor = U23
d_inhibitor.seq = u2c* u2d* d2c* d2b* d2a* coreb* corea3*
#
# prevent sequence patterns
#
prevent = AAAA, CCCC, GGGG, UUUU, KKKKKK, MMMMMM, RRRRRR, SSSSSS,
WWWWWW, YYYYYY
#
# design material, temperature (C), and trials
#
material = dna
temperature = 25.0
dangles = some
trials = 1
f
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A3.2.12 NUPACK Code for Design 8 – Fourth Layer
#############################################################################
################
#
# ASL5.8 - trying to use upstream enzymes with 8bp binding arms
#
#% downstream_name = B5
#% upstream_name = C
#% link_type = ASL8-8_3Prime
#% num_iterations = 1500
#% pyxis_tests = asl:50
#% max_leak_pct = 10
#% min_act_pct = 30
#% temp = 25
#% test_conc = 1e-6
#
#############################################################################
################
#
# sequence domains
#
domain u1a = N4
domain u1b = N4
domain clva = G
domain clvb = A
domain u2a = T
domain u2b = N2
domain u2c = N4
domain u2d = N
domain d1 = ACATGCCG
domain d2a = AC
domain d2b = A
domain d2c = GGGGA
domain clamp = N5
domain corea1 = TCC
domain corea2 = GA
domain corea3 = GCC
domain coreb = GGTCGAA
# Communicator
structure asl = D7 ( D6 ( U10 ) U6 ) U4
asl.seq = u1b* clva* clvb* u2a* u2d* d2c* coreb d2a d2b d2c u2d u2c u2b u2a clvb clva u1b u1a
# Downstream activator
structure d_activator = U37 # there will be some secondary structure due to weak hairpin and 817 core
d_activator.seq = u1b* clva* clvb* u2a* u2d* d2c* coreb d2a d2b d2c u2d u2c u2b u2a clvb
# Waste strand from cleavage
structure waste = U9
waste.seq = clva u1b u1a
# Upstream enzyme
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structure u = U9 D3 ( U3 ) U13
u.seq = u1a* u1b* corea1 corea2 corea3 coreb u2a* u2b* u2c* u2d*
# Downstream enzyme
structure d = U9 D3 ( U3 ) U13
d.seq = d1 corea1 corea2 corea3 coreb d2a d2b d2c
# Downstream inhibitor
structure d_inhibitor = U23
d_inhibitor.seq = u2c* u2d* d2c* d2b* d2a* coreb* corea3*
#
# prevent sequence patterns
#
prevent = AAAA, CCCC, GGGG, UUUU, KKKKKK, MMMMMM, RRRRRR, SSSSSS,
WWWWWW, YYYYYY
#
# design material, temperature (C), and trials
#
material = dna
temperature = 25.0
dangles = some
trials = 1
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A3.2.13 NUPACK Code for Design 8 – Fifth Layer!
#############################################################################
################
#
# ASL5.8 - trying to use upstream enzymes with 8bp binding arms
#
#% downstream_name = C4
#% upstream_name = D
#% link_type = ASL8-8_3Prime
#% num_iterations = 1500
#% pyxis_tests = asl:50
#% max_leak_pct = 10
#% min_act_pct = 30
#% temp = 25
#% test_conc = 1e-6
#
#############################################################################
################
#
# sequence domains
#
domain u1a = N4
domain u1b = N4
domain clva = G
domain clvb = A
domain u2a = T
domain u2b = N2
domain u2c = N4
domain u2d = N
domain d1 = GGTAGCGC
domain d2a = AT
domain d2b = A
domain d2c = TTTGT
domain clamp = N5
domain corea1 = TCC
domain corea2 = GA
domain corea3 = GCC
domain coreb = GGTCGAA
# Communicator
structure asl = D7 ( D6 ( U10 ) U6 ) U4
asl.seq = u1b* clva* clvb* u2a* u2d* d2c* coreb d2a d2b d2c u2d u2c u2b u2a clvb clva u1b u1a
# Downstream activator
structure d_activator = U37 # there will be some secondary structure due to weak hairpin and 817 core
d_activator.seq = u1b* clva* clvb* u2a* u2d* d2c* coreb d2a d2b d2c u2d u2c u2b u2a clvb
# Waste strand from cleavage
structure waste = U9
waste.seq = clva u1b u1a
# Upstream enzyme
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structure u = U9 D3 ( U3 ) U13
u.seq = u1a* u1b* corea1 corea2 corea3 coreb u2a* u2b* u2c* u2d*
# Downstream enzyme
structure d = U9 D3 ( U3 ) U13
d.seq = d1 corea1 corea2 corea3 coreb d2a d2b d2c
# Downstream inhibitor
structure d_inhibitor = U23
d_inhibitor.seq = u2c* u2d* d2c* d2b* d2a* coreb* corea3*
#
# prevent sequence patterns
#
prevent = AAAA, CCCC, GGGG, UUUU, KKKKKK, MMMMMM, RRRRRR, SSSSSS,
WWWWWW, YYYYYY
#
# design material, temperature (C), and trials
#
material = dna
temperature = 25.0
dangles = some
trials = 1

!
258

Appendix 4
A4.1 Oligonucleotide sequences and concentrations

All oligonucleotide sequences are listed 5’ to 3’. Functional domains have been color-coded to match the corresponding

domains in the figures, and strand names have been annotated with the corresponding labels from the figures. The

dinucleotide junctions that are cleaved in the substrate strands have been highlighted using a yellow background and

Conc (nM)
100
125
125
125
125
125
125
100
100
100
50

mismatched bases are underlined. The RNA base at the cleavage site in each substrate strand is represented as rA, and
the fluorophore (fluorescein) and quencher (TAMRA) are represented as FAM and TAM respectively.

Sequence
GAACTATCTCCGAGCCGGTCGAAAACTAAGAAACAACACTC
ATAGGGTTGAGTGTTGTT CTCCA TCTTAGTT TTCGACCGGC
ATAGGGTTGAGTGTTGTT CTCCT TCTTAGTT TTCGACCGGC
ATAGGGTTGAGTGTTGTT CTCGA TCTTAGTT TTCGACCGGC
ATAGGGTTGAGTGTTGTT CTGCA TCTTAGTT TTCGACCGGC
ATAGGGTTGAGTGTTGTT CTCGC TCTTAGTT TTCGACCGGC
ATAGGGTTGAGTGTTGTT CATCTCGC TCTTAGTT TTCGACCGGC
GGTCGAAAACTAAGATGGAG
GGTCGAAAACTAAGATGGAGATG
AACAACACTCAACCCTAT
FAM-TCTTAGTTrAGGATAGTTCAT-TAM

Table A4.1 Oligonucleotide sequences and concentrations for Figure 6.2
Strand
Dz
INH
INH (P1)
INH (P2)
INH (P3)
INH (P1,2)
INH (P1,2,L8)
Fuel
Fuel (L8)
Target
Substrate
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Sequence
GAACTATCTCCGAGCCGGTCGAAAACTAAGAAACAACACTC
ATAGGGTTGAGTGTTGTT CTCCA TCTTAGTT TTCGACCGGC
ATAGGGTTGAGTGTTGTT CTCGA TCTTAGTT TTCGACCGGC
ATAGGGTTGAGTGTTGTT CTGCA TCTTAGTT TTCGACCGGC
ATAGGGTTGAGTGTTGTT CTCGC TCTTAGTT TTCGACCGGC
ATAGGGTTGAGTGTTGTT CATCTCGC TCTTAGTT TTCGACCGGC
GGTCGAAAACTAAGATGGAG
GGTCGAAAACTAAGATGGAGATG
AACAACACTCAACCCTAT
FAM-TCTTAGTTrAGGATAGTTCAT-TAM

Table A4.2 Oligonucleotide sequences and concentrations for Figure 6.3/6.4
Strand
Dz
INH
INH (P2)
INH (P3)
INH (P1,2)
INH (P1,2,L8)
Fuel
Fuel (L8)
Target
Substrate

Sequence
GAACTATCTCCGAGCCGGTCGAAAACTAAGAAACAACACTC
ATAGGGTTGAGTGTTGTT CTCCA TCTTAGTT TTCGACCGGC
ATAGGGTTGAGTGTTGTT CTCCT TCTTAGTT TTCGACCGGC
ATAGGGTTGAGTGTTGTT CTCGA TCTTAGTT TTCGACCGGC
ATAGGGTTGAGTGTTGTT CTGCA TCTTAGTT TTCGACCGGC
ATAGGGTTGAGTGTTGTT CTCGC TCTTAGTT TTCGACCGGC
ATAGGGTTGAGTGTTGTT CATCTCGC TCTTAGTT TTCGACCGGC
GGTCGAAAACTAAGCTGGAG
GGTCGAAAACTAAGGTGGAG
GGTCGAAAACTAAGCTGGAGATG
GGTCGAAAACTAAGGTGGAGATG
AACAACACTCAACCCTAT
FAM-TCTTAGTTrAGGATAGTTCAT-TAM

Table A4.3 Oligonucleotide sequences and concentrations for Figure 6.5
Strand
Dz
INH
INH (P1)
INH (P2)
INH (P3)
INH (P1,2)
INH (P1,2,L8)
CT Fuel
GT Fuel
CT Fuel (L8)
GT Fuel (L8)
Target
Substrate

Conc (nM)
100
125/50
125/50
125/50
125/50
125/50
100/40
100/40
100/40
250

Conc (nM)
40
50
50
50
50
50
50
40
40
40
40
40
250
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Sequence
GAACTATC TCCGAGCCGGTCGAA AACTAAGA AACTACAACA
CTTGTGGCTGTTGTAGTTCTCCATCTTAGTTTTCGACCGGC
AACTACAACAGCCACAAG
GAACTATC TCCGAGCCGGTCGAA AACTAAGA AACAACACTC
ATAGGGTTGAGTGTTGTT CTCCA TCTTAGTT TTCGACCGGC
AACAACACTCAACCCTAT
rArArCrArArCrArCrTrCrArArCrCrCrTrArT
GAACTATC TCCGAGCCGGTCGAA AACTAAGA TGGATGAACG
GTCTATTTCGTTCATCCAGTTGTTCTTAGTTTTCGACCGGC
TGGATGAACGAAATAGAC
GAACTATC TCCGAGCCGGTCGAA AACTAAGA GAAGGGAGAA
GTCCGCCTTTCTCCCTTCGTTGTTCTTAGTTTTCGACCGGC
GAAGGGAGAAAGGCGGAC
GGTCGAAAACTAAGATGCAG
GGTCGAAAACTAAGAACTAC
FAM-TCTTAGTTrAGGATAGTTCAT-TAM

Conc (nM)
40
50
100
100
250

Conc (nM)
100
125
100
100
125
100
100
100
125
100
100
125
100
500
500
50

Table A4.4 Oligonucleotide sequences and concentrations for Figure 6.6. Figure 6.6E also contains 100 and 50 nM fuel,
as indicated on the graph.
Strand
Dz R1
INH R1
Target R1
Dz R2
INH R2
Target R2
rTarget R2
Dz R3
INH R3
Target R3
Dz R4
INH R4
Target R4
Fuel R1,R2
Fuel R3,R4
Substrate

Sequence
GAACTATCTCCGAGCCGGTCGAAAACTAAGAAACAACACTC
ATAGGGTTGAGTGTTGTT CATCTCGC TCTTAGTT TTCGACCGGC
GGTCGAAAACTAAGGTGGAGATG
pRSET emGFP
FAM-TCTTAGTTrAGGATAGTTCAT-TAM

Table A4.5 Oligonucleotide sequences and concentrations for Figure 6.7.
Strand
Dz
INH (P1,2,L8)
GT Fuel (L8)
Target
Substrate

!
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Sequence
GAACTATCTCCGAGCCGGTCGAAAACTAAGAACCTTCCT
ACCTGGGGGAGTATGTGCGGAGGAAGGTCTCCATCTTAGTTTTCGACCGGC
GGTCGAAAACTAAGATGCAG
ATP
FAM-TCTTAGTTrAGGATAGTTCAT-TAM

Table A4.6 Oligonucleotide sequences and concentrations for Figure 6.8 and Figure 6.14.
Strand
Dz
INH (P3)
Fuel
Target
Substrate

Sequence
GAACTATC TCCGAGCCGGTCGAA AACTAAGA GATACTTTGAACCTT
GGATAT AAGGTTCAAAGTATC CTCCATCTTAGTTTTCGACCGGC
GATACTTTGAACCTTATATCCCAATATAGT
GAACTATC TCCGAGCCGGTCGAA AACTAAGA GCCAAACCAACTATG
GACAGT TCATAGTTGGTTTGGC CTCCATCTTAGTTTTCGACCGGC
GCCAAACCAACTATGAACTGTC
GAACTATC TCCGAGCCGGTCGAA AACTAAGA ATTTTACTGGAAAAA
GGTGCT TTTTTCCAGTAAAAT CTCCATCTTAGTTTTCGACCGGC
TCTGATATTTTACTGGAAAAAAGCACC
GAACTATC TCCGAGCCGGTCGAA AACTAAGA AGTATAACCTTTTAC
ATGAAA GTAAAAGGTTATACT CTCCATCTTAGTTTTCGACCGGC
AGTATAACCTTTTACTTTCATGACAGGA
GAACTATC TCCGAGCCGGTCGAA AACTAAGA CATACACTCCTAAAT
CAACAG ATTTAGGAGTGTATG CTCCATCTTAGTTTTCGACCGGC
CATACACTCCTAAATCTGTTGATGGTA
GAACTATC TCCGAGCCGGTCGAA AACTAAGA TGTCATTCGTGACAA
GAATGG TTGTCACGAATGACA CTCCATCTTAGTTTTCGACCGGC
TGTCATTCGTGACAACCATTC
GGTCGAAAACTAAGATGCAG
FAM-TCTTAGTTrAGGATAGTTCAT-TAM

Table A4.7 Oligonucleotide sequences and concentrations for Figures 6.9 and 6.10.
Strand
Dz O26
INH O26
Target O26
Dz O45
INH O45
Target O45
Dz O103
INH O103
Target O103
Dz 121
INH O121
Target O121
Dz O145
INH O145
Target O145
Dz O157
INH O157
Target O157
Fuel
Substrate

Conc (nM)
100
125
100
0.1,1 mM
250

Conc (nM)
100
125
50
100
125
50
100
125
50
100
125
50
100
125
50
100
125
50
500
50
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Sequence
GAACTATC TCCGAGCCGGTCGAA AACTAAGA GCCAAACCAACTATG
GACAGT TCATAGTTGGTTTGGC CTCCATCTTAGTTTTCGACCGGC
GCCAAACCAACTATGAACTGTC
GGTCGAAAACTAAGATGCAG
FAM-TCTTAGTTrAGGATAGTTCAT-TAM

Conc (nM)
100
125
100
100
100
50

Conc (nM)
100
125
100
100
100
125
100
100
100
50

Conc (pM)
100
125
1/5/10
100
250000

Table A4.8 Oligonucleotide sequences and concentrations for Figure 6.11. Gate concentrations for this figure are listed in
pM.
Strand
Dz O45
INH O45
Target O45
Fuel
Substrate

Sequence
GAACTATCTCCGAGCCGGTCGAAAACTAAGACGTCACCTAC
GGTAGGTAGGTGACGGTTGTTCTTAGTTTTCGACCGGC
TCACCTACCTACCTACATC
GCTGGCGTrAGTACAAATGGGTCGAAAACTAAGAACTACGC
CATTTGTATCCGAGCCGGTCGAAACGCCAGCCCATAACCCT
GGGTGAGGGTTATGGATTGTGCTGGCGTTTCGACCGGC
CCATAACCCTCACCCCATCTA
GTAACATAAGGTCGAAACGCCAGCACTATCC
GACGGGATAGTAACATAAGGTCGAAACGCCAGCACTATCC
FAM-TCTTAGTTrAGGATAGTTCAT-TAM

Table A4.9 Oligonucleotide sequences and concentrations for Figure 6.13.
Strand
Dz1
INH1
Input1
SCS1
Dz2
INH2
Input2
ACT2
SCS2
Substrate

Sequence
GAACTATCTCCGAGCCGGTCGAAAACTAAGACGTCACCTAC
GGTAGGTAGGTGACGCGCGTACCTCTTAGTTTTCGACCGGC
TCACCTACCTACCTACATC
GCTGGCGTAGTACAAATGGGTCGAAAACTAAGGACTACGCG
GTACAAATGGGTCGAAAACTAAGGACTACGCG
FAM-TCTTAGTTrAGGATAGTTCAT-TAM

Table A4.10 Oligonucleotide sequences and concentrations for Figure 6.14.
Strand
Dz1
INH1
Input1
SCS1
ACT1
Substrate
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Sequence
GGGAGGCGTAATAAT GAACTATC TCCGAGCCGGTCGAA AACTAAGA
GGGAGGCGTAATAAT A GAACTATC TCCGAGCCGGTCGAA AACTAAGA
GGGAGGCGTAATAAT TA GAACTATC TCCGAGCCGGTCGAA AACTAAGA
GGGAGGCGTAATAAT CTA GAACTATC TCCGAGCCGGTCGAA AACTAAGA
GGGAGGCGTAATAAT TCTA GAACTATC TCCGAGCCGGTCGAA AACTAAGA
GGGAGGCGTAATAAT TTCTA GAACTATC TCCGAGCCGGTCGAA AACTAAGA
CCG GCTCGGA GATAGTTC TAGAA ATTATTACGCCTCCC ATTATTGGCG
TTCTAGAACTATCTCCGAGCC
CGCCAATAAT GGGAGGCGTAATAAT
FAM-TCTTAGTTrAGGATAGTTCAT-TAM

Table A4.11 - Oligonucleotide sequences and concentrations for Figure A4.6.
Strand
Dz4.0
Dz4.1
Dz4.2
Dz4.3
Dz4.4
Dz4.5
Inh
Fuel
Target
Substrate

Sequence
GAACTATC TCCGAGCCGGTCGAA AACTAAGA AACAACACTC
ATA GG GTT GAGTGTTGTT CATCTCGCTCTTAGTT TTCGACCGGC
AACAACACTC AAC CC TAT
GGTCGAAAACTAAGGTGGAGATG
AACAACACTC AAC CC TCT
AACAACACTC AAC CC GAT
AACAACACTC AAC CA TAT
AACAACACTC AAC GC
AACAACACTC AAA CC TAT
AACAACACTC AAC CC GCT
AACAACACTC AAC CA TCT
AACAACACTC AAC CG GAT
AACAACACTC AAC GA TAT
AACAACACTC AAA CA TAT
AACAACACTC AAA GC TAT
AACAACACTC ATA CC TAT
FAM-TCTTAGTTrAGGATAGTTCAT-TAM

Table A4.12 Oligonucleotide sequences and concentrations for SNP detection (Figure A4.8 and A4.9).
Strand
Dz R2
INH P1, P2, L8
Target
Fuel
SNP2
SNP3
SNP4
SNP5
SNP6
SNP2,3
SNP2,4
SNP3,4
SNP4,5
SNP4,6
SNP5,6
SNP6,7
Substrate

!

Conc (nM)
100
100
100
100
100
100
125
100
100
50

Conc (nM)
100
125
100
100
100
100
100
100
100
100
100
100
100
100
100
100
50
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Sequence
GAACTATCTCCGAGCCGGTCGAAAACTAAGA
CTCCATCTTAGTTTTCGACCGGC
TCCCACCAACAGCAGGGATATTAAA
AACAGCAGGGATATCTGCAGCCGGTCGAAAACTAAGATGGAG ATATCCCTGCTGTTGGTGGGA
FAM-TCTTAGTTrAGGATAGTTCAT-TAM

Table A4.13 Oligonucleotide sequences and concentrations for DSL detection (Figure A4.10)
Strand
Dz
INH
Target
DSL
Substrate

Sequence
GAACTATCTCCGAGCCGGTCGAAAACTAAGA
CTCCATCTTAGTTTTCGACCGGC
AACTAAGATGGAGGGGATATTAAA
AATATCCCCTCCATCTTAGTT
TTTAATATCCCCTCCATCTTAGTT
AGCCGGTCGAAAACTAAGATGGAGGGG
FAM-TCTTAGTTrAGGATAGTTCAT-TAM

Table A4.14 Oligonucleotide sequences and concentrations for VSD detection (Figure A4.11)
Strand
Dz
INH
Target
VSD-Inh5
VSD-Inh8
VSD-Act
Substrate

Conc (nM)
100
120
100
varies
50

Conc (nM)
100
120
100
100
100
100
50
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Figure A4.1 – Leak dependency on fuel concentration. Using the P3 gate
structure (sequence is O45 DNAzyme and inhibitor, Table A4.7), gate response
and leakage is directly related to the amount of fuel strand present in solution.
Reducing fuel concentration decreases rate of both the positive response and the
leakage. Concentrations were 100 nM O157 gate, 25 nM excess inhibitor, 50 nM
substrate, 50 nM target, varied concentrations of fuel with 1 mismatch.

Figure A4.2 – Effect of longer blocking sequences on ATP aptamer activation.
Only the 8bp blocking sequence is sufficient for activation (blue). Longer
sequences, such as the 11bp (green) or 15 bp (red) lengths, blocked the ATP
from displacing the detection domain, resulting in no gate activation.
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Figure A4.3 – Characterization of the O157 gate (P3 mismatch) (Table A4.7) in
the presence of various preparation of a random DNA background (Section
6.5.5). a) Control experiment with no background. b) Characterization in
presence of background DNA. c) DNAzyme-inhibitor complexes were annealed
in the presence of herring sperm DNA, allowing the possibility of gate misfolding
due to interactions with the background. d) DNAzyme-inhibitor gate complexes
and the background DNA were heated separately, and the background was
quenched on ice before adding to the solution, to prevent rebinding of the
background DNA. All experiments used 100 nM O157 gate, 25 nM excess
inhibitor, 50 nM target strand, 500 nM fuel, 250 nM substrate. Experiments in
background also contained 1 µM herring sperm DNA (Promega, Madison, WI).
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Figure A4.4 – Additional investigation of detection limits of O45 sensor gate.
Serial dilutions of circuit components were used to reduce the concentration of
the entire circuit (substrate was held constant at 250 nM). Colored line traces (left
axis) show response with various input concentrations. The background signal in
absence of input has been subtracted from all traces. Solid lines are average
fluorescence values from 5 replicates, and dashed lines are one standard error
above and below the mean in each case. Red data points (right axis) are
detection limits at 3σ above the standard error of the background at various time
points, calculated using the standard IUPAC definition. a) 10 nM O45 gate, 1 nM
excess inhibitor, 10 nM fuel with 1 mismatch, 250 nM substrate, 1 ug/mL
background, varied target concentrations. b) 1 nM O45 gate, 100 pM excess
inhibitor, 1 nM fuel with 1 mismatch, 250 nM substrate, 1 ug/mL background,
varied target concentrations (4 replicates). Note that a higher sampling frequency
was used for the fluorescence measurements in this reaction, causing the traces
to appear more jagged. c) 100 pM O45 gate, 10 pM excess inhibitor, 100 pM fuel
with 1 mismatch, 250 nM substrate, varied target concentrations.
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Figure A4.5 – Full characterization of STEC detection gates with additional
controls. The inclusion of a mismatched base in the fuel strands significantly
reduces the response in the absence of the target strand by reducing unwanted
binding of the fuel strand to the deoxyribozyme-inhibitor complex. Experiments
with only the incorrect target strands demonstrate sequence specificity as well as
highlighting that unwanted fuel binding is the dominant source of leakage in
these reactions. Experiments in columns 1 & 2 were performed using 50 nM
substrate, column 3 was performed with 250 nM substrate (this explains the
comparatively lower leak in column 3). All experiments used 100 nM
deoxyribozyme-inhibitor complexes, 25 nM excess inhibitor, 50 nM of each
corresponding target strand used in the reaction, and 500 nM fuel.

269

Fluorescence / a.u.

800

INH4.0
INH4.1
INH4.2
INH4.3
INH4.4
INH4.5

600
400
200
0

0

10

20

30

40

50

60

Time / minutes
Figure A4.6 – Examination of loop toehold length on activation and leakage. The
activation (solid line) and leakage (dash line) for each looped toehold length was
tested. Starting from inhibitor 0 (black), bases were added to the enzyme strand
to hybridize to the inhibitor, decreasing the available size of the toehold.
Interestingly, it appeared that binding one (red) or two (orange) bases serves to
increase both activation and leakage. Binding of all five bases (purple) eliminated
binding of fuel and prevented gate activation.
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Figure A4.7 – Kinetic profile of P1, P2, L8 gate with various detection targets.
Gate and substrate only (black dash) was nearly identical to the untreated
(dsDNA) plasmid target. The single-stranded target (green) activated the gate
quickly whereas direct plasmid detection was much slower, indicating the
significant effect of diffusion and steric hindrance on gate activation.
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A4.2 Discussion of P3 Leak Profiles
Additional controls (Figure A4.5) showed that the DNAzyme-inhibitor complexes
are highly stable in the absence of the fuel strand, even in the presence of the
target sequence. The fuel strand is the major source of non-specific background
signal, which varies in a concentration dependent manner (Figures A4.1 and
A4.5). We surmise that imperfections in the sensor gate complex and breathing
of the duplexes near to the secondary toehold bulge may allow strand invasion
via the secondary toehold in the absence of the target sequence, allowing the
fuel strand to displace a catalytically active deoxyribozyme even though the
inhibitor in the detection module remains bound. To address this, we used fuel
strands with a rationally introduced mismatched base in the toehold domain,
which considerably reduced the rate of spurious activation due to the fuel strand
binding to the toehold in the bulge (Figure A4.5). The use of excess inhibitor also
helps to inhibit the deoxyribozymes more efficiently in the face of concentration
variations. However, the excess inhibitor may hinder circuit operation by binding
to target strands, preventing them from activating the gates, and by rebinding
activated deoxyribozyme strands to deactivate them, thereby reducing assay
sensitivity. We also strengthened the inhibitor binding to the gate by extending
the inhibitor by 3 nt beyond the length of the fuel strand, and used an excess of
substrate relative to the deoxyribozyme concentration to enable a higher
maximum signal-to-background ratio through multiple-turnover amplification.
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A4.3 Use of modular gates for SNP detection
Using the P1, P2, L8 gate design and R2 detection sequence, we hypothesized
that the addition of mismatches to simulate a single nucleotide polymorphism
would result in a significant change in the kinetic response of the gate. We tested
this under various shortened toehold lengths of 5bp and 3bp. We instituted a
single mismatch between the target strand and the inhibitor toehold (detection
domain), corresponding to the location of the SNP on the target strand in relation
to the toehold. This was followed by the addition of a second mismatch between
the target and the detection domain, where the location of the SNP could be at
either position. The SNP targets are labeled for the location the SNP was placed,
relative to the 3’ end of the target strand and the 5’ side of the inhibitor (Table
A4.11). SNP locations were chosen at positions either in the middle of the
toehold (3bp – P2; 5bp – P4), the last base of the single stranded toehold (3bp –
P3; 5bp – P5), the first base of the double stranded detection domain (3bp – P4;
5bp – P6) or the second base of the double stranded detection domain (5bp –
P7).
Overall, the best results were using two mismatches with a 5bp toehold
(Figure A4.8). However, the results were somewhat curious from both the 5bp
toehold as well as the 3bp toehold (Figure A4.9). In the case of the 5bp toehold,
the position of the a single mismatch or two mismatches had very little effect on
the kinetic rates, a result in striking contrast to our earlier optimization of gate
structure (Section 6.2.2). Although these results are not directly comparable, as
the aforementioned optimization was with the fuel strand binding, rather than the
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target strand, it was surprising we did not see a larger difference in rate. This is
especially true with the 3bp toehold, where the addition of two mismatches in the
2&3 position would have left only a single base toehold on the 5’ end, yet still
performed similarly to the target strand with no mismatch (T2). While the addition
of a mismatch in the P4 position did decrease the gate response, the rate was
still far higher than would be expected given a 1-X-1 (X) toehold (in the SNP2,4
example) or a 2-X (X) toehold (in the SNP 3,4 example), where X indicates the
position of the mismatch in the 3bp toehold and first position of the detection
domain.
Although this mechanism shows promise, more work must be done before
to further increase the signal difference between SNP and non-SNP detection.
Although many of the obvious SNP locations have been tested, further
experiment to verify kinetic response is necessary. It is unclear the cause of the
high fluorescent response with multiple mismatches and whether this can be
overcome through a more judicious choice of SNP location or if a structural
alteration in gate design is necessary. It may be possible to sequester the outer
toehold, currently in a linear form, to a looped form like the inner toehold, and
whether such a change would result in a more pronounced SNP detection
response.
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Figure A4.8 – SNP detection with a 5bp toehold. SNP names indicate the
position of the SNP relative to the 3’ end of the target strand. SNPs with a single
mismatch are relative to the T2 target, which contains no mismatches. SNPs with
two mismatches can have the SNP location in either position and kinetic traces
are relative to targets with only a single mismatch.
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Figure A4.9 – SNP detection with a 3bp toehold. SNP names indicate the
position of the SNP relative to the 3’ end of the target strand. SNPs with a single
mismatch are relative to the T2 target, which contains no mismatches. SNPs with
two mismatches can have the SNP location in either position and kinetic traces
are relative to targets with only a single mismatch.
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A4.4 Alternative biosensor designs
Several different attempts were made to develop an arbitrary sequence
biosensor compatible with the DNAzyme displacement gates from Chapter 3.
The two most interesting were “detection stem loop” (DSL, Figure A4.10), and a
“viral strand displacement” (VSD, Figure A4.11). For the DSL, the target strand
would bind the toehold and displace the stem. The activator, sequestered in the
DSL loop, would then become single-stranded and able to displace the inhibitor
from the Dz-Inh complex. This stem loop was fairly sensitive, generating a signal
even at 10 pM (Figure A4.10C), but still resulted in significant leakage (black
dash, Figure A4.10B). For the VSD, the target displaced the activator from the
VSD complex, which could then displace the inhibitor from the Dz-Inh complex.
However, to shorten the complex, the toehold and substrate binding arm of the
DNAzyme were made to match the target strand. Although this also resulted in a
robust response, the sequence overlap may constrain the design of cascades
and require a new substrate for each new enzyme. Even still, the performance of
this complex may be worth revisiting in the context of the new cascade designs.
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Figure A4.10 – Detection stem loop for arbitrary sequence detection. (A)
Mechanism of DSL and target interaction. Target binds to the toehold on the DSL
and displaces the stem. This opens the loop, which contains a sequestered
activator. This activator then binds to the gate and removes the inhibitor,
producing an active DNAzyme. (B) 100 nM Dz-Inh gate with 10 nM DSL. (C) 100
nM Dz-Inh gate with 10 pM DSL.
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Figure A4.11 – Viral strand displacement for arbitrary sequence detection. (A)
Mechanism of VSD and target interaction. Binding of the target strand to the VSD
complex releases the activator, which binds to the Dz-Inh complex to produce
active DNAzyme. (B) 100 nM gate with 100 nM VSD and target using a 5bp
toehold. (C) 100 nM gate with 100 nM VSD and target using an 8bp toehold.
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Appendix 5
A5.1. Oligonucleotide sequences
All oligonucleotide sequences are listed 5’ to 3’. Functional domains (substrate
binding arms and cleavage sites) have been color-coded to match with the
corresponding domains. The dinucleotide junctions that are cleaved in the
substrate strands have been highlighted using a yellow background, and
mismatched bases are highlighted in red text. The RNA base at the cleavage site
in each substrate strand is represented as rA. For Sub1, the fluorophore
(fluorescein) and quencher (TAMRA) are represented as FAM and TAM
respectively. For Sub2, the fluorophore (Cy5) and quencher (Black Hole
Quencher-2) are represented as Cy5 and BHQ2 respectively. Concentrations are
listed in regards to each experiment.
Table A5.1 – Corresponding sequences for each DNAzyme and substrate pair.
Dz1 and Sub1 were sequences used for all screening experiments.
Strand
DNAzyme 1 (Dz1)
Substrate 1 (Sub1)
DNAzyme 2 (Dz2)
Substrate 2 (Sub2)

Sequence
GAACTATC TCCGAGCCGGTCGAA AACTAAGA
FAM-TCTTAGTT rAG GATAGTTC AT-TAM
CTGTCCGC TCCGAGCCGGTCGAA AATACCCAT
Cy5-CATGGGTATT rAG GCGGACAGG-BHQ2

A5.2 Reaction Concentrations
Table A5.2 – Concentrations of DNA strands and EDTA, as well as relative
percentages of DMF and DMSO in solution.
Experiment
Figure 7.2A
Figure 7.2B

Dz
0/50/250
0/50

Sub
250
250

% DMF/DMSO
---

Figure 7.2C
Figure 7.2D
Figure 7.4
Figure 7.5
Figure 7.6
Figure 7.7
Figure 7.8

0/15/200
0/15
100
0/25/50/100/200
0/15
0/50
100

250
250
50
250
250
250
50

--1
-0/0.5/1/1.5/2/5/10
---
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EDTA
-10uM, 100uM,
1mM, 10mM
-100mM
------

1

2
1160956
1362236
1352385
1246371
1392252
1117242
1270741
1144201

2
1169
1170
1171
1172
1174
1275
1276
1319

1
346398
340073
339824
338329
2969002
2798717
3002459
2957693

2
74
93
92
82
95
70
84
73

loCntrl
loCntrl
loCntrl
loCntrl
hiCntrl
hiCntrl
hiCntrl
hiCntrl

1
0
0
0
0
239
223
242
238

6
1416276
1048850
1348071
1120997
1362617
1421102
1476005
1429603

5
6
1481
882
1433
531
1295
914
1277
506
1387
886
1409 sc_1mg/ml
1509 sc_1mg/ml
1002 sc_1mg/ml

7
79
91
98
87
100
75
91
82

7
1235443
1369578
1441687
1319852
1471431
1182522
1362775
1261858

7
1169
1170
1171
1172
1174
1275
1276
1319

1"mg/ml,"10%"DMF/water
3
4
1324
1420
1343
1421
1344
1422
1345
923
1346
924
1347
1455
1418
1456
1419
1477
1"mg/ml,"10%"DMF/water
3
4
5
1097086
1224929
1132013
1100808
1214068
523985
1371194
926771
1370252
1186005
1005065
1303852
1119119
1294964
1388781
1194886
1168509
1381455
1027913
1330354
1447554
1043022
1323712
1280154

6
98
64
91
71
93
98
103
99

1"mg/ml,"10%"DMF/water
3
4
69
80
69
79
94
53
77
60
71
87
78
75
62
90
64
89

5
72
17
93
87
95
94
100
85

A5.3 Additional screening data
Plate Layout

A
B
A
B
C
D
E
F
G
H

Fluorescence

A
B

A
B
C
D
E
F
G
H

% of sc

C
D
A
B
C
D
E
F
G
H

0.5"mg/ml,"5%"DMF/water
8
9
10
1142315
1209988
1061143
1169752
1216460
520746
1383984
1002828
1426392
1277979
1062103
1355520
1190146
1360120
1395822
1285468
1184075
1436120
1115585
1443986
1453416
1114149
1395628
1383977

11
93
64
89
68
98
100
102
98

11
1385696
1064992
1341250
1112626
1443368
1464722
1490734
1448728

10
11
1481
882
1433
531
1295
914
1277
506
1387
886
1409 sc_0.5mg/ml
1509 sc_0.5mg/ml
1002 sc_0.5mg/ml

12
105
109
115
102
109
113
122
110

12
1501695
1540379
1605777
1464218
1538851
1583422
1679572
1549960

12
midCntrl
midCntrl
midCntrl
midCntrl
midCntrl
midCntrl
midCntrl
midCntrl

0.5"mg/ml,"5%"DMF/water
8
9
1324
1420
1343
1421
1344
1422
1345
923
1346
924
1347
1455
1418
1456
1419
1477

10
64
16
96
90
94
97
99
93

0.5"mg/ml,"5%"DMF/water
8
9
71
77
74
78
93
59
83
64
75
90
84
75
69
98
69
94

Table A5.3 – (A) Well layout, as described in Table 7.1. (B) Raw fluorescent values (C) Relative fluorescent values,
based off of the average of three solvent control replicates.
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Table A5.4 – Statistical values of the various screening controls.
loCntrl
hiCntrl
midCntrl
sc_1mg/ml
sc_0.5mg/ml

Mean
341156
2931968
1557984
1442237
1468061

SD
3579
90844
65917
29552
21201

CV
1.0
3.1
4.2
2.0
1.4

A5.4 Assay screening parameter controls
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Figure A5.1 – Comparison of typical buffer conditions (1M NaCl, 50 mM HEPES,
1 mM ZnCl2, pH7), with the addition of either 1% DMSO (red trace) or 1% DMF
(yellow trace).
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Figure A5.2 – Comparison of various concentrations of the 8-17 DNAzyme (Dz1)
kinetic profiles vs. DNAse I, cleaving the substrate (Sub1). Performance of
DNase was significantly below DNAzyme, making it an ineffective control for
substrate cleavage.
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Figure A5.3 – Assessment of the Dz1/Sub1 performance in the presence of
increasing percentages of DMF in solution. Only the 10% DMF solution appears
to have any effect on DNAzyme activity.
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Figure A5.4 – Optilux plate usage has a moderate effect on fluorescent signal
obtained on the plate reader when compared to a non-optical 96 well plate. This
demonstrates the necessity of using standardized products for accurate
comparison of fluorescent values.
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Figure A5.5 – Use of a slightly lower pH buffer resulted in a more prominent
signal from the Cy5-labeled Sub2 cleavage. It also appeared to stabilize the
negative control, which trended downward over time. It is unknown what caused
this effect, and whether the pH7 buffer removed this effect due to a different pH
or just being a newly made buffer.
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